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Japanese encephalitis virus (JEV), a mosquito-borne flavivirus capable of causing fatal 
encephalitis, is maintained in nature between infected mosquitoes and viremic swine and avian 
species, with humans as a dead-end host. At present, JEV is only endemic to parts of the Asia-
Pacific region, but the presence of large numbers of susceptible vertebrate hosts and competent 
vectors outside its endemic areas is a significant concern in its potential for dispersal into new 
territories. Previously, North American avian species and Culex species mosquitoes have been 
shown to be susceptible and competent for JEV transmission. A critical but missing gap of 
knowledge is whether or not the swine species in the United States are also susceptible to JEV. 
The objective of this dissertation was to address this important research gap and determine the 
susceptibility profile and pathogenesis of JEV in North American pigs. 
Three specific aims were pursued to test the central hypothesis that North American 
domestic and feral pigs are susceptible to JEV and can potentially support its transmission. In Aim 
1, the susceptibility of North American domestic pigs to JEV was determined through the invasive 
challenge of intravenous inoculation. All pigs became viremic, seroconverted, and developed 
similar pathologic outcomes as observed in published studies. In Aim 2, our approach was to 
mimic the natural route of transmission more closely via intradermal inoculation. In the same 
experiment, mosquito salivary gland extract (SGE) was inoculated with infectious viruses to 
investigate the effects of mosquito saliva in the disease pathogenesis of JEV. Piglets were 
simultaneously co-inoculated with JEV and SGE to recapitulate the actual infection route in nature. 
In contrast to the enhanced virus infection and disease severity reported in mice, the presence of 
mosquito saliva in the JEV inoculation altered the fever and viral nasal shedding kinetics but, 
interestingly, did not impact the dynamics and severity of viremia, clinical signs, and 
  
neuroinvasion. Lastly, Aim 3 was conducted to establish a feral pig model for JEV, using the 
Sinclair miniature research swine that has been bred to have a feral genotypic and phenotypic 
background. Intradermal JEV challenge of these pigs resulted in high viremia, viral nasal shedding, 
and systemic dissemination comparable to JEV infection in domestic pigs.  
Together, our results indicate that many potential enzootic hosts needed for JEV 
transmission cycle are present in North America. These findings provided a better understanding 
of how JEV behaves in its enzootic hosts – the domestic and feral pigs. The work presented in this 
dissertation provides valuable data and novel animal models of JEV to further our understanding 
of this significant pathogen and contribute to the development of effective countermeasures to 
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The earliest case of Japanese encephalitis (JE) or “summer encephalitis” was described in 
1871 in Japan (Hiroyama, 1962). The significance of the disease and its epidemic potential were 
not highlighted until years later when waves of outbreaks occurred in several Asian countries in 
the early 20th century (Hiroyama, 1962; Taniguchi et al., 1936; Vasilakis et al., 2019). The first 
documented large outbreak of JE occurred in 1924 in Japan, which resulted in more than 6,000 
cases with a 60% fatality rate (Hiroyama, 1962). In the same year, the filterable agent was isolated 
from the brain tissue of a human patient using rabbits (Erlanger et al., 2009; Tsai, 1990). However, 
it was not until 1934 when the isolated virus was proven to be the causative agent of JE by 
demonstrating the disease through the intracranial challenge of monkeys (Tsai, 1990). Amidst the 
ongoing outbreaks in Japan in the 1930s, the role of mosquitoes, particularly Culex 
tritaeniorhynchus, in JE transmission was determined and later helped establish the role of water-
wading birds and pigs as important amplifying hosts of the enzootic cycle (Erlanger et al., 2009; 
Hammon et al., 1949; Scherer et al., 1959a; Tsai, 1990). Frequent large outbreaks continued into 
the 1960s in Japan, Korea, China, and later included parts of Southeast Asia (Hiroyama, 1962; 
Hullinghorst et al., 1951; Kono and Kim, 1969; Tsai, 1990), earning the description of JE as the 
“plague of the orient” (Monath, 1988). 
While JE cases have significantly decreased from the 1970s through the implementation of 
vaccine programs, Japanese encephalitis virus (JEV) is still a significant pathogen today that 
warrants further ongoing research for the development of efficacious preventative and therapeutic 
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treatments. Japanese encephalitis virus is currently the leading viral cause of fatal pediatric 
encephalitis in the Asia-Pacific region (Centers for Disease Control and Prevention, 2019; World 
Health Organization, 2019). Although efficacious vaccines are available, approximately 68,000 
cases are still reported each year in the endemic countries, of which about 75% occur in children 
under 15 years of age (Campbell et al., 2011; World Health Organization, 2019). An estimate of 3 
billion people are at risk of JEV infection in 24 endemic countries (Erlanger et al., 2009; World 
Health Organization, 2019). While primarily recognized as a human pathogen, JEV also has 
veterinary and agricultural importance because it is capable of causing reproductive diseases in 
pigs. Currently, JEV is a notifiable disease to the World Organization for Animal Health (OIE) 
and is listed as a high-priority biosafety level 3 pathogen for biodefense and emerging disease 
research by several federal agencies (National Institute of Allergy and Infectious Diseases, 2018; 
Yang, 2019). 
The potential dispersal of JEV into new geographic areas is, therefore, an important public 
and veterinary health concern. While JEV is currently endemic to large parts of Asia and the 
Pacific region, the presence of competent arthropod vectors and susceptible amplifying vertebrate 
hosts outside its current geographic distribution could potentially lead to the dispersal and 
subsequent establishment into new territories. Although the disease has not been reported in North 
America, a proactive approach in identifying the susceptible arthropod and vertebrate species and 
understanding the consequences of their infection is critical to assess risk and develop effective 
countermeasures against a potential introduction and the establishment of a JEV transmission cycle 
in a new region. It would be nearly impossible to present the entire biology of JEV, so for our 
purpose the literature review focused on topics relevant to understanding and exploring this subject 
of dispersal and emergence potential of JEV in North America. Below is a general overview of the 
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etiological agent of JE with attention to the following topics: clinical disease, transmission cycle, 
diagnostic techniques, vaccines, geographic distribution, and pathogenesis.  
 
Classification of the virus 
The International Committee on Taxonomy of Viruses classifies JEV as an enveloped RNA 
virus in the Flaviviridae family under genus Flavivirus (International Committee on Taxonomy of 
Viruses, 2021). The Flaviviridae family is one of the major families of arthropod-borne viruses 
(arboviruses) and contains several important human or zoonotic pathogens including dengue 
viruses and yellow fever virus (Simmonds et al., 2017). By definition, arboviruses are “viruses 
which are maintained in nature principally, or to an important extent, through biological 
transmission between susceptible vertebrate hosts by hematophagous arthropods; they multiply 
and produce viremia in the vertebrates, multiply in the tissues of arthropods, and are passed on to 
new vertebrates by the bites of arthropod after a period of extrinsic incubation” (World Health 
Organization, 1967). At present, there are four genera within the Flaviviridae family: Hepacivirus, 
Pegivirus, Pestivirius, and Flavivirus (Kemenesi and Bányai, 2019). More than 70 members 
belong in the Flavivirus genus, which is composed of viruses that can replicate in a diverse range 
of invertebrates and vertebrate cells (Clark et al., 2012; Cook and Holmes, 2006). Flaviviruses can 
be mosquito-borne, tick-borne, or have no known arthropod vectors and with or without mammals 
and birds as the primary hosts (Kemenesi and Bányai, 2019). There are also insect-only 
flaviviruses (International Committee on Taxonomy of Viruses, 2021). More than 50% of the 
known flaviviruses can be pathogenic to humans and/or animals, capable of causing a range of 
clinical signs from asymptomatic to severe diseases including hemorrhagic fever, shock, or 
neurologic disease (International Committee on Taxonomy of Viruses, 2021). 
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Prior to genetic sequencing becoming available, flaviviruses were arranged into 
antigenically distinct serological complexes or serocomplexes based on serum cross neutralization 
assays. Japanese encephalitis virus belongs to the JE serocomplex, which contains the largest 
number of mosquito-borne viruses associated with neuroinvasive disease including West Nile 
virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, and Usutu virus (Murphy et 
al., 1999; Schweitzer et al., 2009). The majority of its members have enzootic cycles primarily 
involving birds and cause diseases in epizootic spillovers to humans and other susceptible 
vertebrate hosts (Schweitzer et al., 2009).  
 
Clinical disease 
 Clinical outcomes in human patients 
Japanese encephalitis virus is the most important cause of viral encephalitis in Asia, 
recognized for its potential to cause fatal infections of the central nervous system (World Health 
Organization, 2019). Japanese encephalitis disease is mainly observed in immunologically-naïve 
individuals in endemic areas. Clinical symptoms in infected individuals can range from 
nonspecific flu-like symptoms including headache, high fever, and lethargy to severe clinical 
manifestations such as paralysis, motor and memory deficits, and seizures (Ghosh and Basu, 2009; 
Monath, 2002). Young children are more commonly affected (Campbell et al., 2011). In infants or 
young children, initial symptoms may also include anorexia, nausea, abdominal discomfort or 
pain, vomiting, diarrhea, and/or acute convulsions or seizures (Tsai, 1990). The incubation period 
usually ranges between 5 to 15 days with illness first starting with a high fever, change in mental 
status, and gradual decline in speech or motor functions (Tsai, 1990). Generalized weakness, 
hypertonia, and hyperreflexia are usually the most common motor abnormalities reported in early 
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JE patients (Tsai, 1990). Although these symptomatic infections are rare, mortality rates from 
Japanese encephalitis cases can reach 30%, leading to an estimate of 10,000 to 15,000 deaths every 
year (Campbell et al., 2011; Chen et al., 2015). Additionally, up to 50% of the survivors may suffer 
from serious permanent neurologic disabilities such as cognitive, motor, and coordination 
abnormalities, further increasing the public health burden in the affected countries (Hegde and 
Gore, 2017; Tsai, 1990; World Health Organization, 2019). Poor prognosis is usually associated 
with clinical signs such as short prodromal period (time between initial symptoms to full disease), 
prolonged fever, deep obtundation, respiratory dysfunction, and status epilepticus (Tsai, 1990). 
Presence of high virus concentrations and low antibody titers in the cerebrospinal fluid, which are 
reflective of uninhibited viral proliferation in the brain, are also highly associated with fatal 
outcome (Tsai, 1990).  
Although very rare, JEV infection has also been associated with abnormalities in human 
pregnancy (Chaturvedi et al., 1980; Mathur et al., 1985; Tsai, 1990). This was documented when 
JEV was first introduced into northern India (Tsai, 1990; Tsai, 2006). In a series of outbreaks in 
Uttar Pradesh, India between 1978 and 1980, women who became infected with JEV in the first 
or second trimesters miscarried and the virus was isolated from the placenta and fetal brain (Tsai, 
1990). However, those who were infected with JEV in the third trimester did not experience any 
adverse pregnancy outcomes (Tsai, 1990). The occurrence of congenital infections of JEV is most 
likely rare because, where JEV is endemic, children are either exposed or vaccinated and become 
immune at an early age so very few young women may be at risk of infection at or during 
pregnancy (Tsai, 1990; Tsai, 2006). This rare reproductive outcome could potentially become 
more apparent in an immunologically-naïve human population in a new territory, but this is only 
a speculation.   
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 Clinical outcomes in infected swine 
Although primarily known as a human pathogen, JEV is also an agricultural pathogen that 
can greatly impact the swine and pork industry (Ghosh and Basu, 2009). Clinical disease in pigs 
caused by JEV infection is age-specific. Infection in sexually matured adult pigs can result in 
reproductive failure in forms of abortions and transient infertility (Desingu et al., 2016; Joo, 1981; 
Shimizu et al., 1954; Takashima et al., 1988). Abortions, abnormal farrowing, mummified fetuses, 
and weak piglets are most commonly observed if the pregnant sow became infected before 60 to 
70 days of gestation (Platt and Joo, 2006; Shimizu et al., 1954). Reports estimate that 
approximately 40% to 53% of unvaccinated pregnant sows had stillbirths and abortions in Japan 
during the epidemic seasons between 1947 and 1969 (Fujisaki, 1971; Imoto et al., 2010; Shimizu 
and Kawakami, 1949). Reproductive disease from JEV infection can also affect boars. Infected 
boars can develop edematous or congested orchitis with abnormal spermatozoa but are capable of 
recovering completely most of the time (Hashimura et al., 1976; Ogasa et al., 1977). 
In young pigs, JEV can invade the central nervous system similar to human cases and cause 
nonsuppurative meningoencephalitis (Yamada et al., 2004). However, natural infection and 
disease of young piglets are not commonly reported from the endemic areas, possibly due to the 
presence of maternal antibodies which can last up to 6 months of age (Platt and Joo, 2006; Scherer 
et al., 1959b). While non-specific clinical signs such as fever, anorexia, and depression are 
observed early with JEV infection, neurologic signs such as hind limb tremors or ataxia can 
sometimes develop after 5 days post-infection (Fujisaki, 1975; Kodama et al., 1968; Yamada et 
al., 2009). Some infected pigs can progress into developing a wasting-like syndrome (Yamada et 
al., 2004; Yamada et al., 2009). Nonetheless, JEV infection in pigs is generally not considered a 
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lethal swine disease. Most pigs survive, seroconvert after infection, and are even capable of 
developing secondary JEV infections when infected with a different genotype under laboratory 
conditions (García-Nicolás et al., 2017). However, pigs are important in the JEV transmission 
cycle because infected pigs can also pose a further threat to human and public health because they 




Understanding how a virus is transmitted and maintained in nature is an important part of 
infection risk mitigation. The transmission cycles of arthropod-vectored viruses involve a complex 
interaction amongst the hematophagous vectors, virus, vertebrate host, and environment. This is 
complicated further by the several separate factors that impact each of these components that 
significantly influence the disease outcome, as summarized in Figure 1.1 (Anez et al., 2012; 
Chouin Carneiro and Dos Santos, 2017). Therefore, how a specific emerging arbovirus and their 
eventual outbreaks might behave, especially in new territories, can be fairly complicated. Different 
types of transmission cycles can occur in a location depending on the type of hosts (i.e. wild, 
domestic, or human) and vectors (i.e. urban, primary, or accessory) involved: enzootic or sylvatic 
cycle in the wild, epizootic or rural cycle, and epidemic or urban cycle involving human cases 
(Anez et al., 2012; Go et al., 2014). The enzootic or sylvatic cycle is the natural transmission of 
the virus between the wild vertebrate hosts and primary or enzootic arthropod vectors that leads to 
the amplification and maintenance of the virus in nature (Go et al., 2014). The epizootic or rural 
cycle is the transmission of virus between the domestic animals and primary or accessory 
arthropod vectors (Go et al., 2014). This usually leads to viral outbreaks in the domestic animal 
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population in which the virus is amplified and often has implications extending to the humans by 
the arthropod vectors. Lastly, the epidemic or urban cycle is the virus cycle between humans as 
the source of infection due to being capable of developing high level of viremia and the urban 
arthropod vectors (Go et al., 2014). With humans being dead-end or incidental hosts for JEV, 
meaning that they cannot produce sufficient viremia capable of infecting mosquitoes, JEV only 
has enzootic and epizootic transmission cycles, as shown in Figure 1.2. Out of these, the enzootic 
transmission cycle is the most important to understand for our purpose because it is responsible 
for viral maintenance in a specific geographic region. 
 
 
Figure 1.1. Complex relationships in arbovirus transmission and disease outcome. 
 
Japanese encephalitis is primarily a rural agricultural disease (Tsai, 1990). It is maintained 
in mosquito to bird or pig to mosquito cycle with incidental transmission to humans through bites 
from infected Culex species mosquitoes (Buescher et al., 1959). Pigs and birds are the natural 
amplifying hosts of JEV, which means that they develop high and often prolonged duration of 
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viremia capable of infecting arthropod vectors. Most epidemics in Asia are driven by the close 
association between amplifying hosts and humans with mosquitoes linking the two types of hosts: 
(1) domestic pigs and humans in backyard pig farming and (2) water-wading birds and humans in 
rice paddy fields (Le Flohic et al., 2013; Tsai, 1990). The susceptible avian and swine species also 
play important roles in enzootic transmission in the wild, establishing the endemic status to a 
location. There are many other vertebrate species that are susceptible to JEV including cattle, 
goats, horses, dogs, bats, reptiles, and chickens (Cleton et al., 2014; Ghosh and Basu, 2009; Gould 
et al., 1964; Murphy et al., 1999). However, most are dead-end hosts and only those that are 
capable of developing high level of viremia sufficient to infect competent mosquitoes are 
important in the natural transmission cycle of the virus. 
 
 




 Amplification hosts 
 Avian species 
Birds play one of the central roles in the transmission cycle of JEV due to their development 
of high viremia and migratory behaviors that are important for viral maintenance and dispersal. 
Over 90 bird species are known to be potential amplifying and reservoir hosts of JEV (Le Flohic 
et al., 2013). Wild water-wading birds, especially egrets and herons of the Ardeidae family, are 
highly susceptible to JEV infection (Boyle et al., 1983; Le Flohic et al., 2013). Many of them are 
widely distributed, migratory, and thereby are suspected to be potentially responsible for the 
dispersal of JEV to new geographic regions (Le Flohic et al., 2013; Solomon et al., 2003; Yang et 
al., 2011). Migratory birds, in general, play a significant role in the ecology and circulation of 
emerging infectious diseases, often leading to the dispersal and establishment of new endemic 
locations along the migration routes (Georgopoulou and Tsiouris, 2008; Reed et al., 2003). Each 
fall, billions of birds travel through the different major global flyways that connect the north and 
south hemispheres (BirdLife International, 2021; Reed et al., 2003). Migratory birds have been 
identified as potential long-distance vehicles for many zoonotic diseases including viruses such as 
West Nile virus (Owen et al., 2006; Reed et al., 2003), Usutu virus (Engel et al., 2016), and 
influenza A virus (Reed et al., 2003; Webby and Webster, 2001; Zhang et al., 2014) as well as 
enteropathogens (Hudson et al., 2000; Reed et al., 2003). Therefore, migration of susceptible birds 
can likely be a potential driver in the dispersal of JEV. 
The black-crowned night heron (Nycticorax nycticorax) is implicated to be involved in the 
primary cycle of JEV and thereby plays a significant role in the maintenance and transmission of 
JEV (Buescher et al., 1959; Solomon et al., 2003). In JEV endemic regions, neutralizing maternal 
antibodies in these birds usually wane by 3 weeks of age and they become fully susceptible 
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afterwards (Scherer et al., 1959a). Infected birds are asymptomatic. Upon infection, maximum 
viral titers are generally higher in young birds (i.e. 2- to 5-months of age producing approximately 
104 to 105 mouse median lethal dose [LD50]/ml) compared to older birds (i.e. greater than 8-months 
of age producing 103 to 104 mouse LD50/ml) (Boyle et al., 1983). Viremia in these birds generally 
last 3 to 5 days after becoming detectable at 1 or 2 days post-infection (Boyle et al., 1983). The 
Asiatic cattle egret (Bulbulcus ibis coromandus) is another important migrating bird that may 
contribute to the maintenance of JEV transmission (Solomon et al., 2003). 
 
 Swine species  
Domestic pigs (Sus scrofa) are another amplifying host of JEV and may play a more 
significant role than birds in the ecology of JEV due to the close interactions with humans through 
farming and agriculture. Numerous JEV isolates have been detected in infected pigs (Desingu et 
al., 2016; Ladreyt et al., 2019; Yamada et al., 2004). In contrast to birds, infected pigs can develop 
pathologic outcomes, as described in a previous section. Under laboratory conditions, pigs infected 
with JEV can reach peak viremia titers of approximately 104 median tissue culture infectious dose 
(TCID50)/ml at 2 or 3 days post-infection with evidence of viral tissue dissemination and 
neuroinvasion by that time point (Ricklin et al., 2016a; Ricklin et al., 2016b; Young et al., 2020). 
Viremia is transient and generally becomes undetectable after 4 to 5 days post-infection (Ricklin 
et al., 2016a). Interestingly, previous infection with one genotype virus may not fully prevent a 
secondary infection with another genotype in experimental settings (García-Nicolás et al., 2017). 
Although not as robust, the heterologous infection can still lead to detection of low viral RNA 
loads in lymphoid or nervous tissues and in oronasal swabs within 10 days post-infection (García-
Nicolás et al., 2017). Additionally, pigs with neutralizing antibodies against JEV were documented 
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to still be susceptible to JEV infection by mosquito bites and developed viremia of sufficient 
magnitude to infect a low percentage of biting mosquitoes (Hurlbut, 1964). 
The majority of all modern pig breeds have derived from the wild Eurasian boar (still 
classified as Sus scrofa), with domestication dating back approximately 7,000 to 9,000 years ago 
(Gutierrez et al., 2015). Much like their domestic counterparts, wild boars have been identified as 
relevant drivers of JEV outbreaks in the endemic areas (Ruiz-Fons, 2017). By definition, wild or 
feral boars are a group of Sus scrofa biotypes that includes feral or escaped domestic pigs, Eurasian 
or Russian wild boars, and their cross-bred hybrids (Ruiz-Fons, 2017). High seroprevalence of 
JEV, ranging from around 66% to 83% in some regions (Nidaira et al., 2014; Nidaira et al., 2007; 
Ohno et al., 2009; Yang et al., 2012a), and RNA isolation (Nidaira et al., 2008) have been 
documented in wild boars sampled from Korea and Japan. However, despite their presumed 
importance as a JEV enzootic host, how JEV impacts feral pigs in terms of clinical signs or 
pathology remains undetermined.   
 
 Arthropod vectors 
The mosquito (Order Diptera, Family Culicidae) plays the critical role of arthropod vector 
in the mode of JEV transmission. Japanese encephalitis virus has been isolated from a variety of 
field-collected specimens of different Culex, Aedes, Anopheles, and Mansonia species as well as 
in midges (Lasiohelea taiwana) and even in ticks (Haemaphysalis japonica) (Le Flohic et al., 
2013; Rosen, 1986). However, not all of them have epidemiological and/or ecological importance. 
For example, the isolation of JEV in these arthropods does not exclude the possibility of detection 
due to recent engorgement of viremic blood. The insect may also not be susceptible to the arboviral 
infection. This susceptibility is necessary for the virus to replicate in the arthropod and disseminate 
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into the salivary glands for eventual transmission of the virus. For the arthropod vector to be of 
importance, it must be a competent vector. By definition, competent vector species must be capable 
of acquiring the virus infection in nature, transmit the infection by feeding on susceptible 
vertebrate hosts, and be abundant enough to be significant (Rosen, 1986). The major vectors that 
fit these criteria include Culex tritaeniorhynchus, Cx. gelidus, Cx. vishnui, and Cx. annulirostris 
(Le Flohic et al., 2013; Rosen, 1986). From this short list, Cx. tritaeniorhynchus is recognized as 
the principal vector of JEV due to its high susceptibility, transmission rate, and wide distribution 
(Clark et al., 2012; Gresser et al., 1958; Rosen, 1986). Culex species mosquitoes generally use 
ground pools, especially flooded rice paddies, for surface egg-laying and larval habitat (Tsai, 
1990). They are most active and feed during the crepuscular periods (Tsai, 1990). They are usually 
primarily exophilic, seeking hosts outdoors, and zoophilic, preferring animals to humans for 
feeding (Tsai, 1990). Of these species, Cx tritaeniorhynchus, in particular, have a predilection to 
feed on pigs, further supporting the role of pigs as important amplifying hosts (Misra and Kalita, 
2010). These behaviors also highlight the importance of Cx. tritaeniorhynchus as primary vectors 
in the enzootic transmission cycle of JEV.  
Virus replication in the arthropod vector is crucial for the maintenance and transmission of 
the arbovirus. The 50% infective dose for Cx tritaeniorhynchus is between 2 to 3 log mouse LD50 
(Hurlbut, 1964) but viremia as low as 1 log mouse LD50 has been documented to be capable of 
infecting a low percentage of feeding mosquitoes (Gould et al., 1964; Sasaki et al., 1982). 
Following a viremic blood meal, the virus titer in the mosquito midgut lumen must be high enough 
to overcome the midgut barrier and immune system, infect the gut epithelial cells, and disseminate 
into the haemocoel (Hardy et al., 1983). The virus then disseminates and infects the salivary glands 
so that it is excreted with salivary components when the mosquito feeds upon the next host (Hardy 
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et al., 1983). An average of 5 log focus-forming units (FFU)/ml of JEV can be detected in the 
saliva of infected Cx. tritaeniorhynchus (Faizah et al., 2021), but the transmitted dose can range 
from 1 to 7 log plaque forming units (PFU) of virus (Schneider and Higgs, 2008). However, 
successful blood feeding is not necessary as mosquito can also transmit virus simply by probing 
(Gresser et al., 1958; Styer et al., 2006). Non-viremic transmission, or non-replicative 
transmission, is also possible in which mosquitoes get infected by feeding nearby an infected 
mosquito on a vertebrate host, whether amplifying or incidental and/or already immune to the virus 
of interest (Higgs et al., 2005; Huang et al., 2019). Additionally, vertical transmission of JEV in 
mosquitoes, either transovarial or at oviposition, has been demonstrated under laboratory 
conditions for several known vectors including Cx. pseudovishui, Cx. tritaeniorhynchus, Cx. 
annulus, Cx. quinquefasciatus, Armigeres subalbatus, Aedes albopictus, and Aedes togoi (Mourya 
et al., 1991; Rosen et al., 1989; Rosen et al., 1978). The real ecological role is unknown. In 
summary, the presence of both competent vectors and amplifying hosts are necessary for the 
enzootic transmission of JEV. The presence of JEV competent mosquitoes in a region is what 
mainly drives disease transmission, but susceptible amplification hosts are necessary to sustain the 
viral cycle.  
 
 Other modes of transmission 
Although JEV is primarily transmitted by bites from infected mosquitoes, mucosal 
transmission could be theoretically possible in humans based on the recent evidence of oral 
shedding of viral RNA in JE patients detected via throat swab sampling (Bharucha et al., 2018). 
Laboratory workers, in particular, are in high occupational risk for mucosal or aerosol exposure of 
high virus concentrations (AJTMH, 1980; Hills et al., 2019). There have been at least 22 
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laboratory-acquired JEV infections reported thus far (AJTMH, 1980; Hills et al., 2019). 
Additionally, there has been documented experimental infections of several mammalian hosts, 
such as macaques, mice, guinea pigs, and pigs, with JEV through the oronasal or intranasal route 
(Fujisaki, 1975; García-Nicolás et al., 2018; García-Nicolás et al., 2017; Li et al., 2012; Myint et 
al., 2014; Ricklin et al., 2016a; Yamada et al., 2009). For example, Ricklin et al. (2016a) 
demonstrated that pigs are highly susceptible to oronasal infection with viral titers as low as 10 
TCID50 and are also susceptible to nose-to-nose contact with infected pigs via viral nasal 
secretions, resulting in systemic infection, oronasal viral shedding, and antibody production 
comparable to needle challenge. In another study, even the empirically-derived live attenuated 
JEV SA14-14-2 vaccine caused systemic infection, oronasal viral shedding, histopathologic 
lesions in the brain and lungs, and antibody response after intranasal inoculation in mice (Chai et 
al., 2019). Additionally, in a recent study by Chai et al. (2019), direct intranasal, contact, and 
aerosol transmissions between infected and naïve mice were also experimentally demonstrated, 
prompting the authors to hypothesize that such potential route of transmission may be possible in 
humans in densely populated endemic regions. Although not as efficacious as the traditional needle 
routes, mice can be immunized orally with live JEV to induce a productive immune response 
(Ramakrishna et al., 1999). A conjunctival route of JEV transmission has recently been 
documented in mice (Sethi et al., 2019).  
These studies further highlight the potential of non-vector transmission in nature and are 
consistent with the observation that mucosal exposure, whether accidental or experimental, can 
lead to systemic infection. Intranasal administration, for example, is considered a delayed form of 
intracranial inoculation for encephalitic viruses and can lead to viral dissemination to the brain via 
the olfactory neurons (Monath et al., 2000). However, a lot of these studies were conducted in 
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research settings. No true clinical cases of vector-free transmission have been reported to date. The 
accumulating body of evidence that JEV can be detected in body fluid samples other than blood 
may also be consequences of the availability of more sensitive methods to detect the presence of 
nucleic acids. Therefore, the epidemiologic importance of mucosal routes of transmission needs 
further investigation. Nonetheless, it is important to be aware of these additional, although 
relatively uncommon, routes of infection to aid in clinical or field diagnosis of JEV disease.  
 
Diagnostic methods 
 Diagnosis in human patients 
Japanese encephalitis diagnosis in infected humans based on patient history and clinical 
symptoms is generally unreliable due to the initial non-specific symptoms and the list of other 
more common differential diagnoses based on locality. In North America, the common differential 
diagnoses for infectious encephalitis in children include herpes simplex virus, enterovirus, human 
parechoviruses, and arboviruses including La Crosse, West Nile, Eastern equine encephalitis, 
Powassan, and St. Louis encephalitis viruses (Messacar et al., 2018). The diagnosis can be further 
complicated by cross-reactivity issues in serology as some of these agents, particularly the 
flaviviruses, are closely related to each other. Therefore, laboratory diagnosis and confirmation are 
ultimately necessary. The test recommended by the World Health Organization (WHO) for JEV 
diagnosis is anti-JEV antibody capture enzyme-linked immunosorbent assay (JEV MAC-ELISA) 
to detect anti-JEV IgM in cerebrospinal fluid or serum samples (Bharucha et al., 2018; World 
Health Organization, 2019). This test is capable of detecting up to 75% of JE-positive patients 
within the first four days after onset of symptoms and almost 100% of JE-positive patients after a 
week of illness (Tsai, 1990). However, it requires trained professionals, appropriate resources, and 
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several hours for results (Bharucha et al., 2018). Four-fold or greater change in antibody titer based 
on hemagglutination inhibition (HI), enzyme-linked immunosorbent assay (ELISA), and/or 
neutralization assays can also be used as confirmatory tests (Tsai, 1990). One of the biggest 
challenges for these serologic tests is to have paired samples. False positive results can also occur 
from cross-reactive heterologous flavivirus infection, but this can be differentiated with further 
testing such as with epitope blocking ELISA (Kitai et al., 2007; Tsai, 1990). Virus isolation on 
cell culture and viral genome detection methods, such as TaqMan one-step quantitative reverse-
transcriptase polymerase chain reaction (RT-qPCR) assay targeting nonstructural protein 5 (Pyke 
et al., 2004; Williams et al., 2001) or the 3′ non-translated region (Yang et al., 2004), could further 
help circumvent the problem of cross-reactive antibodies. However, RNA detection has a short 
window of time in which it can be a useful tool for human diagnosis.  
Currently, most endemic countries conduct some form of national JE surveillance and/or 
perform subnational surveillance in risk areas with sentinel animal monitoring (Heffelfinger et al., 
2017). While JE is reportable to WHO, reporting is highly variable and incomplete due to the 
varying intensity and quality of JE surveillance and the availability of diagnostic laboratory testing 
throughout the world (Campbell et al., 2011). For example, in countries where few or no cases 
have ever been reported prior to 2000, such as Indonesia, Philippines, and Malaysia, hospital-based 
studies revealed JE to be the true etiology in 17% to 50% of hospitalized encephalitis cases, which 
were not reflected in the official notifications (Tsai, 2000). As such, the true global incidence of 
JE may be significantly underestimated and warrants a better reporting system (Campbell et al., 




 Diagnosis in infected swine 
Infection of swine or birds generally follows closely in time with the onset of detectable 
mosquito infection but precedes human infection by several weeks (Buescher et al., 1959; Scherer 
et al., 1959a). Domestic pigs are, thus, considered a good sentinel animal for JEV surveillance. 
Diagnosis of JEV in pigs can be based on virus isolation in the brain post-mortem (i.e. via cell 
culture or intracranial challenge of suckling mice), detection of specific IgM and IgG antibodies 
in cerebrospinal fluid or serum samples via ELISA, and viral RNA detection in a variety of samples 
such as brain, blood, placental tissues, and cerebrospinal fluid (World Organization for Animal 
Health, 2019; Yang, 2019). Other serology-based tests to further confirm exposure or active 
infection include virus neutralization assay, HI test, and complement fixation test (World 
Organization for Animal Health, 2019; Yang, 2019). However, these tests can be hindered by the 
presence of maternal antibodies, which may remain detectable until 6 months of age (Scherer et 
al., 1959b). A less invasive and easier alternate is the rope-based method to collect and sample oral 
fluids from pig pens to detect JEV RNA from the oronasal secretions within 7 days of infection 
(Lyons et al., 2018). However, this method has not been tested in the field yet.  
Accurate diagnostic capability is critical to detect the presence of the virus in a new 
territory, but equally important is to understand and review the currently available arsenal in place 
to combat against this disease in the event of potential virus introduction.  
 
Vaccines 
 Human vaccines 
At present, there are no approved antivirals or specialized therapies available to treat JE. 
With no specific treatments available, the prevention of JE via vaccination is key (World Health 
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Organization, 2019). WHO highly recommends the integration of JE vaccines into the national 
immunization schedules in countries where the disease is a public health priority (Heffelfinger et 
al., 2017; World Health Organization, 2019). There are currently several inactivated and live 
attenuated licensed vaccines available as intramuscular or subcutaneous doses that can provide 
effective means of protection from infection and subsequent disease (Chen et al., 2015; Hills et 
al., 2019). As summarized in Table 1.1, the three types of licensed vaccines available at this time 
are: (1) inactivated Vero cell-derived vaccines, (2) live attenuated vaccine, and (3) live chimeric 
vaccine (Chen et al., 2015; Hegde and Gore, 2017; Hills et al., 2019).  
 
Table 1.1. Currently available human vaccines for JEV.  
Vaccine types Vaccine names (virus strain) Dose regimen 
Inactivated Vero cell-
derived vaccine (JE-VC) 
JEIMMUNUGEN, TC-JEV, or 
JE-BIK-V (Beijing-1) 
Three doses (day 0, 7, and 28) 
at 12-24 months of age; Booster 
after 12-14 months and every 3-
5 years 
IXIARO, JESPECT, or JEEV 
(SA14-14-2) 
Two doses (day 0 and 28) as 
early as 2 months of age; 
Booster after 1 year 
Live attenuated vaccine CDJEVAX (SA14-14-2) Single dose at 8-9 months of 
age; Booster after 3-12 months 
and at 6-7 years of age 
Live chimeric vaccine IMOJEV (ChimeriVax-JE) Single dose with booster after 5 
years for those >18 years old; 
Single dose with booster at 12-
24 months for those between 
ages of 9 months to 18 years 
old 
References: (Chen et al., 2015; Hegde and Gore, 2017) 
 
Although efficacious products, there are some shortcomings and disadvantages depending 
on the type of vaccine. With inactivated JEV vaccines, one of the major problems is the 
requirement of multiple doses and boosters to achieve adequate durable protection, making 
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vaccination programs costly and potentially compromising compliance (Fei-fei et al., 2008; Lin et 
al., 1998; Tsai, 2000). There are also concerns of potential allergic or hypersensitivity reactions to 
certain components of its formulation, such as protamine sulfate, thimerosal, gelatin, and proteins 
of neural origin and/or rodent origin (Chen et al., 2015; Hegde and Gore, 2017; Tsai, 2000). 
Another concern is the induction of an incomplete neutralizing antibody profile due to the 
alteration of antigenicity and immunogenicity of some neutralizing epitopes by formalin 
inactivation (Fan et al., 2015). Although the product is well tolerated, there are still safety concerns 
in their production because they are produced from infectious virulent strains and require the 
appropriate containment facilities that subsequently increase the cost of the product (Imoto et al., 
2010).  
In contrast, live attenuated vaccines can induce strong humoral and cellular immunity by 
mimicking natural infection and are capable of eliciting long protective immunity from a single 
dose (Tsai, 2000; Wang et al., 1999; World Health Organization, 2005; Zheng et al., 2020). 
However, despite the excellent safety record (Hills et al., 2019; World Health Organization, 2005), 
there is an inherent risk of reversion to virulence as an empirically derived strain (Fan et al., 2010; 
Hegde and Gore, 2017; Yang et al., 2014a). For example, serial passage of SA14-14-2 in suckling 
mouse brain resulted in emergence of adaptive mutations and increased virulence in mice (Yang 
et al., 2014a). Potential reversion was also observed in pigs vaccinated with SA14-14-2 in China. 
Isolates from the cerebrospinal fluid of aborted fetuses or stillborn piglets that were randomly 
collected in piggeries in central China were very closely related to the SA14-14-2 vaccine strain 
based on phylogenetic analysis of the E gene and were demonstrated to be fatal to suckling mice 
(Fan et al., 2010; Hegde and Gore, 2017).  
Nonetheless, vaccination has been proven to be the most cost-effective measure to protect 
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people against JEV, significantly reduce JE incidence rates, and decrease the public health burden 
of JE in the endemic countries (Chen et al., 2015; Hills et al., 2019; Tsai, 1990; Tsai, 2000). Before 
the production and widespread use of JE vaccines, more than several million cases of JE were 
reported from East Asia with the highest risk areas having incidence rates as high as 20 cases per 
100,000 children per year prior to the 1970s (Campbell et al., 2011; Gao et al., 2014; Hegde and 
Gore, 2017; Hills et al., 2019; Tsai, 2000). Now, in countries with long-standing and high-quality 
vaccination programs such as Japan, Korea, China, and Taiwan, the annual incidence rates have 
decreased to less than one case per 100,000 children (Campbell et al., 2011; Gao et al., 2014; Hills 
et al., 2019). Economic analysis of Thailand and Shanghai, China demonstrated that the 
implementation of vaccination programs was estimated to save $73,000 U.S. dollars per one 
prevented case in treatment cost, disability care, and future lifetime earnings in Thailand (Chen et 
al., 2015; Siraprapasiri et al., 1997) or up to $500,000 U.S. dollars per 100,000 persons from 
treatment cost of neurologic sequelae from JEV infection in China (Chen et al., 2015; Ding et al., 
2003). A more comprehensive cost-effective analysis of JEV immunization programs for 14 
endemic countries demonstrated that vaccination would result in a decrease of approximately 
190,000 cases, reduction of close to 6,600,000 disability-adjusted life years, and savings of about 
$19 million U.S. dollars in acute case hospitalization costs in a period of 14 years (Hegde and 
Gore, 2017; Suraratdecha et al., 2007).  
With support from the PATH (Program for Appropriate Technology in Health) and Gavi 
Vaccine Alliance international organizations, additional countries, especially those of low-income 
with high burden of JE, have received support for the introduction of JE vaccines and for improved 
surveillance systems (Gavi, 2020; PATH, 2018). Approximately more than 300 million children 
have been successfully vaccinated with the support from PATH, Gavi, and their partners (Gavi, 
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2020; PATH, 2018). It is estimated that between 2000 and 2015, approximately 308,000 JE cases 
were averted due to vaccination globally (Quan et al., 2020). However, an estimate of 68,000 
annual JE cases affecting mainly young children still occur worldwide (Campbell et al., 2011). 
Therefore, the increase of vaccine coverage is still needed to maintain control of this disease. 
Further understanding of JEV and its pathogenesis through animal models or closer mimicry of 
the natural infection process can also help in the development of therapeutics such as antiviral 
drugs.  
 
 Swine vaccines 
Despite the potential for reproductive disease and JEV-infected pigs as a source for 
epizootic spillover, there are currently no licensed JEV vaccines for pigs. There are only regionally 
approved vaccines, including live attenuated at222, ML17, and anyang300 vaccines, that are 
available for local use in Japan, China, and Korea (Fan et al., 2013; Fujisaki, 1975; Lee et al., 
2012; Nah et al., 2015). While not licensed for swine use, the live attenuated SA14-14-2 human 
vaccine is also commonly adopted to immunize swine herds in China at the recommended dose of 
105 PFU with a booster in 3 to 4 weeks (Fei-fei et al., 2008; Wei et al., 2019; Xu et al., 2004). 
However, even though the SA14-14-2 vaccine has an excellent safety record for human use, 
reversion to virulence may be a concern when the vaccine is used in amplifying host like pigs 
because virus isolates closely related to the SA14-14-2 vaccine strain were detected from the 
cerebrospinal fluid of aborted fetuses or stillborn piglets from some vaccinated pigs in China (Fan 
et al., 2010). Additionally, while most of these vaccines are live attenuated vaccines that should 
elicit robust immune response based on their vaccine type, all of them require boosters to elicit 
adequate protection (Nah et al., 2015). Even the locally commercialized formalin-inactivated 
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vaccines also provide inadequate immune response with the addition of boosters (Konishi et al., 
2000). As a result, vaccinating pigs against JEV is hard to practice because of costs associated 
with multiple shots. More research is, therefore, warranted to protect an immunologically naïve 
population of pigs from JEV infection and disease.  
A comprehensive census of pigs between 2007 and 2009 in Bangladesh demonstrated that 
JEV infected about 20% of susceptible pigs annually (Khan et al., 2014). Based on their SEIR 
(Susceptible-Exposed-Infective-Recovered) model, vaccinating almost 50% of pigs each year 
(with assumed 95% vaccine efficacy based on SA14-14-2 efficacy in humans) would result in an 
estimated 82% reduction in annual incidence in pigs (Khan et al., 2014). Even with a vaccine with 
50% efficacy, a significant reduction of 53% in infection incidence of pigs is expected (Khan et 
al., 2014). As such, improvements of the current vaccine platforms and/or development of novel 
vaccine candidates for swine use could still be an effective countermeasure to protect the animals 
from reproductive or neurologic disease that could negatively impact the agricultural industry. 
However, the cost associated with the vaccine and practice may be a big challenge. Recent swine 
vaccine research and development for JEV include the use of DNA vaccines (Imoto et al., 2010; 
Konishi et al., 2000), recombinant pseudorabies virus vector (Xu et al., 2004), lentiviral vector 
(García-Nicolás et al., 2017), and virus-like particles (Fan et al., 2018) to deliver immunogenic 
viral antigens capable of eliciting robust humoral and cellular immune responses. However, none 
have been implemented yet for use as part of a routine swine vaccination program.  
While reduction of JE disease and viremia in swine may be possible through pig 
immunization, it is important to understand that vaccination of domestic pigs cannot be solely 
relied upon to prevent the risk of human JEV infection and disease to the same extent as direct 
human immunization (Tsai, 2000). In addition to the rapid turnover of the pig population, the 
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associated high costs, and the logistics of implementing a new swine vaccination program, 
alternate vertebrate hosts, such as wild feral pigs or birds, can still amplify the virus and maintain 
the transmission cycle in the area (Erlanger et al., 2009; Tsai, 2000). For example, based on 
serological evidence, JEV transmission has continued in Singapore into recent years through the 
local wild boar and migratory bird population despite the abolishment of domestic pig farming in 
the early 1990s (Yap et al., 2019). Since the mosquito biting rate is important in the transmission 
process based on mathematical modeling by Diallo et al. (2018), limiting the potential contact of 
pigs with JEV-infected mosquitoes may be another method in reducing JE transmission intensity 
and JE swine disease within pig populations and, thus, subsequent risk for humans. In Australia, 
the relocation of domestic pigs away from human habitation (approximately 2.5 km for five years) 
was tested to reduce the contact between the amplifying hosts and mosquito vector, but it did not 
eliminate JEV risk to humans based on the positive detection of JEV in the local mosquito 
population (van den Hurk et al., 2008). Movement of domestic pigs of more than 5 km from human 
habitations may be necessary to see any impact because mean flight distance of mosquitoes, such 
as Cx. annulirostris, is approximately 4.4 km (Bryan et al., 1992; Solomon, 2006). Additionally, 
JEV may still circulate within vaccinated or previously exposed pig populations (Fan et al., 2010; 
García-Nicolás et al., 2017; Ladreyt et al., 2019). These findings suggest that swine immunization 
is helpful to reduce disease in the pig population, but its contribution to reducing transmission risk 
to humans may not be significant and is probably relatively minimal. The potential high cost and 





Geographic distribution and molecular epidemiology 
Japanese encephalitis virus is currently endemic to large parts of Asia and the Pacific 
region (Centers for Disease Control and Prevention, 2019; World Health Organization, 2019). The 
large distribution of JEV in Asia covers from southeastern Russia to Japan, Eastern China, 
Southeast Asia, and India (Platt and Joo, 2006), expanding to Pakistan in the 1980s and Northern 
Australia through the Torres Strait in the 1990s (Erlanger et al., 2009; van den Hurk et al., 2019). 
There are two distinct epidemiologic patterns of JE depending on the climate type of the region. 
The temperate zones, such as Korea, Japan, China, and Nepal, usually experience large epidemics 
in the summer months (Erlanger et al., 2009). On the other hand, tropical areas, such as Vietnam, 
Thailand, Malaysia, and Philippines, generally have sporadic cases throughout the year with peak 
transmission during the rainy months (Erlanger et al., 2009). However, further dispersal of JEV is 
likely. In Italy, antibodies against JEV and JEV RNA have been detected in local birds sampled 
from 1996 to 2000 (Preziuso et al., 2018) as well as JEV RNA in field-collected Cx. pipiens 
mosquitoes in 2011 (Ravanini et al., 2012). In addition, the possibility of local transmission of 
JEV in Africa was reported when JEV genome was detected in a human patient who had not 
traveled abroad during the 2016 yellow fever outbreak in Angola (Simon-Loriere et al., 2017). The 
geographic distribution could also potentially change in the future through various forms of 
introductions or dispersal into new regions including through bird and human migrations, 
accidental transportation of vectors, and climate change affecting the distribution of vectors or 
vertebrate hosts (Erlanger et al., 2009). For example, JEV was likely introduced to Northern 
Australia by wind-blown mosquitoes from Papua New Guinea (Erlanger et al., 2009). As such, the 
emergence of JEV in new regions is a constant threat. Upon introduction, the presence of 
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susceptible mammalian or avian hosts and competent vectors in the new regions could establish 
the virus in the location permanently.  
 
 Distribution of genotypes 
At the nucleotide level, divergence of 10% in nucleotide sequences has been used to 
distinguish genotypes of flaviviruses (Beasley et al., 2001). Based on the sequences of the envelope 
gene, JEV is clustered into five genotypes (I, II, III, IV, and V) (Fan et al., 2013). Genotype I is 
further classified into two clades (Ia and Ib) (Schuh et al., 2013). In the order of evolution, 
genotype IV represents the oldest lineage (Solomon et al., 2003). The majority of the natural 
circulating JEV isolates belong to genotypes Ib and III (Solomon et al., 2003). Except for genotype 
IV, all are capable of causing human disease (Pan et al., 2011; Solomon et al., 2003). However, 
there is no clear evidence that there is a clear-cut relationship between genotype and virulence in 
mouse models (Le Flohic et al., 2013).  
The geographic distribution of these genotypes is shown in Figure 1.3. Epidemic outbreaks 
in the temperate zones are usually associated with genotypes Ib and III, whereas genotypes Ia, II, 
and IV are primarily involved with endemic transmission in the tropical regions (Schuh et al., 
2013). Genotype V has recently emerged in 2009 in China and 2010 in South Korea after 
remaining undetected for almost 60 years since its first isolation in 1952 in Malaysia (Li et al., 
2011; Nah et al., 2015; Solomon et al., 2003). Antigenic and genetic variation exists within each 
genotype, but all groups differ from one another by only 10% to 20% in nucleotide sequences and 
2% to 6% in amino acid sequences (Beasley et al., 2004; Burke and Monath, 2001; Nah et al., 
2015). Despite this diversity, JEV only has one serotype due to its limited assortment of amino 




Figure 1.3. Geographic distribution of JEV. 
World geographic distribution of JEV genotypes (I to V) with colors representing endemic 
countries, mostly in Asia, and two countries with recent JEV GIII detection outside its endemic 
areas. https://doi.org/10.1371/journal.pntd.0008986.g001. (Image taken from Faizah et al. (2021); 
Published under the Creative Commons Attribution License). 
 
 
Most human JE outbreaks before the 1970s were associated with genotype III, but a gradual 
increase in the detection of genotype Ib has been documented in the last few decades (Pan et al., 
2011). For example, genotype I replaced genotype III as the dominant lineage in Korea after 
genotype I was introduced in 1993 (Nah et al., 2015). Genotype I viruses were identified in the 
majority of samples collected in Japan after 1994, in Thailand after 2000, and in China after 2001 
(Morita, 2009; Nah et al., 2015; Pan et al., 2011; Yang et al., 2014b). Following the trend, genotype 
I displaced genotype III within a year after being introduced in Taiwan in 2008 (Chen et al., 2011; 
Fan et al., 2013).  
Interestingly, Han et al. (2014) found a correlation in an epidemiology study that most 
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isolates identified as genotype I were collected from mosquitoes and pigs while the majority of 
human cases were associated with genotype III. However, this observation in host preference does 
not mean that people are safer in genotype I dominated regions, because acute encephalitis from 
genotype I has been documented in Japan, India, and China (Pan et al., 2011; Zhang et al., 2011). 
Instead, while there is no apparent difference in virulence between the two genotypes, minor 
genetic mutations may have increased the fitness or replication capacity of genotype I viruses in 
hosts or vectors without altering the pathogenicity or clinical presentation (Nga et al., 2004; Saito 
et al., 2007; Uchil and Satchidanandam, 2001). Efficient transmission from mosquitoes to pigs or 
birds and a more efficient overwintering mechanism, which allows the virus to spread and remain 
year-round in temperate Asia, as additional potential reasons have been proposed (Han et al., 2014; 
Nemeth et al., 2012; Schuh et al., 2013).  
Consequently, several research groups attempted to investigate the possible reasons why 
genotype Ib displaced genotype III and emerged as the new dominant lineage. In one study, while 
genotype Ib and III viruses had similar infection rates and reached comparable replication titers in 
Cx. tritaeniorhynchus mosquitoes after oral infection via infected blood meal, genotype Ib viruses 
generated higher viral titers in cells derived from amplifying hosts than genotype III viruses, 
especially at elevated temperatures (Fan et al., 2019). Inoculation of pigs, ducklings, and young 
chickens were also consistent with this finding and demonstrated that genotype Ib infections 
resulted in earlier and higher viremia when compared to infections by genotype III (Fan et al., 
2019). A separate study also demonstrated that experimental infection of a variety of avian species 
with JEV produced viremia that was relatively higher and of longer duration with genotype Ib 
infection, suggesting another mechanism of why it has replaced genotype III as the dominant 
circulating lineage (Nemeth et al., 2012). Mutations of the viral NS2B/NS3 protease may be 
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responsible for the enhanced infectivity of genotype I (Fan et al., 2019). At the same time, other 
studies have demonstrated no difference between genotype I and III in the magnitude or duration 
of viremia in chicks, young ducklings (Cleton et al., 2014), and pigs (Xiao et al., 2018a). 
Understanding the pathogenesis of JEV may provide additional insight into the major drivers of 
genotype emergence.  
 
Molecular biology and pathogenesis 
 Virus structure and genome 
Japanese encephalitis virus is an enveloped and spherical virus with an icosahedral 
geometry and is approximately 40 nm in diameter, as displayed in Figure 1.4 (Tsai, 1990; Wang 
et al., 2017b). The surface of the virus is covered by 180 heterodimers of envelope (E) and 
membrane (M) glycoproteins lying antiparallel to each other (Wang et al., 2017b). Encapsidated 
under this envelope is a single-stranded, positive-sensed, 11 kb RNA genome flanked by 5′ and 3′ 
untranslated regions in a polyhedral capsid (Li et al., 2017b; Platt and Joo, 2006). As shown in 
Figure 1.5, the genome consists of one single open reading frame that is translated into a single 
polyprotein that is cleaved post-transcriptionally by viral and host enzymes into ten important viral 
proteins. There are three structural proteins (C, prM/M, and E) involved in viral maturation, 
attachment, and entry and seven nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, 
and NS5) that are critical for viral RNA replication, translation, and immune escape (Li et al., 
2017b; Schuh et al., 2013; Yang et al., 2014a). The major functions of each viral protein are 
reviewed in Table 1.2.  
Members of the JE serocomplex express an additional form of NS1 designated as NS1′ 
protein (Rastogi et al., 2016), a -1 programmed ribosomal frameshift product that results in the 
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addition of 52 amino acids to the C-terminus of NS1 (Melian et al., 2010). It is expressed in 
approximately 30% to 50% of translational events (Melian et al., 2014; Melian et al., 2010; Young 
et al., 2015) and likely shares NS1 functions (Satchidanandam et al., 2006; Takamatsu et al., 2014; 
Young et al., 2015) in addition to having unique immune evasive functions (Zhou et al., 2018; 
Zhou et al., 2020). 
 
 
Figure 1.4. Structure of Japanese encephalitis virus. 
Image from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB 
PDB [rcsb.org]) of PDB ID 5WSN (Wang et al., 2017b). Data files contained in the archive are 









Table 1.2. Summary of the major functions of JEV proteins. 
Protein type Viral proteins Major functions References 
Structural 
proteins 
Capsid (C) ▪ Binds with viral RNA to form the 
ribonucleoprotein complex 





▪ Pr peptide prevents premature viral 
fusion by obscuring the fusion loop on 
the E protein of immature virions 
▪ M is a chaperone for the correct folding 
of E protein 
(Carbaugh and 
Lazear, 2020) 
Envelope (E)  ▪ Role in viral attachment, membrane 
fusion, and neuroinvasion 
▪ Domain I – contains the N-terminus 
signal peptide sequence to direct the 
endoplasmic reticulum (ER) membrane 
topology of the flavivirus structural 
polyprotein region; structurally the 
central domain of E protein 
▪ Domain II – contains the dimerization 
domain and hydrophobic fusion loops 
necessary for virus-host membrane 
fusion to release the viral genome into 
the host cytoplasm 
▪ Domain III – mediates virus attachment 




Fan et al., 2012; 
Robbiani et al., 
2017; Wahala 
and Silva, 2011; 







▪ ER-lumen component of the virus 
replication complex 
▪ Frequently used as a diagnostic marker 
of infection due to its highly 
immunogenic and conserved nature 
among flaviviruses 
▪ Triggers endothelial hyperpermeation 
▪ Immune evasive functions: e.g. inhibits 
complement activation, inhibits TLR3, 
and suppresses ROS and JAK-STAT 
pathways in the mosquito midgut 
(Chung et al., 
2006; Liu et al., 
2016; Puerta-
Guardo et al., 
2019; Wang et 
al., 2019; Wilson 
et al., 2008) 
NS1′ ▪ Can substitute NS1 in the virus 
replication complex 
▪ Associated with neuroinvasion and 
neurovirulence in mice 
▪ Immune evasive functions: e.g. 
antagonizes interferon (IFN)-β 
production by targeting MAVS 
(Satchidanandam 
et al., 2006; 
Takamatsu et al., 
2014; Ye et al., 
2012; Young et 
al., 2015; Zhou 
et al., 2018; 
Zhou et al., 
2020) 
NS2A ▪ Transmembrane component of the virus 
replication complex 
(Li et al., 2017b; 
Liu et al., 2006; 
Qiu et al., 2020) 
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 Virus replication 
Upon recognition and attachment of specific receptors, such as heparin sulfate, DC-SIGN 
(dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) or CD29, and 
mannose receptor, on the cell surface, JEV is internalized via clathrin-mediated endocytosis (Das 
▪ Generates virus-induced membranes for 
virus assembly in the ER 
▪ Immune evasive functions: e.g. 
suppresses RNA interference and 
suppresses IFN-β transcription 
NS2B ▪ Transmembrane component of the virus 
replication complex 
▪ Forms the viral protease with NS3 as an 
essential co-factor 
(Lu et al., 2017; 
Shah et al., 
2018) 
NS3 ▪ Cytoplasmic component of the virus 
replication complex 
▪ N-terminal serine protease with NS2B 
▪ C-terminal helicase and nucleoside 5’-
triphosphatase 
(Lu et al., 2017; 
Shah et al., 
2018) 
NS4A ▪ Transmembrane component of the virus 
replication complex 
▪ Remodels ER membranes to create the 
replication site 
▪ Immune evasive functions: e.g. inhibits 
dsRNA-activated protein kinase R 
(Fan et al., 2016; 
Shah et al., 
2018) 
NS4B ▪ Transmembrane component of the virus 
replication complex 
▪ Immune evasive functions: e.g. 
interferes with type I IFN signaling, 
RNAi, formation of stress granules, and 
unfolded protein response 
(Zmurko et al., 
2015) 
NS5 ▪ Cytoplasmic component of the virus 
replication complex 
▪ Largest protein 
▪ RNA methyltransferase and RNA-
dependent RNA polymerase 
▪ Immune evasive functions: e.g. inhibits 
IFN-β-induced apoptosis, suppresses 
type I IFN production, interferes with 
dsRNA-induced nuclear translocation of 
IRF3 and NF-kB, and blocks IFN-
stimulated JAK-STAT signaling 
(Li et al., 2017b; 
Lin et al., 2006; 
Shah et al., 
2018; Weng et 
al., 2018; Ye et 
al., 2017) 
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et al., 2009; Kaufmann and Rossmann, 2011; Zhao et al., 2020). Following endocytosis, the acidic 
environment of the endosome causes conformational changes of the E proteins from dimers to 
trimers, which exposes its hydrophobic fusion loops to initiate the pH-mediated fusion of the viral 
and endosomal membranes (Kaufmann and Rossmann, 2011; Li et al., 2017b; Stiasny and Heinz, 
2006). This results in the release of the viral genome into the cytoplasm, leading to its translation 
into polyproteins that are post-transcriptionally cleaved into the structural and nonstructural viral 
proteins and to initiate the synthesis of viral RNA (Yang et al., 2014a). Virus replication and 
assembly then occurs in the endoplasmic reticulum to produce immature, fusion-incompetent viral 
particles that undergo pH- and furin-dependent maturation during their transit through the 
secretory pathway via the trans-Golgi network to the cell surface (Kaufmann and Rossmann, 
2011). The newly assembled immature virions have a rough spikey surface composed of E trimers 
associated with prM (Wang et al., 2017b). The acidic environment in the trans-Golgi network 
causes conformational changes in the E protein and allows the glycosylated N-terminal pr fragment 
to be cleaved by the cellular endoproteinase furin from the prM protein (Kaufmann and Rossmann, 
2011). The pr fragment remains associated with the virion until they are shed during exocytosis 
and release of the virus, resulting in the membrane-anchored M proteins to reorganize with the E 
proteins into dimers and into their mature infectious metastable structural state (Kaufmann and 
Rossmann, 2011). 
 
 Pathogenesis of JEV in the vertebrate host 
 Human infections 
The primary insult starts with the injection of JEV into the skin through the bite of an 
infected mosquito, infecting a variety of skin-resident cells including keratinocytes, Langerhans 
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cells, stromal cells, dendritic cells, and macrophages (Fong et al., 2018). The local infection then 
triggers the recruitment of additional susceptible immune cells to the site, leading to the migration 
of infected antigen presenting cells, such as Langerhans and dendritic cells, to local draining lymph 
nodes where more susceptible cells are populated (Johnston et al., 2000; Wang et al., 2017a). 
Consequently, the virus infection spreads from the regional lymph nodes through the lymphatics 
to blood, leading to viremia. As a highly neurotropic virus, it ultimately reaches the central nervous 
system after additional nonspecific replication in tissues such as skeletal muscle and liver (Platt 
and Joo, 2006). As such, the permissiveness of myeloid dendritic cells and macrophages to JEV 
infection is closely associated with the degree of neuroinvasion (Wang and Deubel, 2011).  
However, the exact mechanisms of neuroinvasion is unclear. One of the proposed routes 
of neuroinvasion by JEV is the increase of permeability and subsequent breakdown of the blood-
brain barrier by the production of inflammatory cytokines (Mathur et al., 1992; Monath et al., 
1983; Myint et al., 2014; Nagata et al., 2015). Mathur et al. (1992) demonstrated that a JEV-
induced cytokine, splenic macrophage-derived neutrophil chemotactic factor, caused dose-
dependent vascular leakage of the blood-brain barrier, which also correlated to clinical sickness 
and virus titer in the brain, without inducing morphological damage to the endothelium in mice. 
Japanese encephalitis virus could also potentially reach the brain through other routes including 
via blood (Myint et al., 1999; Redant et al., 2020; Yamada et al., 2004), infected endothelial cells 
(Myint et al., 1999), infected lymphocytes (Mathur et al., 1988; Myint et al., 1999; Nagata et al., 
2015; Yamada et al., 2004), transcytosis (Clark et al., 2012; Liou and Hsu, 1998), and retrograde 
axonal transport through the olfactory pathway (Clark et al., 2012; Yamada et al., 2009). 
Ultimately, JEV most likely reaches the central nervous system through a combination of these 
proposed routes, followed by viral dissemination in the brain through the extracellular space and/or 
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by direct intercellular spread (Ayala-Nunez and Gaudin, 2020; Tsai, 1990). 
Once within the brain, JEV causes neuronal cell death via direct killing through viral 
replication and induction of apoptosis in addition to indirect damage by inducing a massive 
inflammatory response (Ghosh and Basu, 2009). Neuronal death then activates microglia and 
astrocytes to release pro-inflammatory cytokines, such as tumor necrosis factor-α, reactive oxygen 
species, and interleukin-6, that causes further tissue damage and promote massive leukocyte 
migration and infiltration into the brain (Ghosh and Basu, 2009; Ghoshal et al., 2007; Myint et al., 
2014). Consequently, more subsequent neuronal death stimulates the inflammatory cycle to 
continue inappropriately (Ghosh and Basu, 2009). Uncontrolled inflammatory cytokine production 
in the brain is a characteristic immunopathology of JE in humans (Ghosh and Basu, 2009). The 
observed persistent neurologic deficits in survivors are most likely consequences of the profound 
destruction of neurons during the acute infection involving virus-induced neuronal death, host 
inflammatory responses, and autoimmunity to previously hidden neural antigens (Clark et al., 
2012; Desai et al., 1994). Neuronal necrosis, vascular disruption, and moderate to severe 
inflammation in the brain, especially in the gray matter, are the most prominent histopathological 
changes (Clark et al., 2012).  
 
 Swine infections 
In contrast to the extensive increase of pro-inflammatory cytokines observed in humans, 
primates, and mice, JEV replication in the brain of pigs is mostly efficiently suppressed, 
predominantly by type I interferon-independent activation of OAS1 (2'-5'-oligoadenylate 
synthetase 1) expression and increased interferon-gamma activity (Redant et al., 2020). In other 
words, the acute inflammatory responses in the brain are differently regulated in humans and pigs. 
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In the study by Redant et al. (2020), no marked increases in mRNA expression of pro- and anti-
inflammatory cytokine genes were detected in JEV-infected porcine brain tissues. Expression 
profiles of interferon-α and -β were also unchanged, but the antiviral OAS1 gene was moderately 
upregulated in the brain tissues of JEV-infected pigs, resulting in the activation of RNase L, which 
has a critical role in the degradation of viral RNA and suppression of viral protein synthesis 
(Redant et al., 2020; Silverman, 2007). This tight regulation or inhibition of the pro-inflammatory 
response may partly explain why JEV infection in pigs is mostly mildly clinical without the 
induction of significant neurological signs (Redant et al., 2020). Additionally, JEV does not induce 
a systemic inflammatory cytokine response in infected pigs, supporting a rapid control of virus 
replication (Ricklin et al., 2016b). Production and levels of inflammatory cytokines, including 
interferon-α, interleukin-1β, tumor necrosis factor-α, and interleukin-6, remained unchanged and 
were indistinguishable between the needle-infected and non-infected control pigs (Ricklin et al., 
2016b). These observations could be partly explained by a study conducted by Espada-Murao and 
Morita (2011) that demonstrated that the cytosolic exposure of double-stranded JEV RNA during 
virus replication was significantly delayed in interferon-competent porcine cells (i.e. porcine 
kidney PS, PK, and ESK cells) compared to primate cells (i.e. rhesus monkey kidney LLC-MK2 
cells), correlating with the delayed detection, delayed interferon response, and subsequent 
enhanced viral dissemination.  
In pigs, the different modes of JEV infection (i.e. needle [intravenous and intradermal] vs. 
oronasal vs. direct contact) result in similar pathologic outcomes and immune responses (Redant 
et al., 2020; Ricklin et al., 2016a). Peak viremia is reached at 2 to 3 days post-infection with 
evidence of viral tissue dissemination and neuroinvasion at that time point (Redant et al., 2020; 
Ricklin et al., 2016a; Ricklin et al., 2016b; Young et al., 2020). Lymphoid tissues typically only 
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demonstrate slight follicular hyperplasia (Ricklin et al., 2016a). In young pigs, central nervous 
system lesions typical of nonsuppurative encephalitis, consisting of perivascular cuffing with 
lymphocytes, multifocal gliosis, and neural degeneration and necrosis are most prominent at 5 
days post-infection (Fujisaki, 1975; Ricklin et al., 2016a; Ricklin et al., 2016b; Yamada et al., 
2009). In pregnant sows, virus can reach the fetus by day 7 post-infection (Platt and Joo, 2006). If 
the sow is infected before 60 to 70 days of gestation, sequential infection of litter similar to porcine 
parvovirus may occur, leading to a mixture of normal, weak, stillborn, and/or mummified fetuses 
of different stages (Platt and Joo, 2006; Shimizu et al., 1954; Sugimori et al., 1975). Stillborn 
piglets commonly demonstrate pathological lesions in the brain such as hydranencephaly, diffuse 
edema, congestion, dilation of ventricular spaces, and neuronal degeneration along with congested 
lymph nodes (Desingu et al., 2016). Subcutaneous edema, hydrothorax, cerebellar hypoplasia, and 
spinal hypomyelinogenesis can also be observed (Burns, 1950; Morimoto, 1969). In addition, viral 
oronasal sheddings capable of infecting immunologically-naïve pigs by direct nose-to-nose contact 
can be detected within the first week post-infection in pigs under laboratory settings (García-
Nicolás et al., 2017; Redant et al., 2020; Ricklin et al., 2016a). The shedding source is most likely 
a combination of virus release from the nasal epithelium (García-Nicolás et al., 2018) and indirect 
reflection of blood as oral mucosal transudate (Thompson and Benjamin, 2019), but not necessarily 
from the tonsil (García-Nicolás et al., 2017). The majority of these pathogenesis studies have been 
performed in Europe or Asia with their local domestic commercial pigs, primarily with genotype 
III, through intravenous challenge, and without the involvement of mosquito saliva, which is an 




 Effect of mosquito saliva in JEV pathogenesis 
Infectious viruses are not the only thing being inoculated into the vertebrate host when an 
infected mosquito feeds on the host. Mosquitoes inject approximately 30% to 40% of their active 
salivary factors or the equivalent of 0.3 to 0.4 salivary gland pairs/ml in the skin during a feed 
(Schneider and Higgs, 2008). Mosquito saliva is a complex concoction of more than 100 proteins, 
majority of which have functions yet to be determined (Thangamani and Wikel, 2009; Vogt et al., 
2018). An estimate of around 140 putative secreted proteins are found in the mosquito saliva that 
could modulate the host immune responses and consequently impact the disease pathogenesis of 
the arbovirus in the vertebrate host (Thangamani and Wikel, 2009). Exogenous microRNAs are 
also secreted in the mosquito saliva that can potentially alter the efficiency of virus replication 
(Maharaj et al., 2015). Based on several mouse studies, it is becoming increasingly recognized that 
mosquito salivary components can antagonize the host antiviral immune response and 
subsequently cause enhancement of virus replication and disease severity. Reported effects of 
mosquito saliva that may facilitate and promote virus replication in the host include induction of 
anti-inflammatory cytokines (Schneider et al., 2004; Vogt et al., 2018), inappropriate polarization 
from a Th1 to Th2 immune response (Schneider et al., 2004; Thangamani et al., 2010), and 
suppression of the host innate immune response (Schneider and Higgs, 2008; Thangamani et al., 
2010). In addition, mosquito salivary components can promote extensive cutaneous edema which 
leads to prolonged retention of virus at the inoculation site (Pingen et al., 2016), enhance 
recruitment of inflammatory cells to the site as additional cellular targets of virus replication 
(Conway et al., 2014b), and disrupt endothelial barriers which may facilitate virus dissemination 
(Fong et al., 2018; Schneider and Higgs, 2008). Altogether, these modulatory effects of the 
mosquito saliva in the host may help explain why enhanced virus replication, dissemination, and 
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clinical disease has been observed in many challenge studies of several arboviruses including La 
Crosse (Osorio et al., 1996), Cache Valley (Edwards et al., 1998), and West Nile viruses (Moser 
et al., 2016; Styer et al., 2006; Styer et al., 2011). Brief summaries of these studies are provided in 
Table 1.3.  
Nevertheless, the significance of mosquitoes on the pathogenesis of arboviruses requires 
further investigation. The reported effects of mosquito saliva through the bites of infected 
mosquitoes and/or its equivalent of co-injecting virus and salivary gland extract has not been 
universal or consistent across all studies. For example, no demonstrable changes were observed in 
the infection or pathology outcomes by mosquito bite infection of chickens with Western equine 
encephalitis (Reisen et al., 2000) or West Nile viruses (Langevin et al., 2001) and of hamsters with 
West Nile virus (Sbrana et al., 2005) compared to virus-only needle inoculations. This raises the 
question of why do not all hosts develop more severe arbovirus infections by administering 
mosquito saliva in these experimental needle challenges? Other important factors may be at play 
which contribute to the overall impact of the mosquito in the pathogenesis of arboviral disease in 
the vertebrate host including the dose ratio of mosquito saliva to virus (Le Coupanec et al., 2013; 
Moser et al., 2016), the age of the susceptible host (Styer et al., 2006), and the source or species 








Table 1.3. Examples of studies demonstrating the enhancement of arbovirus infection and 
disease by the addition of mosquito saliva. 
Virus Results Reference 
La Crosse virus 
(LACV) 
White-tailed deer and chipmunks developed 
higher and longer viremia when infected with 
bites from LACV-infected Aedes triseriatus 
mosquitoes compared to virus-only needle 
challenge 
 
(Osorio et al., 1996) 
Cache Valley virus 
(CVV) 
Outbred ICR mice resistant to virus-only 
needle challenge developed viremia and 
antibody response when CVV was injected 
into feeding sites of non-infected mosquitoes 
(Aedes triseriatus, Aedes aegypti, and Culex 
pipiens) 
 
(Edwards et al., 1998) 
West Nile virus 
(WNV) 
Dose-dependent enhancement of viremia in 
C57BL/6 mice was observed with the number 
of Culex tarsalis mosquitoes spot-feeding at 
the inoculation site or with the amount of 
salivary gland extract administered with the 
needle WNV challenge 
 
(Moser et al., 2016) 
Higher viral titers in serum, oral swabs, and 
cloacal swabs were detected in chicks earlier 
when infected by bites from WNV-infected 
Culex pipiens mosquitoes compared to virus-
only needle challenge  
 
(Styer et al., 2006) 
C57BL/6 mice infected by bites from WNV-
infected Culex tarsalis mosquitoes developed 
higher viremia, higher tissue titers, and faster 
neuroinvasion compared to virus-only needle 
challenge 
 
(Styer et al., 2011) 
 
Studies investigating the impact of mosquito saliva in the disease pathogenesis of JEV has 
been limited. Furthermore, the results that has been published thus far are inconsistent with each 
other. In the mouse study by de Wispelaere et al. (2017), infection dynamics and outcomes were 
indistinguishable when challenge was conducted by virus-only needle inoculation, injection of 
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JEV-infected mosquito saliva, or co-administration of JEV and salivary gland extract collected 
from European populations of Cx. pipiens or Aedes albopictus. However, the population source of 
the mosquito species could be a factor in these observations, because specific mosquito species 
from different geographic locations can be genetically distinct (Fonseca et al., 2004). In contrast, 
2-day-old ducklings infected by bites from JEV-infected Cx. pipiens resulted in 30% mortality rate 
from viral encephalitis by 3 days post-infection and displayed neurologic signs of opistothonos 
(Di et al., 2020), which were not observed with subcutaneous injection challenge of JEV (Xiao et 
al., 2018b). These two model systems established thus far provide inconsistent results. How 
mosquito saliva may truly affect the development of disease in humans or its common immunology 
animal model, the pig, remains undetermined. 
 
 Host adaptive immune response to JEV infection 
Characterizing the host immune response to virus infection provides important information 
on how the virus establishes its infection in the host. Neutralizing antibody response to JEV 
infection can be detected as early as 5 days post-infection in infected pigs (Ricklin et al., 2016b). 
Early and high neutralizing antibody responses may be crucial for preventing viral neuroinvasion 
and host fatality (Wang and Deubel, 2011). Protection by neutralizing antibodies to JEV is well 
established such that neutralizing antibody titers of ≥ 1:10 are accepted as evidence of protection 
and seroconversion (Fujisaki, 1975; Tsai, 1990; Turtle et al., 2016). Cellular immunity to JEV is 
less well studied, but its induction of strong and persistent memory T cell responses is one of the 
important hallmarks for successful vaccination and therefore possibly as protection marker 
(Salerno-Gonçalves and Sztein, 2006). However, no simple correlation of T cell response exists 
for protection against JEV (Robinson and Amara, 2005). Nonetheless, several studies have 
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demonstrated the importance of cell mediated immunity to induce an effective antiviral response 
against JEV infection. For example, many studies have demonstrated that the adaptive transfer of 
JEV-primed T cells was capable of protecting mice from lethal JEV challenge (Larena et al., 2013; 
Mathur et al., 1983; Murali-Krishna et al., 1996; Wang et al., 2020) in addition to mediating cross-
protection against Zika virus challenge better than the passive transfer of JEV immune sera to 
protect against Zika virus (Wang et al., 2020). In clinical cases, the type of CD4+ T cell response 
has been associated with disease outcome of JE patients such that the higher quality and 
polyfunctional cellular responses were closely correlated with complete recovery from JE (Turtle 
et al., 2016). Additionally, interferon-gamma, which is primarily produced by activated T cells, 
has been identified as a critical component in viral clearance and patient recovery by suppressing 
virus replication in the central nervous system (Larena et al., 2013; Zia et al., 2017).  
In summary, the activation of the humoral and cellular immune responses in the infected 
host are necessary to target, neutralize, and eliminate the virus from the body. Although very 
uncommon, JEV can sometimes successfully evade and remain hidden from the host immunity 
and cause persistent infections.  
 
 Persistent infection of JEV 
While JEV infections are primarily described as acute infection and disease, recrudescence 
of symptoms and persistent JE infection can be observed in humans (Tsai, 1990). Persistent and 
latent infections of JEV has been previously reported in several cell cultures such as murine 
neuroblastoma (Chen et al., 1996) and murine microglial cells (Thongtan et al., 2010), mice models 
(Mathur et al., 1982; Mathur et al., 1986a, b; Mathur et al., 1989; Thongtan et al., 2010), and in T-
lymphocytes (Sharma et al., 1991) and nervous system (Ravi et al., 1993) of human patients. 
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Reactivation of JEV has been possible in some of these studies through immunosuppressant drugs 
(Mathur et al., 1986b), pregnancy (Mathur et al., 1982; Mathur et al., 1986a, b), and allogeneic 
(Mathur et al., 1986a) or xenogeneic (Sharma et al., 1991) stimulation.  
Pigs present a good model to investigate persistent JEV infection, especially in immune-
related cell types. Persistence of JEV in tissues long after the acute phase of infection is a recent 
novel observation in pigs (Ricklin et al., 2016a). Persistence of JEV in the tonsil of infected pigs 
have been detected for up to 46 days post-infection based on RT-qPCR, suggesting that the virus 
may somehow be hidden from the host immune response (García-Nicolás et al., 2017). JEV RNA 
was also detectable in the brain at 21 day post-infection after oronasal challenge (Ricklin et al., 
2016a). These findings warrant further investigation to determine if pigs, in addition to being 
efficient amplifiers, can also function as “silent” carriers of JEV, capable of re-shedding and/or 
developing recurrent infections after initial exposure. Such knowledge can help better define the 
roles of pigs as an amplifying host in nature. 
 
Justification for research 
The overarching goal of this dissertation is to determine the susceptibility of North 
American pigs to JEV infection. It is undoubtedly clear that JEV is an important pathogen that 
requires continued studies and further research to control the disease. The potential introduction 
and subsequent outbreaks of JEV in new territories is, thus, a significant concern for both public 
and animal health worldwide. Although JEV is currently only reported to be endemic to the Asia-
Pacific region (World Health Organization, 2019), there is available evidence that highlight the 
possibility of this exotic arbovirus becoming established in North America after a dispersal or 
introduction event.  
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 Competent mosquito species are present in North America 
Based on experimental infections of laboratory colonies with JEV genotype III strain, 
several western North American mosquito species have been identified that are competent 
transmitters of JEV (Reeves and Hammon, 1946). The potential vector species included Cx. 
pipiens, Cx. quinquefasciatus, Cx. tarsalis, Ae. nigromaculis, Ae. dorsalis, Culiseta incidens, and 
Culiseta inornata, most of which are also known vectors of encephalitic arboviruses already 
endemic in the region such as Western equine encephalitis and St. Louis encephalitis viruses 
(Reeves and Hammon, 1946). In a more recent study, susceptibility following oral challenge with 
genotypes I and III viruses was demonstrated for Cx. quinquefasciatus collected from Valdosta, 
Georgia (Huang et al., 2016a; Huang et al., 2015). Transmission of JEV was possible by 14 days 
post-infection based on the detection of viral RNA in the mosquito saliva, suggesting that Cx. 
quinquefasciatus is a competent vector of JEV (Huang et al., 2016a; Huang et al., 2015). These 
mosquitoes are opportunistic blood feeders and can be primarily anthrophilic in urban settings 
(Farajollahi et al., 2011; Lourenço-de-Oliveira et al., 2018), thereby capable of having a role in 
enzootic or epizootic JEV cycles.  
Since evidence suggests that several North American Culex species mosquitoes are 
competent for JEV transmission, their geographic distribution would provide the basis for mapping 
of high risk areas. As shown in Figure 1.6, Cx. pipiens can be primarily found in the urban areas 
in the north, Cx. quinquefasciatus in the sub-urban temperate and tropical regions in the south, and 
Cx. tarsalis in areas west of the east coast (Evans et al., 2017; Farajollahi et al., 2011). 
Additionally, they are the most common mosquitoes in urban areas and altogether cover the entire 
country in geographic distribution (Diaz-Badillo et al., 2011). This could be one of the reasons 
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West Nile virus quickly spread nationwide after its initial introduction in 1999 in New York, 
because these mosquitoes are also considered the primary vectors of WNV in North America 
(Diaz-Badillo et al., 2011). Since West Nile virus is a close relative to JEV with similar enzootic 
cycle characteristics, JEV could potentially exploit the same mechanisms and become established 
in the region.  
 
 
Figure 1.6. Distribution maps of Culex pipiens, Culex quinquefasciatus, and Culex tarsalis in 
the continental U.S. 
(Image modified from (Evans et al., 2017); Published under the Creative Commons Attribution 
License). 
 
 Susceptible North American avian species have been identified 
Hematophagous arthropod vectors are just one component of arboviral transmission cycles. 
Without the presence of amplifying vertebrate hosts, transmission cycles of most arboviruses in a 
region cannot be established. As such, the susceptibility of several species of birds found in North 
America to JEV infection have been determined. Researchers from Colorado demonstrated that 
these birds can develop viremic profiles capable of supporting JEV transmission as amplifying 
hosts (Nemeth et al., 2012). In addition to water-wading birds that JEV is usually closely associated 
with such as egrets, other avian species including rock pidgeons (Columba livia), house finches 
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(Carpodacus mexicanus), and common grackles (Quiscalus quiscula) were capable of developing 
high and prolonged viremia after subcutaneous inoculation with JEV (Nemeth et al., 2012). While 
no clinical disease ever developed, viremia reached approximately as high as 104 TCID50/ml and 
lasted up to 7 days post-infection in some species (Nemeth et al., 2012). This study also helped 
identify the important avian species to focus for optimal JEV surveillance.  
 
 The role of North American domestic and feral pigs in JEV transmission 
Pigs are another important amplifying host of JEV, but it has yet to be investigated whether 
the pig populations from North America are susceptible to JEV and could serve as amplifying 
hosts. This critical but missing knowledge is essential to properly assess the potential for JEV to 
establish local enzootic transmission cycles in North America.  
Although domestic pigs from different regions are still classified under the same scientific 
name Sus scrofa, variation in disease susceptibility based on locality or breed has been observed 
in both experimental and natural conditions. In particular, breed is recognized as an important 
factor that determines resistance or susceptibility in pigs to several viral infections (Blacksell et 
al., 2006; Meng et al., 2018; Mujibi et al., 2018; Opriessnig et al., 2006; Xing et al., 2014). For 
example, the local indigenous pig breeds or those with higher local breed ancestry were associated 
with being more robust against classical swine fever (Blacksell et al., 2006) or African swine fever 
virus (Mujibi et al., 2018) infections. Breed-dependent differences in susceptibility in terms of 
severity of clinical disease have been demonstrated for porcine reproductive and respiratory 
syndrome virus (Meng et al., 2018; Xing et al., 2014) and porcine circovirus type 2 virus infection 
(Opriessnig et al., 2006). Additionally, the same breed category can be genetically different based 
on the place of origin. In a study of pig genetic diversity, Landrace pigs from different countries 
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(Sweden and Germany) formed distinct separate clusters as two different breeds based on a panel 
of microsatellite markers recommended by the Food and Agriculture Organization of the United 
Nations for diversity analysis (Laval et al., 2000). With JEV, breed or strain differences in the 
impact of JE reproductive disease has been suggested in pigs (Lindahl et al., 2012; Sugawara et 
al., 1974) and demonstrated in mice (Fujisaki et al., 1976). These findings suggest that it is 
important to directly assess the susceptibility of animals from specific regions to the virus of 
interest to obtain the most correct information.  
In addition to characterizing the susceptibility profile of the domestic pigs from North 
America to JEV, the potential role of the North American feral swine must also be investigated 
because they are presumed to be important in the endemic areas. Since the first introduction of 
pigs into the United States in the 13th century, subsequent accidental escapes, and deliberate release 
for game (McCann et al., 2018), there is now a significant wild pig population in North America. 
Currently, there is an estimate of over 6 million feral wild pigs roaming in the United States in at 
least 35 states and their overpopulation has created significant cost of approximately $1.5 billion 
U.S. dollars in damages and control measures associated with agriculture, property, and disease 
transmission (Animal and Plant Health Inspection Service, 2020; McCann et al., 2018). Their 
explosive population and distribution continue to expand northward (McCann et al., 2018; Ruiz-
Fons, 2017). Wild swine is still considered Sus scrofa, but it is widely established that they are 
genetically distinct from domestic pigs so how a virus establishes its infection in one or the other 
host cannot be rationally extrapolated. Several different panels of microsatellite markers developed 
to aid in the selection of economically important traits, such as growth rate, fecundity, and disease 
resistance, can be used to distinguish wild boar from domestic pigs (Conyers et al., 2012; Costa et 
al., 2012; Lowden et al., 2002). Although limited, evidence also exists showing that wild pigs can 
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have different susceptibility profiles or disease outcome from viral infections compared to 
domestic pigs. For example, Brugh et al. (1964) demonstrated that wild swine had shorter 
prodromal periods and faster rates to death from classical swine fever virus infection compared to 
domestic pigs. Genetics, parasitic infections, and inoculum dosage versus pig size were identified 
as potential factors that contribute to the observed differences (Brugh et al., 1964). With JEV, it is 
known that feral pigs are susceptible and exposed in nature based on serological data, but their 
infection outcomes including clinical and pathological changes are unknown at this time.  
 
 Hypothesis and specific aims 
Despite the extensive studies on JEV since its initial isolation in 1924 (Erlanger et al., 2009; 
Tsai, 1990), much of its pathogenesis, especially in North American domestic and feral pigs, still 
requires further investigation. The objective of this dissertation was to address this important 
research gap and determine the susceptibility profile and pathogenesis of JEV in North American 
pigs. The central hypothesis for this study is that North American domestic and feral pigs are 
susceptible to JEV and can potentially support its transmission. 
The following three specific aims were pursued to test the central hypothesis:  
Specific aim 1. To determine the susceptibility of North American domestic pigs to 
JEV after intravenous challenge. Three-week-old domestic piglets were intravenously 
challenged with JEV genotype Ib JE-91 strain to characterize their clinical signs, viremia kinetics, 
viral shedding profiles, and other pathological changes. The invasive intravenous challenge route 
was selected to induce the artificial viremia needed for viral tissue dissemination and evaluate if 
pathology or disease will establish in the animal. It was also selected because other JEV challenge 
studies used the similar approach for disease characterization (Ricklin et al., 2016b; Yamada et al., 
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2004). This will allow the comparison of susceptibility and infection outcomes between domestic 
pigs in North America and other regions. Results are reported in Chapter 3 of this dissertation.  
Specific aim 2. To evaluate the effect of mosquito saliva in JEV pathogenesis in North 
American domestic pigs. The natural route of transmission was mimicked more closely via 
intradermal inoculation of JEV supplemented with mosquito salivary gland extract. Three-week-
old domestic piglets were challenge using this established method of inoculation to investigate the 
effects of mosquito saliva in the disease pathogenesis of JEV. Data from this study is presented in 
Chapter 4.  
Specific aim 3. To establish a North American feral swine model for JEV 
pathogenesis. To determine the susceptibility of feral pigs to JEV infection, the Sinclair miniature 
research swine was selected as a feral pig representative of North America. Three-week-old piglets 
from this breed was intradermally challenged with JEV to characterize the pathogenesis and 
compare the infection outcomes to those observed in infected domestic pigs. Chapter 5 contains 
the results of this experiment.  
Together, the findings from these studies will provide a better understanding of how JEV 
behaves in its enzootic hosts – the domestic and feral pigs. The knowledge generated from the 
proposed studies will make a positive impact on public health and the security of U.S. agriculture 
and livestock. The animal models generated through this dissertation work will provide invaluable 
aid in the development and implementation of effective countermeasures against this disease and 








This chapter provides the collective research approaches, technical methods, and materials 
used to conduct the dissertation studies since common methods were used for many of the 
experiments. Details of the publication citation or status of the materials presented in this chapter 
can be found in their respective sections (i.e. Chapters 3, 4, and 5).  
 
Virus and cell lines 
Japanese encephalitis virus strain JE-91, originally isolated in 1991 from mosquitoes 
collected in Korea (Huang et al., 2016a; Schuh et al., 2010), was used as a representative for 
genotype Ib for all virus infections and challenges. The nucleotide and amino acid sequences of 
its envelope protein has been previously determined (GenBank access number: GQ415355). Prior 
to the experiments, the virus was passaged once in African green monkey (Cercopithecus aethiops) 
kidney epithelial Vero76 cells and once in Aedes albopictus C6/36 cells. The virus stock was stored 
at -80 °C until use.  
Both Vero76 and C6/36 cell lines were maintained in Leibovitz (L-15) media 
supplemented with 10% heat-treated fetal bovine serum (FBS), 10% tryptose phosphate broth 
(TPB), 100 U/ml of penicillin, 100 µg/ml of streptomycin, and 2 mM of L-glutamine mixture, as 
previously described (Huang et al., 2016a). Vero76 and C6/36 cells were maintained at 37 °C and 
28 °C, respectively, without CO2. Vero76 cells were primarily used for the titration of virus stock 
or experimental samples and for serology work. C6/36 cells were used for virus propagation.  
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Preparation of mosquito salivary gland extract 
Salivary glands were dissected from a colony of Cx. quinquefasciatus (F>30) originally 
obtained from Vero Beach, FL (Ayers et al., 2018; Huang et al., 2016b). The colony was tested 
negative for known flaviviruses using the pan-flavivirus EMF1-VD8 primer set (Cook et al., 
2018). Seven- to ten-day-old female mosquitoes were surface sterilized with 70% ethanol and 
dissected in phosphate buffer saline (PBS) to obtain their salivary glands. Fifty pairs of salivary 
glands were placed in approximately 1 ml of PBS, sonicated, and centrifuged at 13,000 rpm for 10 
minutes at 4 °C to release proteins and pellet cellular debris (Schneider et al., 2010). To obtain the 
salivary gland extract (SGE), the supernatant was collected and stored at -80 °C until the challenge 
experiment for Aim 2 study.  
 
Animal experiments and study design 
The following experimental procedures and animal use were approved by the Kansas State 
University (K-State) Institutional Animal Care and Use Committee (IACUC). All methods were 
carried out in accordance with the approved protocol and relevant regulations. All animal work 
were conducted in biosafety level 3 agriculture (BSL3-Ag) conditions at the Biosecurity Research 
Institute at K-State, Manhattan, KS. Animals were allowed to acclimate for five days in the BSL3-
Ag housing prior to the start of the experiments.  
 
 Aim 1 research design 
The objective for Aim 1 was to characterize the susceptibility of North American domestic 
pigs through the invasive challenge of intravenous inoculation. Fourteen three-week-old U.S. 
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commercial pigs (white-line crossbreed) were inoculated intravenously via the right jugular vein 
with either 1 ml of JE-91 JEV strain at 107 TCID50/ml (n = 10) or 1 ml of sterile saline (n = 4). 
Challenge and control pigs were kept in separate pens to avoid the non-vector transmission 
described by Ricklin et al. (2016a). To characterize the acute and convalescent stages of infection, 
groups of seven pigs (five infected and two control pigs) were sacrificed at days 3 and 28 post-
infection, respectively. For all studies (Aim 1, 2, and 3), group sizes of n = 5 for the experimental 
group and n = 2 for control group were used based on published JEV vaccine or challenge animal 
studies. In these published studies, each experimental group contained a range of 4 to 8 animals 
and each control group contained 2 to 3 animals at each time point to analyze their cardinal data 
with the appropriate statistical tests (Fan et al., 2018; Fei-fei et al., 2008; Xu et al., 2004; Yamada 
et al., 2004; Yamada et al., 2009; Yang et al., 2014a). Below is Table 2.1 summarizing the 
experimental groups designed for Aim 1.  
 
Table 2.1. Summary of the experimental groups for Aim 1. 
Group Intravenous inoculum Total n Necropsy 
at 3 DPI 
Necropsy 
at 28 DPI 
Mock 1 ml sterile PBS n = 4 n = 2 n = 2 
JEV 1 ml 107 TCID50 JEV JE-91 n = 10 n = 5 n = 5 
DPI = day post-infection. PBS = phosphate buffered saline. JEV = Japanese encephalitis virus.  
 
 Aim 2 research design 
The study for Aim 2 was designed to investigate the impact of mosquito salivary proteins 
on the tropism of JEV and tissue viral loads of experimentally challenged domestic pigs, and of 
disease progression. A different route of infection, the intradermal route, was used to closely mimic 
the natural mosquito route of inoculation. A total of 28 three-week-old white-line crossbreed 
domestic pigs were randomly assigned into four groups (n = 4 or 10), as summarized in Table 2.2. 
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Animals were co-injected with either 100 µl equal volume mixtures of SGE and JEV stock 
containing 107 TCID50 of JE-91 strain (SGE+JEV, n = 10) or 100 µl equal volume mixtures of 
SGE and sterile saline (SGE-only, n = 4). The SGE dose per pig was equivalent to 2.5 salivary 
gland pairs. Other groups of animals were injected with a mixture of 50 µl of sterile saline and 50 
µl of JEV stock (JEV-only, n = 10) or 100 µl of sterile saline only (mock, n = 4) to characterize 
JEV pathological outcomes by needle inoculation. All animals were intradermally inoculated 
through a single injection at the base of the left ear. Prior to the injection, each pig was briefly 
anesthetized with isoflurane gas for about five to ten minutes to minimize distress and increase 
safety during the injection process. The anesthetic depth was accessed by toe pinch and jaw tone. 
All pigs recovered rapidly and uneventfully from the anesthesia.  
The four experimental groups (mock, JEV-only, SGE-only, and SGE+JEV) were housed 
in separate pens. Half of the animals in each treatment group (totaling 14 animals) were sacrificed 
at 3 days or 28 days post-infection for the investigation of tissue tropism and viral loads during the 
acute and convalescent phases of JEV infection, respectively. 
 
Table 2.2. Summary of the experimental groups for Aim 2. 
Group Intradermal inoculum Total n Necropsy 
at 3 DPI 
Necropsy 
at 28 DPI 
Mock 100 µl sterile PBS n = 4 n = 2 n = 2 
JEV-only 50 µl sterile PBS + 50 µl 107 TCID50 JEV 
JE-91 
n = 10 n = 5 n = 5 
SGE-only 50 µl SGE + 50 µl sterile PBS n = 4 n = 2 n = 2 
SGE+JEV 50 µl SGE + 50 µl 107 TCID50 JEV JE-91 n = 10 n = 5 n = 5 
DPI = day post-infection. PBS = phosphate buffered saline. JEV = Japanese encephalitis virus. 
SGE = salivary gland extract.  
 
 Aim 3 research design 
Aim 3 was conducted to establish a feral pig model for JEV. The Sinclair miniature 
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research swine was selected as the feral pig representative because they are an established research 
colony bred to have feral genetics background (Schook and Tumbleson, 1996). Originally known 
as the Minnesota or Hormel miniature pig, the Sinclair miniature pig was developed at the Hormel 
Institute of the University of Minnesota in the 1950s (Schook and Tumbleson, 1996). It is derived 
from breeding four feral strains (Guinea hog from Alabama, wild boar from Catalina Island, Piney 
Wood pig from Louisiana, and dwarf Ras-n-Lansa pig from Guam in the Mariana Islands) 
crossbred with the domestic Yorkshire pig (McAnulty et al., 2011). As summarized in Table 2.3, 
a total of 14 three-week-old Sinclair miniature pigs were randomly allocated into two experimental 
groups to be intradermally inoculated at the base of the left ear with the following: 100 µl sterile 
saline (mock group, n = 4) or 100 µl of 107 TCID50 of JEV JE-91 (JEV group, n = 10). Similar to 
Aim 2 study, all pigs were briefly placed under general anesthesia using isoflurane gas for the 
needle injections. The two groups were housed in separate pens for the duration of study. To 
characterize the acute and convalescent stages of infection, groups of seven pigs (five infected and 
two control pigs) were sacrificed at days 3 and 28 post-infection, respectively. 
 
Table 2.3. Summary of the experimental groups for Aim 3. 
Group Intradermal inoculum Total n Necropsy 
at 3 DPI 
Necropsy 
at 28 DPI 
Mock 100 µl sterile PBS n = 4 n = 2 n = 2 
JEV 100 µl 107 TCID50 JEV JE-91 n = 10 n = 5 n = 5 
DPI = day post-infection. PBS = phosphate buffered saline. JEV = Japanese encephalitis virus. 
 
 Sample collection and preparation 
For the duration of the studies, all animals were monitored daily for any clinical signs, 
including fever (≥ 40 °C), depression, diarrhea, weight loss, gait abnormalities, and neurological 
signs. Serum and nasal swab samples were collected to characterize the kinetics of viremia and 
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nasal shedding, respectively. For Aim 1, whole blood samples were collected via the right external 
jugular vein at 0, 3, 5, 7, 14, 21, and 28 days post-infection. While more blood collection time 
points would have provided a better insight into the early stages of viremia (i.e. days 0 to 7 post-
infection), IACUC only approved limited time points for blood collection for this study. For Aims 
2 and 3, blood samples were approved to be collected daily until 7 days post-infection and then 
weekly until 28 days post-infection. Collected blood volumes did not exceed 1% of total blood 
volume of each animal due to the frequent sampling schedule. Serum samples were then obtained 
through the centrifugation of coagulated blood at 2,000 × g for 10 minutes at 4 °C and stored in -
80 °C for later analysis. To characterize viral nasal shedding, individual nasal swab samples were 
obtained daily from 0 to 28 days post-infection from alternating nares using sterile cotton swabs 
and stored in 1 ml of L-15 media. They were then vortexed briefly for two to three seconds, and 
the swab was removed prior to centrifugation at 10,000 x g for 10 minutes. The supernatant was 
collected and stored in -80 °C for downstream analysis.  
At termination days, the pigs were first sedated by intramuscular injection of 10 to 
20 mg/kg of ketamine and 2 to 3 mg/kg of xylazine, and then euthanized with intravenous injection 
of 390 mg/ml of sodium pentobarbital via the external jugular vein. At necropsy, approximately 
5 mm3 blocks of the following tissues were collected in individual 2 mL Eppendorf tube containing 
1 ml of L-15 media and a single stainless-steel homogenizing bead to characterize the viral 
dissemination and tissue tropism of JEV: specific regions of the brain (including olfactory bulb, 
olfactory peduncle, piriform cortex, midbrain, pons, medulla oblongata, cerebellum, thalamus, 
frontal lobe, parietal lobe, temporal lobe, occipital lobe, and caudate nucleus), spinal cord 
(lumbosacral region), sciatic nerve, facial nerve, olfactory neuroepithelium, nasal turbinates or 
epithelium, thymus, tonsil, spleen, lymph nodes (medial retropharyngeal, submandibular, 
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mesenteric, and/or medial iliac), Peyer’s patches (small intestine), and additional tissues such as 
trachea, kidney, and lung. All tissue samples were stored at -80 °C prior to further processing for 
analyses. Prior to virus titration or RNA detection, the tubes containing the tissue samples were 
thawed briefly in 37 °C water bath, weighed individually, and homogenized using the TissueLyser 
II system (Qiagen) at 26 Hz for four minutes. They were then centrifuged at 10,000 x g for 10 
minutes to collect the supernatant for immediate analysis.  
 
Detection of infectious viruses 
 End-point dilution assay 
Infectious virus titers of the stocks were determined via median tissue culture infectious 
dose (TCID50) method with Vero76 cells maintained in L-15 media, as previously described 
(Higgs et al., 2006; Reed and Muench, 1938). The samples were first thawed in 37 °C water bath 
and maintained on ice. Briefly, 100 µl of each sample was loaded in duplicates in the first column 
of a 96-well plate and titrated in serial 10-fold dilution in L-15 media across the plate. A set of 
negative control (sterile L-15 media) and positive control (JEV stock with known viral titer) were 
included in each assay. The loaded plates were then kept on ice prior to the addition of cells. 
Confluent Vero76 cell culture flasks were rinsed with Mg2+/Ca2+ free Dulbecco’s phosphate buffer 
saline (DPBS), and the cells were removed with 0.25% trypsin-EDTA at 37 °C. The Vero76 cells 
were then resuspended with L-15 media with volume adjusted accordingly to the size of cell 
culture flask (i.e. volume of approximately 35 ml for a confluent T75 flask) and each well in the 
loaded 96-well plate received 100 µl of the cell culture fluid. The plates were sealed with parafilm 
and stored in a secondary container at 37 °C.  
After seven days of incubation, the medium was removed from each plate. Each well was 
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fixed and stained overnight with 200 µl of cell staining dye composed of deionized water with 
10% acetic acid, 25% isopropanol, and 0.1% amino black B10 stain. Lastly, the excess dye was 
removed and the plates were gently washed to record the titer values as TCID50/ml based on the 
Reed-Muench method (Reed and Muench, 1938).  
 
 Plaque assay 
To avoid the interference of detection created by the cytotoxicity of serum and 
homogenized tissues, plaque assay using Vero76 cells was performed to detect infectious viruses 
in the serum, nasal swab, and homogenized tissue samples, as previously described (Baer and 
Kehn-Hall, 2014; Nuckols et al., 2015). Briefly, 24-well plates were seeded with Vero76 cells 
using confluent cell culture flasks and left undisturbed at 37 °C for at least five hours to allow the 
cells to adhere to the bottom of the wells. The samples were briefly thawed in 37 °C water bath, 
serially diluted 10-fold with L-15 media three times to 10-3 dilution, and maintained on ice. Media 
was removed from each well of the 24-well plate containing the cells and 50 µl of the sample 
(undiluted, 10-1, 10-2, and 10-3 dilutions) was added per well in duplicates. A set of negative control 
(sterile L-15 media) and positive control (JEV stock with known viral titer) were included in each 
assay. The inocula adsorbed at 37 °C for 45 minutes with gentle agitation of the plate every 10 to 
15 minutes. After the adsorption period, the inoculum was removed and the wells were rinsed with 
500 µl of DPBS/well prior to adding 1 ml of 1.5% methyl cellulose overlay per well. The plates 
were sealed with parafilm and left to incubate at 37 °C.  
The 1.5% methyl cellulose overlay was prepared by autoclaving a 500 ml round media 
bottle in liquid setting containing the following: 7 to 8 g of methyl cellulose, 280 ml of molecular 
biology grade sterile water, and a magnetic stir bar. After completion, 50 ml of chilled TPB, 250 
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ml of chilled 2x L-15 media, 30 ml of FBS, and 10 ml of antibiotics and L-glutamine mixture (100 
U/ml penicillin, 100 µg/ml of streptomycin, and 2 mM of L-glutamine) were added to the bottle. 
Using a magnetic stirrer, it was left to spin for 10 hours or more until the media became uniformly 
viscous. The overlay was then stored in 4 °C and tested for sterility at 37 °C prior to use.  
After five days of incubating the loaded 24-well plates, each well was fixed with 1 ml of 
10% formalin solution (formaldehyde diluted in PBS) for 30 minutes. The overlay and fixative 
mixture were removed, and each well was stained for at least five minutes with 1% crystal violet 
solution (composed of deionized water with 0.5% crystal violet powder and 50% methanol). After 
gently washing the plates, the plaques were counted and the titers of infectious viruses were 
calculated in plaque forming units (PFU)/ml or PFU/g, as shown in Figure 2.1.  
 
 
Figure 2.1. Formulas used to calculate the viral titer in PFU/ml or PFU/g. 
PFU = plaque forming units.  
 
 
Detection of viral genome 
The presence of JEV was further confirmed and detected by a more sensitive method of 
RT-qPCR. It was also important to verify the identity of the viral plaques because the animals were 
not specific-pathogen-free of other virus infections. Genome equivalents of JEV in serum, nasal 
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swabs suspensions, and homogenized tissues were determined using a previously published 
TaqMan one-step RT-qPCR assay targeting the genomic fragment encoding the nonstructural 
protein 5 (Pyke et al., 2004). Viral RNA was first extracted from the serum and nasal swab 
suspension using the QIAamp viral RNA extraction kit (Qiagen). Total RNA was extracted from 
the homogenized tissue samples with Trizol LS (Invitrogen) following the manufacturer’s 
instructions.  
For each sample reaction, the iTaq Universal Probe One-step kit (Bio-Rad) was used to 
prepare 20 µl total reaction mixture containing the following: 10 µl of 2x iTaq Universal Probes 
one-step reaction mix, 0.5 µl of iScript Reverse Transcriptase, 10 pmol (1 µl of 10 µM) of forward 
primer (5′ATCTGGTGYGGYAGTCTCA3′), 10 pmol (1 µl of 10 µM) of reverse primer 
(5′CGCGTAGATGTTCTCAGCCC3′), 4 pmol (0.4 µl of 10 µM) of 5′ 6-carboxyfluorescein 
(FAM)-labeled probe with internal ZEN and 3′ tetramethylrhodamine quencher (5′FAM-
GGAACGCGATCCAGGGCAA-IABkFQ3′), 3.1 µl of molecular grade water, and 4 µl of RNA 
sample. Reactions were performed on the CFX96 Real-Time PCR Detection System (Bio-Rad) 
with the cycling parameters described by Pyke et al. (2004), as shown in Table 2.4. 
 
Table 2.4. Cycling parameter for the selected RT-qPCR assay, as established by Pyke et al. 
(2004). 
Step Temperature and time setting 
1 50 °C for 30 minutes 
2 95 °C for 3 minutes 
3 95 °C for 15 seconds 
4 48 °C for 3 minutes 
5 Repeat cycling 44 times between Step 3 
and Step 4 
 
For each reaction, a standard curve was generated by 10-fold serial dilution of RNA extract 
derived from a JEV stock of known titer at 8.52 log10TCID50/ml (Figure 2.2). A negative blank 
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control was included for each reaction. Results were reported as genome equivalent to 
log10TCID50/ml (geq-TCID50/ml) or log10TCID50/g (geq-TCID50/g). Samples were considered 
positive when the Ct value was lower than 34. 
 
 
Figure 2.2. Sample output of standard curve generated per each reaction. 
 
Plaque reduction neutralization test 
To determine the neutralizing antibody titers, plaque reduction neutralizing tests (PRNT) 
were performed following the procedures described by Roehrig et al. (2008). All serum samples 
were first heat inactivated at 56 °C for 30 minutes and then serially diluted 2-fold starting at 1:10 
to 1:640 dilutions in deep 96-well plates. Approximately 75 PFU of JEV JE-91 strain was added 
to each serum concentration and incubated for 1 hour at 37 °C prior to infection of Vero76 cells in 
six-well plates. Media was removed from the 6-well plates containing the cells and 200 µl of each 
serum-virus mixture was added per well in duplicates. A set of negative control (sterile L-15 
media) and virus only control was included in each assay. The adsorption process and the rest of 
the procedure for PRNT followed the same protocol described for the plaque assay. After an 
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adsorption period of 45 minutes at 37 °C, the wells were gently washed with DPBS and overlaid 
with 1% methyl cellulose. The plates were then sealed with parafilm and stored at 37 °C. 
After five days of incubation, the wells were fixed with 10% formalin solution and then 
stained with 1% crystal violet stain. The plaques were counted and the neutralizing antibody titers 
were calculated based on a 50% or greater reduction in plaque counts (PRNT50). 
 
Statistical analyses 
The SAS software (version 9.4, SAS Institute, Cary, NC) and SPSS Statistics software 
(IBM) were used for all statistical analyses. The R software (versions 3.4.1 to 4.1.0, The R 
Foundation) was used for data graphical display. All statistical analyses were performed on raw 
data. Shapiro-Wilk test was used to test the normality of raw and log-transformed data. Viral loads 
in tissue samples collected from the experimental groups were evaluated by nonparametric 
Kruskal-Wallis tests with post hoc Dunn’s multiple pairwise comparison test adjusted with 
Bonferroni correction (Dunn-Bonferroni test) and post hoc Mann-Whitney U tests. Owning to the 
violation of normality assumption and considering time as a factor, nonparametric Kruskal-Wallis 
tests and post hoc Dunn-Bonferroni tests were performed to compare temperature, viremia levels, 
and nasal shedding levels between the groups when appropriate. Mann-Whitney U tests were used 
to compare antibody titers and onset of ataxia between two virus-challenged groups when 
applicable. For the differences in the duration of nasal shedding between virus-challenged groups, 
Student’s t-test was used for such an evaluation. Fisher’s exact tests were used to analyze the 
difference in fever, nasal shedding, and ataxia incidence between the virus-challenged groups 
when appropriate.  
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Chapter 3 - Susceptibility of North American domestic pig to JEV 
infection via intravenous challenge 
 
 
The objective of Aim 1 was to determine the susceptibility of North American domestic 
pigs to JEV through the invasive challenge of intravenous inoculation to test the working 
hypothesis that North American domestic pigs are susceptible to JEV infection. The intravenous 
route was selected because it is an efficient delivery method of introducing the pathogen into the 
animal to induce viremia and observe if pathology or disease can be established. The work 
displayed here in this chapter has been published by Springer Nature in Scientific Reports journal, 
available online at https://doi.org/10.1038/s41598-018-26208-8. All manuscript sections have 
been altered from when it was originally published and has not undergone peer-review. 
 
Published in Scientific Reports 
Park, S.L., Huang, Y.-J.S., Lyons, A.C., Ayers, V.B., Hettenbach, S.M., McVey, D.S., Burton, 
K.R., Higgs, S., Vanlandingham, D.L. 2018. North American domestic pigs are susceptible to 





Previous studies have identified competent mosquitoes and susceptible avian species in 
North America that can sustain the enzootic transmission of JEV, designating the pathogen as a 
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significant health threat (Huang et al., 2016a; Huang et al., 2015; Nemeth et al., 2012). Despite the 
significant role that pigs play in JEV-endemic regions as efficient amplifying hosts (Platt and Joo, 
2006; van den Hurk et al., 2009), the susceptibility of North American swine to JEV infection and 
its disease outcomes remains largely unknown. At the time when these dissertation studies were 
conducted starting in 2016, several pathogenesis studies have been performed with pigs derived 
from endemic regions, as summarized in Table 3.1. However, the results from these JEV challenge 
experiments cannot be extrapolated to directly demonstrate the degree of susceptibility to JEV 
among the domestic pigs in North America used for swine and pork production. This is mainly 
because disease resistance or susceptibility can vary based on the breed or population locality of 
the animals, which has been demonstrated in pigs for several viral infections (Blacksell et al., 2006; 
Meng et al., 2018; Mujibi et al., 2018; Opriessnig et al., 2006). Additionally, the majority of the 
published studies were performed with JEV strain belonging to genotype III, which was previously 
dominant in the endemic region but has been displaced by the rapidly emerging strains under the 
clade b of genotype I (Desingu et al., 2016; Ilkal et al., 1994; Pan et al., 2011; Williams et al., 
2001; Yamada et al., 2004). Such a gap of knowledge precludes the comprehensive assessment 
needed to estimate the risk and develop effective countermeasures against the potential emergence 








Table 3.1. Examples of previous JEV challenge studies of pigs. 






day 36 to 97) 
Yorkshire hybrid 
pigs (groups of n = 
1) 
IV with 106 to 109 
mouse LD50 of JEV 
Fuji or Kanagawa 
strains (GIII) 
• JEV is a causative agent of 
reproductive failure 
(stillbirths) in infected 
pregnant swine 
(Shimizu et al., 
1954) 
10- to 20-day-old 
piglets of local 
breed from India 
(groups of n = 3-4) 
SQ with 104 to 105 
mouse LD50 JEV 




• WNV infection provided 
partial cross-reactive 
immunity in pigs against 
JEV 




pigs (groups of n = 
3) 




• Cross-reactive immunity 
against MVEV and KUNV 
was demonstrated in pigs 
after JEV infection 
(Williams et al., 
2001) 
3-week-old SPF 
piglets (groups of n 
= 1-3) 
IV with ~106 TCID50 
JEV IB 2001 or AS-6 
strains (genotype 
undetermined) 
• JEV-induced encephalitis in 
pigs was characterized 
• Immunohistochemical 
distribution of viral antigens 
of JEV and the 
neurotropism of JEV were 
demonstrated in JEV-
infected pigs 
(Yamada et al., 
2004) 
7-week-old Swiss 
Large white pigs 
(groups of n = 2-3) 
ID/IV with 106 to 107 
TCID50 JEV 
Nakayama strain 
(GIII); Oronasal with 
103 to 107 TCID50 
Nakayama; ID or IV 
with 106 TCID50 JEV 
Laos strain (GI) 
• Vector-free transmission of 
JEV was demonstrated 
experimentally in pigs  
• Similar pathogenesis can be 
observed regardless of the 
different modes of infection 
and JEV genotype 
(Ricklin et al., 
2016a) 
7-week-old Swiss 
Large white pigs 
(groups of n = 3) 
ID/IV with ~107 
TCID50 Nakayama 
strain (GIII) 
• The tissue dissemination 
pattern of JEV in pigs was 
determined 
• JEV has tropism for both 
CNS and lymphoid tissues 
in pigs 
 
(Ricklin et al., 
2016b) 
IV = intravenous. ID = intradermal. SQ = subcutaneous. JEV = Japanese encephalitis virus. MVEV 
= Murray Valley encephalitis virus. KUNV = Kunjin virus. G = genotype. DPI = days post-
infection. SPF = specific pathogen free. CNS = central nervous system.  
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The first step in addressing this research gap was to conduct a challenge study using the 
intravenous challenge. In this study, the common North American white-line crossbreed of 
domestic pigs were intravenously inoculated with a representative strain for genotype Ib to 
determine their susceptibility to the newly emerging genotype of JEV. Fourteen three-week-old 
piglets were inoculated with JE-91 (JEV genotype Ib strain) at approximately 107 TCID50 (n = 10) 
or sterile saline (n = 4) and euthanized at day 3 or 28 post-infection to characterize the acute and 
convalescent phases of infection, as illustrated in Figure 3.1. The intravenous challenge route and 
dose were selected because of the pathological findings described in other experiments utilized the 
similar approach, as detailed in Table 3.1. This will allow the comparison of susceptibility and 
infection outcomes between domestic pigs in North America and other regions. Most importantly, 
the intravenous route was chosen as it is an efficient and invasive route of injection to introduce 
the pathogen to the animal and observe if pathology, disease, and/or clinical signs will develop. 
The direct delivery of the infectious viruses into blood will induce viremia needed to support the 
hematogenous route of viral dissemination and help determine if infection and disease can be 
established. Data from this study will serve as preliminary findings to support the future 
experiments using routes of experimental challenge that resemble natural infections. 
Pathogenic outcomes and tissue tropism were characterized by detection of infectious 
viruses and viral genomes. Challenged animals developed detectable levels of viremia, systemic 
spread through lymphoid tissues, oronasal shedding, neuroinvasion, and viral persistence in the 
tonsils, suggesting that North American pigs are susceptible to JEV and are capable of sustaining 




Figure 3.1. Schematic diagram of Aim 1 experimental design. 
DPI = day post-infection. JEV = Japanese encephalitis virus.  
 
Results 
 Clinical outcomes and viremic profiles of JEV-infected pigs 
The animals were healthy and seronegative to JEV prior to the experimental challenge. 
Fever, weight loss, depression, lethargy, and hind limb ataxia were observed in JEV-infected pigs 
after inoculation, but most clinical signs resolved within one week. All JEV challenged pigs (n = 
10) demonstrated nonspecific clinical signs, with three exhibiting mild hind limb ataxia and gait 
abnormalities. High fevers up to 41 °C were observed in infected pigs as early as day 1 post-
infection and lasted four to five days before temperatures decreased to within normal limits 
(<40 °C). Although not statistically significant, minor weight loss was recorded in 50% (5/10; 
Mann-Whitney U test, p = 0.454) of infected pigs between 1 and 2 days post-infection and in all 
infected pigs (10/10; Mann-Whitney U test, p = 0.635) between 3 and 4 days post-infection. 
Challenged pigs also exhibited depression and lethargy since day 1 after challenge. While all 
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returned to bright, alert, and responsive states after day 5 post-infection, one pig continued to be 
slightly depressed until 13 days post-infection. The same animal also developed a second fever 
peak of 40.4 °C on day 8 post-infection that resolved in three days. Mild ataxia in the rear legs was 
then subsequently observed between 10 to 13 days post-infection. Two other infected pigs also 
exhibited gait abnormalities of the rear legs on day 19 post-infection that resolved by day 27 post-
infection.  
Viremia was detected in all of the infected animals tested. Figure 3.2 summarizes the viral 
titers of serum samples collected at day 3 post challenge. Serum samples from two infected pigs 
showed detectable levels of infectious viruses by plaque assay, reaching up to 2.0x101 PFU/ml 
(Figure 3.2a). The presence of JEV was further confirmed and detected by RT-qPCR. It was also 
important to verify the identity of the viral plaques because the pigs in this study were not specific-
pathogen-free of other virus infections. Results from RT-qPCR demonstrated that at least eight 
animals developed viremia at day 3 post-infection with viral RNA loads ranging between 1.34x102 
and 4.2x103 geq-TCID50/ml (Figure 3.2b). Serum viral load of 6.07 geq-TCID50/ml was detected 
in one challenged animal at day 5 post-infection. These results suggest that clearance of viremia 
in domestic pigs can take place as early as three days after intravenous challenge. The recovery 
from the acute phase of infection was also demonstrated as all animals developed neutralizing 




Figure 3.2. Viremia at day 3 post-infection. 
Viral titers of serum collected at day 3 following JEV challenge quantified by plaque assay (a) and 
RT-qPCR (b). PFU = plaque forming units. DPI = day post-infection.  
 
 
 Viral shedding in nasal secretions 
To characterize the nasal shedding dynamics of JEV in pigs, secretions from the nose were 
collected daily from alternating nares for virus titration. Infectious virus was detected in the nasal 
swab samples by day 2 post-infection for up to five days, as shown in Figure 3.3a. Up to 90% 
(9/10) of the infected pigs were actively shedding infectious virus at various time points for a 
period of one to five days. At 3 days post-infection, the highest infectious titer was observed at 
4.8x102 PFU/ml. About 60% (3/5) of infected pigs continued to shed viruses to day 4 post-
infection. Shedding of infectious virus persisted for up to six days in an infected pig. By 7 days 
post-infection, no nasal swabs were positive for JEV.   
Similar shedding kinetics were observed via RT-qPCR, as summarized in Figure 3.3b. 
JEV shedding was detectable at day 2 post-infection, at average titers of 1.6x101 geq-TCID50/ml. 
At day 3 post-infection, 80% (8/10) of the challenged pigs shed between 5.62 and 8.18x102 geq-
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TCID50/ml. A peak titer of 4.76x10
4 geq-TCID50/ml was detected at 4 days post-infection. While 
most challenged animals stopped shedding after day 6 post-infection, viral shedding of up to 
1.4x101 geq-TCID50/ml was detectable from one animal up to 10 days post-infection.  
 
 
Figure 3.3. Kinetics of viral nasal shedding after intravenous JEV challenge. 
Nasal shedding of JEV by experimentally infected pigs quantified by plaque assay (a) and RT-
qPCR (b). PFU = plaque forming units. DPI = day post-infection. Geq-TCID50 = genome 
equivalent-50% tissue culture infectious dose. Bar lines indicate the mean of the values collected 
from the challenged animals. 
 
 Dissemination of JEV at the acute phase of infection 
The dissemination of JEV at the acute phase of infection were determined by the titration 
of tissue samples harvested at day 3 post-infection. The presence of infectious virus in the central 
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nervous system (CNS) and peripheral nervous tissues demonstrated that infection of JEV can lead 
to neuroinvasion among North American domestic pigs. As shown in Figure 3.4a, infectious virus 
was recovered from six nervous tissue samples (facial nerve, olfactory bulb, olfactory 
neuroepithlium, optic nerve, piriform cortex, and thalamus) with titers ranging from 5.0x101 
PFU/g to 1.9x102 PFU/g. Infectious virus was present in the olfactory neuroepithelium of 60% 
(3/5) of infected pigs, reaching titers up to 2.1x103 PFU/g but not statistically significantly higher 
(Dunn-Bonferroni test, p ≥ 0.999) compared to other positive neural tissues.  
As summarized in Figure 3.4b, infectious virus was also detected in the lymphatic system 
of challenged animals, indicating the systemic spread of JEV at the acute phase of infection. 
Mesenteric lymph nodes and spleen of all challenged animals were positive for infectious viruses 
at average titers of 3.1x103 PFU/g and 9.0x102 PFU/g, respectively. Mesenteric lymph nodes had 
significantly higher viral titers (Dunn-Bonferroni test, p = 0.005) than most other positive neural 
tissues. The presence of infectious virus was also observed in the tonsil of one animal at the titer 
of 7.3x103 PFU/g. Dissemination of JEV was observed in other tissues including the trachea, lungs, 
and kidneys (Figure 3.4c). Out of the positive peripheral tissues, nasal epithelium had a 
particularly high mean infectious viral titer of 7.53x102 PFU/g, with a peak of 2.6x103 PFU/g in 
one challenged pig but the infectious titers of the nasal epithelium were not statistically significant 
(Dunn-Bonferroni test, p ≥ 0.999). Other CNS, lymphoid, and visceral tissues including different 
regions of the cerebral cortex, brainstem, cerebellum, spinal cord, Peyer’s patches, liver, skeletal 
muscle, and reproductive tract, did not contain detectable amounts of infectious viruses.  
The systemic infection and neuroinvasion of JEV were demonstrated by JEV-specific RT-
qPCR, as depicted in Figure 3.5. Analysis by RT-qPCR was again needed to validate the results 
from the plaque assay. As expected, the RT-qPCR assay used in this study provided a higher 
71 
sensitivity than plaque assay in detecting the presence of JEV. Consistent with the results of plaque 
assays, homogenized olfactory neuroepithelium had the highest viral load at 1.8x106 geq-TCID50/g 
and overall had higher viral loads than most neural tissues (Figure 3.5a). However, the viral loads 
detected from the olfactory neuroepithelium were not statistically different from those of other 
tissues (Dunn-Bonferroni test, 0.502 ≤ p ≤ 0.999). The lowest mean titer of 4.4x101 geq-TCID50/g 
was recovered from the sciatic nerve. Other notable CNS structures with average viral loads above 
103 geq-TCID50/g included the cerebellum (1.6x10
3 geq-TCID50/g), thalamus (1.1x10
3 geq-
TCID50/g), temporal lobe (1.1x10
3 geq-TCID50/g), and frontal lobe (1.0x10
3 geq-TCID50/g). 
However, these structures were not statistically different from one another (Dunn-Bonferroni test, 




Figure 3.4. Tissue dissemination pattern of JEV determined by plaque assay. 
Infectious viral titers of JEV-positive CNS (a), lymphoid (b), and other (c) tissues collected at day 
3 post-infection. PFU = plaque forming units. Bar lines indicate the mean of the values collected 




Figure 3.5. Tissue dissemination pattern of JEV determined by RT-qPCR. 
Viral load of CNS (a) and lymphoid (b) tissues collected at day 3 post-infection, as estimated by 
RT-qPCR. Geq-TCID50 = genome equivalent-50% tissue culture infectious dose. Bar lines indicate 
the mean of the values collected from the challenged animals.  
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Among the lymphoid structures of the infected pigs, the submandibular lymph nodes had 
the lowest viral load ranging from 1.7x101 to 1.0x103 geq-TCID50/g (Figure 3.5b). Similar to the 
infectious viral titer results, tonsils, mesenteric lymph nodes, and the spleen produced the highest 
average viral RNA titers of 2.6x104 geq-TCID50/g, 7.6x10
3 geq-TCID50/g, and 9.7x10
3 geq-
TCID50/g, respectively. However, there was no demonstrable statistical difference in viral RNA 
loads between the lymphoid tissues (Dunn-Bonferroni test, p ≥ 0.999). The same infected pig that 
produced the highest viral load in the olfactory neuroepithlieum also produced the highest viral 
load in the tonsils, which reached 1.1x105 geq-TCID50/g. In summary, multiple nervous and 
lymphatic tissues showed the positive detection of viral RNA by RT-qPCR. These results 
demonstrate the high incidence of neuroinvasion and systemic infection among the animals 
challenged with JEV. 
 
 Viral clearance and persistent infection of JEV 
Titration of homogenized tissues collected from the five challenged animals at 28 days 
post-infection failed to detect any infectious viruses. However, viral genome was detected by RT-
qPCR in the tonsils. Viral loads of tonsils collected from three infected pigs ranged between 
4.9x101 to 3.4x102 geq-TCID50/g, indicating that there was active ongoing viral replication 
occurring in this structure although no live viruses could be isolated by plaque assay. It could also 
suggest the possibility of the presence of RNA fragments with no active replication. 
 
Discussion 
The results from this study demonstrate that North American domestic pigs, as used for 
commercial pork production, are susceptible to JEV infection. North American pigs infected with 
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genotype Ib JEV JE-91 strain developed nonspecific clinical signs including depression, fever, and 
minor weight loss. The disease course was then followed by mild to moderate bilateral hind limb 
ataxia, which is a clinical finding often reported with other ambulatory abnormalities in horses 
infected with JEV (Gulati et al., 2011; Sellon and Long, 2007). Previous experimental challenge 
studies with pigs from Asia and Europe inoculated with genotype III virus strains reported similar 
clinical signs (Ricklin et al., 2016b; Shimizu et al., 1954; Yamada et al., 2004; Yamada et al., 
2009), although neurologic signs such as hind limb tremors were only documented in the studies 
conducted in Japan (Yamada et al., 2004; Yamada et al., 2009). This suggests that JEV 
susceptibility between pigs from different regions and/or the infection course of genotypes III and 
Ib in pigs may not be significantly different from each other. Nonetheless, with North American 
pigs being susceptible to JEV, an enzootic JEV transmission cycle can easily become established 
in North America because there is no pre-existing immunity in their pig population to the foreign 
virus.  
Clinical disease was also coupled with viremia and viral shedding. Viral titers as high as 
4.2x103 geq-TCID50/ml were detected at day 3 post-infection in the serum of infected North 
American pigs (Figure 3.2b). This amount of virus in the blood is slightly lower compared to 
previous reports, in which higher than 104 infectious virus quantities per ml were reported (Gresser 
et al., 1958; Konishi et al., 1992; Ricklin et al., 2016a; Ricklin et al., 2016b). As such, while 
viremia was demonstrated in the infected pigs, whether the peak was caught at day 3 post-infection 
following intravenous challenge is unclear. Nonetheless, our reported viremias based on genome 
equivalent data may be sufficient to infect feeding mosquitoes (Platt and Joo, 2006; Takahashi, 
1976). For example, albeit the low infection rates, the highly JEV susceptible Cx. 
tritaeniorhynchus mosquitoes can become infected per os at infectious titers as low as 101.5 LD50 
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(Raengsakulrach et al., 1999; Sasaki et al., 1982; Takahashi, 1976). The event of subsequent 
transmissions to other susceptible vertebrate hosts is possible in the presence of highly susceptible 
mosquito species. The minimal infective dose for JEV competent mosquitoes found in North 
America, such as Cx. quinquefasciatus, remains to be determined. In the meantime, transmission 
in the absence of competent vectors may potentially also occur between susceptible vertebrates 
based on recent findings on the significance of nasal shedding of JEV (Ricklin et al., 2016a). While 
most infected pigs in this study shed an average viral titer of 7.2x101 PFU/ml or 2.25x102 geq-
TCID50/ml in the nasal secretions (Figure 3.3), Ricklin et al. (2016a) demonstrated that viral titers 
as low as 10 TCID50/ml can be infectious to pigs via the intranasal route. Therefore, once a pig 
becomes infected, animal-to-animal transmission may occur throughout the entire herd. The risk 
for vector-free aerosol or contact transmission of JEV from pigs to humans is currently unknown, 
but intranasal infection of JEV has been demonstrated in other vertebrate species including rhesus 
monkeys (Raengsakulrach et al., 1999), macaques (Myint et al., 2014; Myint et al., 1999), and 
mice (Li et al., 2012; Tsuchiya, 1968). 
 In terms of tissue tropism and virus dissemination, JEV behaved similarly as reported in 
previous published studies (Bosco-Lauth et al., 2011; Li et al., 2017a; Ricklin et al., 2016b; Yuan 
et al., 2016) and displayed tropism for nervous and lymphoid tissues in North American pigs. 
Titration and quantification of viral RNA via RT-qPCR of homogenized tissue samples identified 
the following tissues with the highest viral titers at 3 days post-infection: nasal epithelium, 
olfactory neuroepithelium, mesenteric lymph node, spleen, and tonsil. The highest values from 
these structures ranged from 2.1x103 PFU/g to 1.2x104 PFU/g or 3.5x103 geq-TCID50/g to 3.6x10
4 
geq-TCID50/g (Figures 3.4 and 3.5). Such high titers at the acute stage of infection, particularly in 
the nasal epithelium and olfactory epithelium, highlight two significant findings. Firstly, the source 
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of nasal shedding may be attributed to virus replicating in either the nasal epithelium or olfactory 
neuroepithelium, although JEV antigens could not be detected in these structures in Asian pigs 
after JEV intranasal challenge in a previous study (Yamada et al., 2009). Secondly, the high viral 
titers detected in the olfactory neuroepithelium at the acute stage of infection provides support to 
the previous finding that JEV can reach the brain through the olfactory pathway in pigs (Yamada 
et al., 2009). Similarly to alphaviruses capable of causing encephalitis such as Sindbis (Cook and 
Griffin, 2003) and Venezuelan equine encephalitis (Ryzhikov et al., 1995) and encephalitic 
flaviviruses such as St. Louis encephalitis (Monath et al., 1983) and Murray Valley encephalitis 
viruses (McMinn et al., 1996), JEV can bypass the blood-brain-barrier to reach the brain by 
retrograde axonal transport through the olfactory neuroepithelium in addition to the hematogenous 
route of brain infection described in other studies (Clark et al., 2012; Yamada et al., 2004). Since 
JEV neuroinvasion is regarded to be age-dependent (Clark et al., 2012; Grossberg and Scherer, 
1966; Kimura et al., 2013), it would be interesting to investigate if this pattern of viral infection 
and dissemination is also observed in adult pigs, which reportedly only experience reproductive 
disease from JEV infection (Mansfield et al., 2017; Platt and Joo, 2006). 
Another significant finding in this study was viral persistence in the tonsils. While no 
infectious virions could be isolated, viral RNA loads approximately 101 to 102 geq-TCID50/g were 
detected at day 28 post-infection in the tonsils of infected North American pigs. This discrepancy 
between the plaque assay and RT-qPCR may have occurred because the amount of live infectious 
viruses in the tonsil were below the limit of detection of cell-based detection methods like plaque 
assay. Nonetheless, comparable results were also observed in an European study, in which 
upwards of 104 RNA units equivalent to TCID50/g of JEV were detected at 25 day post-infection 
in the tonsils of their local domestic pigs after needle-challenge (Ricklin et al., 2016a). In a more 
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recent study, viral RNA was detected in the tonsil for at least 46 days after challenge, suggesting 
that the virus may be somehow hidden or evading from the host immune system (García-Nicolás 
et al., 2017). This is an important finding, because this may indicate that pigs could remain as 
potential carriers for at least a month after the initial infection, further emphasizing the significant 
role that pigs play in JEV transmission. Whether or not this persistent infection can lead to the 
reactivation of viremia or nasal shedding later on remains undetermined. However, other animal 
viruses that persistently infect tonsils, such as bovine herpesvirus 1 (Winkler et al., 2000) and 
porcine reproductive and respiratory syndrome virus (Bierk et al., 2001; Pileri and Mateu, 2016), 
have been documented to be able to reactivate and cause secondary infections. With JEV, 
reactivation of latent and persistent infection has been documented in mouse models (Mathur et 
al., 1986a, b) and in human cases (Sharma et al., 1991) based on the isolation of infectious virus 
weeks after the initial infection. Therefore, persistent infection of JEV in pigs warrants further 
investigation as it can have potential significant implications to disease transmission and control. 
Pigs can potentially become a model for persistent flavivirus infections.  
It is also important to interpret the results of this study with caution. First, the present study 
demonstrated that juvenile pigs in North America are susceptible to JEV. While young piglets of 
the common domestic white-line crossbreed were used as representative pigs of North America, 
the observations may not be directly extrapolated to the disease pathogenesis of JEV in adult pigs. 
However, their susceptibility to JEV remains important and relevant as there are continuously 
stable populations of young piglets available due to the high turnover rate of pigs in swine and 
pork production. Second, although intravenous injection does not mimic the natural route of 
transmission, it allows the comparison of susceptibility and infection outcomes between domestic 
pigs in North America and other regions as other challenge experiments have used similar 
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approaches (Ricklin et al., 2016a; Ricklin et al., 2016b; Shimizu et al., 1954; Yamada et al., 2004). 
Moreover, Ricklin et al. (2016a) reported that the different modes of infection used in their study 
(i.e. intradermal/intravenous combination and intranasal) did not result in fundamental differences 
in CNS lesions or tropism and level of neutralizing antibody titers. 
Collectively, this study demonstrates for the first time that North American domestic pigs 
can contribute to the JEV transmission cycle as amplifying hosts. Along with the evaluations of 
North American mosquitoes (Huang et al., 2016a; Huang et al., 2015; Reeves and Hammon, 1946) 
and avian species to JEV infection (Nemeth et al., 2012), the present study further highlights that 
there are competent mosquito vectors and susceptible amplifying hosts present in North America 
that can support and maintain JEV transmission. As such, JEV may have the potential to become 
endemic in the United States after an introductory event similar to the recent emergence of West 
Nile virus, a closely related flavivirus (Ciota and Kramer, 2013). With this potential risk, it is 
important to continue the international surveillance of JEV and possibly also locally in the United 
States by implementing JEV diagnostic methods, such as antibody or viral RNA detection, into 
the standard work up for quick identification and response as JEV is both a significant swine and 









The intravenous challenge study in Aim 1 demonstrated the susceptibility of North 
American pigs to JEV, but the inoculation method did not resemble the natural route of infection. 
The next step in characterizing JEV infection and disease in North American pigs was to mimic 
the natural route of JEV transmission more closely via intradermal inoculation in Aim 2. Using 
the intradermal route of challenge will provide a better view into the pathogenesis of JEV. This 
will also allow us to assess the roles of mosquito saliva in JEV infection. The main objective of 
this study was to investigate the effect of mosquito saliva in JEV pathogenesis of North American 
domestic pigs to test the working hypothesis that the addition of mosquito saliva in the needle 
inoculation of JEV will modulate the virus replication and/or disease. The work displayed here in 
this chapter has been published in the Emerging and Reemerging Viruses section of the Frontiers 
in Virology journal. It is available online at https://doi.org/10.3389/fviro.2021.724016. All 
manuscript sections have been altered from when it was originally submitted and has not 
undergone peer-review.  
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Japanese encephalitis virus is transmitted by Culex species mosquitoes that also vector 
several zoonotic flaviviruses (Le Flohic et al., 2013). Despite the knowledge that mosquito saliva 
contains modulatory molecules that may alter flavivirus pathogenesis in the infected host (Conway 
et al., 2014b; Fong et al., 2018; Pingen et al., 2016; Schneider and Higgs, 2008; Thangamani et 
al., 2010), whether or not the deposition of viruses by infected mosquitoes has an impact on the 
kinetics and severity of JEV infection has not been thoroughly examined. It has been examined 
previously in mice (de Wispelaere et al., 2017) and ducklings (Di et al., 2020), both of which have 
limited roles in JE transmission, but not in mammalian species such as swine that are involved in 
the enzootic transmission. Japanese encephalitis pathogenesis has been investigated and 
characterized under laboratory conditions in several animal models such as in mice (Li et al., 2012; 
Mathur et al., 1983; Tsuchiya, 1968), nonhuman primates (Myint et al., 2014; Myint et al., 1999; 
Raengsakulrach et al., 1999), chickens (Cleton et al., 2014), ducklings (Cleton et al., 2014; Xiao 
et al., 2018a; Xiao et al., 2018b), and pigs (Park et al., 2018; Ricklin et al., 2016b; Yamada et al., 
2004). However, the majority of the JEV pathogenesis models for the neuroinvasive disease were 
established using virus-only needle inoculation. Mouse models for West Nile and dengue viruses 
have shown that mosquito saliva can potentiate flavivirus infections and exacerbate disease 
symptoms (Cox et al., 2012; Moser et al., 2016; Schneider et al., 2006; Styer et al., 2011). 
Therefore, the exclusion of the vector and/or its salivary components in the virus infection of the 
vertebrate host may potentially lead to inaccurate representations of the true virulence or 
pathogenesis of the virus in nature.  
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The objective of this study was to determine the impact of mosquito salivary components 
on JEV infection in pigs, a species directly involved in its transmission cycle as an amplifying 
host. The established method of the collection and injection of mosquito salivary gland extract to 
mimic the delivery of mosquito saliva when feeding was used in this study (Le Coupanec et al., 
2013; Moser et al., 2016; Schneider et al., 2004; Styer et al., 2011). We hypothesized that the 
simultaneous delivery of mosquito SGE and infectious viruses might alter the pathological 
outcomes caused by JEV infection in pigs. Modulation of arbovirus infections by mosquito 
salivary components has been primarily demonstrated in laboratory mice but requires further 
evaluation with other animal models. Enhanced disease symptoms have been reported in mouse 
models that received mosquito saliva or SGE and challenged with alphaviruses (Fong et al., 2018; 
Schneider et al., 2004), bunyaviruses (Edwards et al., 1998; Osorio et al., 1996), and flaviviruses 
(Conway et al., 2014b; Cox et al., 2012; Moser et al., 2016; Schneider et al., 2006; Styer et al., 
2011). However, as discussed earlier in Chapter 1, observations in mouse models were not 
consistent with other small animal models. For example, challenge of hamsters (Sbrana et al., 
2005) and chickens (Langevin et al., 2001) with West Nile virus and house finches with Western 
equine encephalitis virus (Reisen et al., 2000) through the bites of infected mosquitoes had no 
demonstrable differences in disease severity nor infection outcomes when compared with needle 
injection. Our work in Aim 2 established a model to study the modulation of JEV infections by 
mosquito salivary components in pigs. This is also the first study that studied the impact of 
mosquito saliva on flavivirus pathogenesis in a mammalian host which develops viremia and can 
support the enzootic transmission of flaviviruses in nature. Understanding how mosquito saliva 
modulates flavivirus infections in mammalian amplifying hosts has significant implications 
because humans play a similar role in the urban transmission of dengue, yellow fever, and Zika 
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viruses. 
In this study, the co-injection of SGE derived from Cx. quinquefasciatus and JEV through 
the intradermal route altered the kinetics of JEV infection in domestic pigs. As illustrated in Figure 
4.1, a total of 28 three-week-old white-line crossbreed domestic piglets were randomly allocated 
into four groups and intradermally inoculated with one of the following: [1] 100 µl of sterile saline 
(mock or control group, n = 4), [2] mixture of 50 µl of sterile saline and 50 µl of JEV JE-91 stock 
containing 107 TCID50 (JEV-only group, n = 10), [3] 100 µl equal volume mixture of SGE (dose 
equivalent to 2.5 pairs of salivary glands) and sterile saline (SGE-only group, n = 4), and [4] 100 
µl equal volume mixture of SGE (dose equivalent to 2.5 pairs of salivary glands) and 107 TCID50 
of JEV JE-91 (SGE+JEV group, n = 10). Half of the animals from each group were euthanized at 




Figure 4.1. Schematic diagram of Aim 2 experimental design. 
DPI = day post-infection. JEV = Japanese encephalitis virus. SGE = salivary gland extract.  
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In contrast to the enhancement of diseases caused by mosquito saliva reported in mouse 
models, SGE reduced the severity of diseases caused by JEV infection as demonstrated by the 
development of milder febrile illness and shortened period of viral nasal shedding. Interestingly, 
the viral loads among the tissues collected from the central nervous system did not differ 
significantly and no demonstrable effect on viremic titers were observed with the co-inoculation 
of SGE and JEV. The findings suggest that the modulation of flavivirus infection by mosquito 
saliva may result in different infection outcomes depending on the vertebrate host species. 
 
Results 
All animals were healthy and had no detectable neutralizing antibodies against JEV at the 
start of the study. Inoculation of co-injection of JEV and SGE or JEV alone, both led to the onset 
of clinical signs including fever and lethargy. Clinical signs of acute infections subsided near to 
the subsidence of fever or the defervescence stage followed by the development of abnormal gait 
changes indicating neurological damage. Kinetics in the onset of clinical signs and differences in 
tissue viral loads were compared to assess the impact of SGE on the kinetics and severity of JEV 
infection in the pigs. 
 
 Modulation of JEV-induced fever, viremia, and nasal shedding by SGE 
The development of fever has been consistently observed in pigs challenged with JEV 
(Park et al., 2018; Ricklin et al., 2016a; Ricklin et al., 2016b; Young et al., 2020). We hypothesized 
that mosquito saliva could potentially modulate the onset and severity of clinical diseases induced 
by JEV as reflected by the observed development of febrile illness (Fong et al., 2018; Schneider 
and Higgs, 2008; Schneider et al., 2004). Elevated body temperatures were detected in both 
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SGE+JEV and JEV-only groups. One notable difference between the SGE+JEV and JEV-only 
groups was the time of fever onset and percentage of animals with elevated temperature, as shown 
in Figure 4.2. Injection with only JEV led to the development of fever in 10% of animals (1/10) 
at 1 day post-infection followed by the highest incidence of fever (80%, 4/5) observed at day 4 
post-infection. The animals that received the co-injection of JEV and SGE showed delayed onset 
of fever and did not reach the highest incidence until day 6 after challenge (40%, 2/5). The average 
body temperatures of animals in the SGE+JEV group were only significantly lower than those in 
the JEV-only group at day 1 post-infection (Dunn-Bonferroni test, p = 0.017) but remained lower 
than those in the JEV-only group on days 2, 3, and 4 post-infection, although the comparisons 
were not statistically significant (Dunn-Bonferroni test, 0.155 ≥ p ≥ 0.999).  
 
 
Figure 4.2. Temperatures of animals in the Aim 2 study after their respective inoculation. 
Average body temperatures of pigs after intradermal challenge with sterile saline (control), 107 
TCID50 of JE-91 strain (JEV-only), salivary gland extract (SGE-only), and 10
7 TCID50 of JE-91 
strain mixed with salivary gland extract (SGE+JEV). DPI = day post-infection. Asterisk (*) 
indicates the significant difference when JEV and SGE+JEV groups were compared to each other 
considering time as a factor using non-parametric Kruskal-Walls test and post hoc Dunn’s multiple 
pairwise comparison test adjusted with Bonferroni correction.  
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Differential kinetics in the development of febrile illness in response to the needle 
inoculation of JEV and the simultaneous delivery of SGE and JEV warranted the comparison of 
viremic and nasal shedding profiles, two important manifestations caused by JEV infection in pigs 
(García-Nicolás et al., 2017; Park et al., 2018; Ricklin et al., 2016a). All virus-challenged animals 
developed transient viremia, as shown in Figures 4.3A and 4.3B. The average viremic titers and 
serum viral loads among the SGE+JEV animals appeared slightly lower than the JEV-only group, 
but the differences were not statistically significant at any time point (Dunn-Bonferroni test, p ≥ 
0.999). The highest average viremic titer observed in both groups were comparable to each other 
(SGE+JEV at day 2 post-infection: 2.2x104 ± 3.3x104 PFU/ml; JEV-only at day 3 post-infection: 
1.1x105 ± 2.9x105 PFU/ml; Dunn-Bonferroni test, p = 0.396) followed by the clearance of viremia 
at either 4 or 5 days after challenge. Data analyzed by plaque assay was consistent with those 
obtained through RT-qPCR. The serum viral loads also peaked in SGE+JEV and JEV-only groups 
at 2 (4.7x104 geq-TCID50/ml) and 3 days post-infection (4.4x10
5 geq-TCID50/ml), respectively. 
No difference was found in the serum viral loads between the two groups of animals at day 2 or 3 




Figure 4.3. Magnitude and duration of viremia of Aim 2 animals post-challenge. 
Viremic profiles of individual animals following intradermal JEV challenge with or without SGE 
quantified by plaque assay (A) and RT-qPCR (B). DPI = day post-infection. PFU = plaque forming 
units. Geq-TCID50 = genome equivalent-50% tissue culture infectious dose.   
 
 
Infectious viruses were isolated in the nasal swabs collected from the experimentally 
challenged pigs, as demonstrated in Figure 4.4A. Forty percent (4/10) of animals in the SGE+JEV 
group began to secrete infectious viruses as early as day 2 post-infection. Similarly, infectious 
virus was detected in nasal secretions collected from 60% (6/10) of pigs in the JEV-only group. 
Detection of infectious viruses persisted in both the SGE+JEV and JEV-only groups for up to day 
6 and 5 after infection, respectively. Detection of viral RNA demonstrated that 80% (8/10) of 
SGE+JEV pigs and 100% (10/10) of JEV-only pigs developed nasal shedding (Figure 4.4B). The 
duration of nasal shedding was prolonged in comparison with the durations of fever and viremia. 
Viral RNA was detected from 2 to 7 days post-infection in the SGE+JEV group whereas nasal 
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shedding was detected up to day 10 after challenge in the JEV-only group. Nasal secretions had 
no demonstrable difference in infectious titers and viral RNA loads at any time point between 
SGE+JEV and JEV-only groups (Kruskal-Wallis test, p = 0.113 in infectious titers and Dunn-
Bonferroni test, p ≥ 0.999 in viral RNA loads). However, the average duration of nasal shedding 
was significantly shorter among SGE+JEV pigs (1.8 ± 1.3 days) than those challenged with JEV 
only (3.8 ± 1.6 days) (one-tailed t-test, t = 1.925, p = 0.045).  
 
 
Figure 4.4. Nasal shedding profiles of JEV-infected animals. 
Nasal shedding kinetics of individual animals following intradermal JEV challenge with or without 
SGE quantified by plaque assay (A) and RT-qPCR (B). PFU = plaque forming units. DPI = day 
post-infection. Geq-TCID50 = genome equivalent-50% tissue culture infectious dose. 
 
In summary, the injection of SGE and JEV modulated the kinetics of fever but not the viral 
titers of viremia or nasal shedding. The delayed onset of fever and shortened periods of nasal 
shedding suggest that the inclusion of SGE in the inocula altered the kinetics of acute disease signs 
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caused by JEV infection. However, the addition of SGE did not have a demonstrable impact in 
quantities of infectious viruses and viral genomes in serum and nasal secretions. 
 
 Impact of SGE on the viral burdens of different tissues  
Detectable viremia led to the dispersal of JEV to lymphoid and nervous tissues through the 
hematogenous route in both SGE+JEV and JEV-only groups at day 3 post-infection, as detailed in 
Figure 4.5.  
 
 
Figure 4.5. Tissue dissemination pattern of JEV in the presence of SGE at the inoculation 
site. 
Average viral loads of several tissues collected at 3 DPI following intradermal JEV challenge with 





Consistent with the comparable viremia titers, the systemic spread of JEV was not 
impacted by the co-administration of SGE and JEV because the infectious titers and viral RNA 
loads of homogenized lymphoid tissues (peripheral lymphoid nodes, thymus, and tonsil) did not 
show demonstratable differences (Dunn-Bonferroni test, p ≥ 0.999 in infectious titers and Kruskal-
Wallis test, p = 0.363 for viral load) (Figure 4.5). The co-injection of JEV and SGE did, however, 
lead to different outcomes of JEV infection in one of the two peripheral nervous tissues examined 
in this study, as shown in Figure 4.6. Homogenized sciatic nerves obtained from SGE+JEV 
animals (2.2x101 ± 4.4x101 PFU/g) had significantly lower amount of infectious viruses than those 
that were injected with JEV alone (2.5x103 ± 4.7x103 PFU/g, Mann-Whitney U test, p = 0.032). 
However, there was no demonstrable statistical difference in the viral RNA load of the sciatic 
nerve samples (Mann-Whitney U test, p = 0.548) (Figure 4.5). Albeit the lack of statistical 
significance (Mann-Whitney U tests, 0.222 ≥ p ≥ 0.999), the average viral RNA loads in the CNS 
collected from the SGE+JEV group were overall lower than those from the animals that were 
injected with JEV alone (Figure 4.5). In summary, SGE altered the viral burden in peripheral 





Figure 4.6. Infectious viral titers of sciatic and facial nerve samples collected from the 
infected animals. 
Asterisk (*) indicates the significant difference when JEV and SGE+JEV groups were compared 
to each other using non-parametric Mann-Whitney U test. 
 
 Neurologic signs and persistent infection in pigs 
Development of trembling, paralysis, and/or ataxia of the hind limbs has been previously 
reported in JEV-infected swine (Fujisaki, 1975; Kodama et al., 1968; Park et al., 2018; Yamada et 
al., 2004; Yamada et al., 2009). Animals in the SGE+JEV and JEV-only groups had a comparable 
incidence of ataxia (SGE+JEV: 80% (4/5); JEV-only: 40% (2/5); Fisher’s exact test, p = 0.110). 
The development of ataxia in both groups is summarized in Table 4.1. In the SGE+JEV group, 
two animals became ataxic in their hind limbs as early as day 6 post-infection and persisted until 
the end of the study. Two additional pigs developed bilateral hind limb ataxia: one at day 11 post-
infection that lasted a week and the other at day 25 after infection that was persistent until the end 
of study. In the JEV-only group, one pig developed gait abnormality at day 15 post-infection until 
the end of the study, while another exhibited only a 2-day period of mild rear limb ataxia between 
day 22 and 23 after challenge. Although the onset of ataxia between the two groups were 
statistically not different (Mann-Whitney U test, p = 0.087), there appeared to be a trend for earlier 
92 
onset of hind limb ataxia in the SGE+JEV group than the JEV-only group. Despite the apparent 
signs of neurologic abnormalities, all animals survived the experimental challenge and developed 
neutralizing antibody responses. Geometric mean PRNT50 titers at day 28 post-infection were 
similar between the SGE+JEV (105.6) and JEV-only (91.9) groups (Mann-Whitney U test, p = 
0.841). 
 
Table 4.1. Timetable for the onset of ataxia in the experimental groups of Aim 2. 
 
ID = pig identification number. D = day. JEV = Japanese encephalitis virus. SGE = salivary gland 
extract. A (in green box) = ataxia.  
 
 
Neurological signs observed during the convalescent phase of JEV infection were 
consistent with the presence of viral RNA in CNS and lymphoid tissues in both groups of animals. 
Viral RNA was detected in at least one CNS tissue in two animals in the SGE+JEV group and one 
animal in the JEV-only group at day 28 post-infection (Figure 4.7).  
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Figure 4.7. Persistent JEV infection of several nervous and lymphoid tissues. 
Viral RNA detected by RT-qPCR in several central nervous and lymphoid tissues collected at 28 
DPI following intradermal JEV challenge with or without SGE. DPI = days post-infection. Geq-
TCID50 = genome equivalent-50% tissue culture infectious dose. 
 
In addition to the detection of viral RNA in CNS tissues at 28 days after challenge, thymus 
and tonsil were potential sites of persistent infection. Viral loads in the thymus collected from 
infected pigs ranged between 3.6x101 to 8.12x101 geq-TID50/g in the SGE+JEV group (n = 3) and 
between 3.85x101 to 4.23x101 geq-TCID50/g in the JEV-only group (n = 2). Tonsils had a higher 
level of viral loads as shown with average viral titers of 5.8x103 ± 2.6x103 geq-TCID50/g from two 
SGE+JEV pigs and 1.6x103 ± 1.4x103 geq-TCID50/g from three JEV-only pigs. However, there 
was no statistical difference across tissue samples collected at day 28 post-infection between the 
groups (Kruskal-Wallis test, p = 0.378), suggesting that SGE had no impact on the persistence of 
JEV infection in pigs. 
In summary, the impact of mosquito SGE on the kinetics and severity of diseases was 
limited to the acute phase of JEV infection. In comparison with pigs inoculated with JEV only the 
co-injection of SGE with JEV led to milder diseases based on the delayed onset of fever, shortened 
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nasal shedding, and slightly reduced CNS viral loads. However, the reduced severity of acute JEV 
infection in the SGE+JEV group had no demonstrable impact on the frequency of neurological 
diseases and persistent infection. 
 
Discussion 
Mosquitoes play an integral role in the transmission of arboviruses. Mosquito salivary 
components have been increasingly recognized as an important factor that modulates vertebrate 
immune responses and, as a consequence, disease pathogenesis caused by arbovirus infections. 
Several studies suggested that mosquito salivary components delivered through feeding or 
injection suppress antiviral immunity and enhance pathological outcomes in mouse models. The 
immunosuppressive effects of mosquito saliva include the stimulation of anti-inflammatory 
cytokines (Schneider et al., 2010; Schneider et al., 2004; Vogt et al., 2018), polarization from a 
Th1 to Th2 immune response (Schneider et al., 2004; Thangamani et al., 2010), and suppression 
of the host innate immune responses (Fong et al., 2018; Schneider and Higgs, 2008; Thangamani 
et al., 2010). However, the enhancement of pathological outcomes caused by arbovirus infections 
has not been consistently observed in all vertebrate species (Langevin et al., 2001; Reisen et al., 
2000; Sbrana et al., 2005). Our study investigated the impact of mosquito SGE on the kinetics and 
severity of JEV infection in pigs, an amplifying host that is directly relevant to JEV transmission 
in nature. This model system is unique from the majority of previously published studies because 
it assesses the impact of mosquito salivary components on flavivirus infections in a mammalian 
amplifying host.   
The co-injection of SGE and JEV, an established approach developed to mimic the bite of 
infected mosquitoes (Le Coupanec et al., 2013; Moser et al., 2016; Schneider et al., 2004; Styer et 
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al., 2011), showed that mosquito salivary components can modulate JEV infection in pigs, 
resulting in reduced fever and decreased nasal shedding duration. Consistent with the hypothesis 
that mosquito saliva suppresses the pro-inflammatory responses in the vertebrate host, the 
simultaneous delivery of SGE and JEV led to a low incidence and delayed onset of fever, as shown 
in Figure 4.2. This effect has also been demonstrated after mosquito bite infection of a humanized 
dengue virus mouse model, which was partially reconstituted with human immune cells to 
recapitulate dengue pathogenesis in humans (Cox et al., 2012). It is also consistent with the anti-
inflammatory properties of Cx. pipiens and Cx. quinquefasciatus saliva reported in human 
keratinocytes (Garcia et al., 2018; Zeidner et al., 1999). Although the mechanism of how mosquito 
saliva caused the observed shortened duration of JEV shedding remains unclear (Figure 4.4A and 
4.4B), lower levels of viral shedding of West Nile virus has also been documented in two 
independent studies that compared chickens challenged via needle inoculation with those infected 
by mosquito bites (Langevin et al., 2001; Styer et al., 2006). Cloacal shedding of West Nile virus 
was less frequently detected in chickens inoculated by infected Cx. tritaeniorhynchus bites than 
chickens infected by subcutaneous injection (Langevin et al., 2001). More efficient viral clearance 
and shortened periods of oral shedding was also reported in chicks exposed to West Nile virus 
from infected Cx. pipiens than those infected parenterally (Styer et al., 2006). However, this trend 
was only documented among chickens within a specific range of age (Styer et al., 2006), 
suggesting that reduced shedding of flaviviruses in avian hosts is also likely to be age-specific. 
Nevertheless, the shortened period of nasal shedding challenges the epidemiologic importance of 
vector-free JEV transmission (Ricklin et al., 2016a). To date, infectious viruses and JEV genome 
in nasal secretions has only been detected under laboratory conditions. The existence of direct pig-
to-pig transmission under field conditions has been further supported using mathematical 
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modelling consistent with swine serological data collected from Cambodia, a country with high JE 
incidence (Diallo et al., 2018). However, to the best of our knowledge, there has been no virus 
isolate or detection of viral genome reported in naturally infected animals, warrants further 
investigation in understanding the degree of importance of nasal shedding of JEV among domestic 
pigs and whether or not it can serve as a mechanism for viral maintenance in nature. 
Our results are comparable with published studies that showed that acute diseases caused 
by flavivirus infections can be modulated by mosquito salivary components (Cox et al., 2012; 
Moser et al., 2016; Styer et al., 2011), but how the disease was impacted and altered was different. 
Feeding by infected mosquitoes or simultaneous injection of mosquito SGE with infectious viruses 
was implicated to enhance systemic diseases caused by flavivirus infections as observed 
previously, such as with inbred mouse strains challenged with West Nile virus (Moser et al., 2016; 
Styer et al., 2011) and humanized mice challenged with dengue virus serotype 2 (Cox et al., 2012). 
Intriguingly, the enhancement of viremia and systemic disease was not observed in our pig model. 
The viremic titers and serum viral loads between the SGE+JEV and JEV-only groups remained 
comparable, as summarized in Figures 4.3A and 4.3B. Additionally, consistent with the 
hematogenous route of neuroinvasion by JEV (Mathur et al., 1992; Monath et al., 1983; Myint et 
al., 2014; Nagata et al., 2015), the unaltered viremia was coupled with viral burdens in the central 
nervous tissues that were comparable between the animals in the SGE+JEV and JEV-only groups 
(Figure 4.5). At the same time, the incidence and severity of febrile illness was reduced among 
animals that received the intradermal injection of SGE and JEV (Figure 4.2). One explanation to 
these observations may be due to the differences in the choice of vertebrate species used in the 
studies. The seemingly contradictory outcomes may reflect the different roles of incidental and 
amplifying hosts in flavivirus transmission. Although a useful laboratory model, mice and other 
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rodent species have no known role in the transmission or maintenance of flaviviruses in nature. 
The development of neurotropic diseases is an important pathological outcome for most mouse 
models after experimental challenges with flaviviruses, which is a hallmark that resembles the 
incidental hosts for JEV and other flaviviruses. On the other hand, as an amplifying host species, 
domestic pigs develop viremia to sustain the transmission of JEV. Therefore, it is speculated that 
the modulation of flavivirus infections by mosquito salivary components can be fundamentally 
different in amplifying hosts, especially mammalian species, and in incidental hosts. Despite the 
limited numbers of amplifying hosts that can be studied under laboratory conditions, understanding 
the differential immunomodulatory outcomes by salivary components of mosquitoes may provide 
an opportunity to investigate how saliva of hematophagous arthropods can affect the transmission 
efficiency of flaviviruses in nature. 
With this in mind, the lack of differences in viremic titers and serum viral loads could 
indicate that the modulation of disease severity by mosquito saliva in amplification hosts 
potentially does not significantly affect the likelihood of transmission via the bite of infected 
mosquitoes. However, this hypothesis requires further investigation. Amplifying hosts that 
develop viremia, but experience no apparent signs of disease, have been recently recognized to be 
advantageous for the transmission and maintenance of flaviviruses, as observed with dengue virus 
(Duong et al., 2015; Ten Bosch et al., 2018) and Zika virus infections in humans (Moghadas et al., 
2017). In a study with dengue patients from Cambodia, infected people with no symptoms or prior 
to the onset of clinical illness were significantly more infectious to Ae. aegypti mosquitoes than 
the patients with symptomatic infection despite the lower average level of viremia in the 
asymptomatic individuals (Duong et al., 2015). As a result, the strong immune response and high 
cytokine production associated with clinical illness in the infected host have been proposed to play 
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a factor in the observed reduction of infectivity to mosquitoes (Duong et al., 2015; Rathakrishnan 
et al., 2012). Based on mathematical modelling analysis of host-viral dynamics and empirical data, 
Ten Bosch et al. (2018) therefore suggested that the asymptomatic individuals with inapparent 
dengue symptoms not detected by the surveillance systems may actually be the primary reservoir 
of dengue virus transmission. In addition, Reinhold et al. (2021) proposed that mosquitoes may 
possibly prefer bloodmeals from body extremities with slightly cooler temperatures due to thermal 
stress and energy cost associated with the ingestion of warm blood meals (Benoit et al., 2011; 
Lahondère and Lazzari, 2012). If supported, this could suggest that the preference by mosquitoes 
for bloodmeals from animals with normothermic or nonfebrile temperatures could be likely. In a 
thermotaxis study with Ae. aegypti mosquitoes, Corfas and Vosshall (2015) demonstrated that 
host-seeking mosquitoes are most attracted to temperature stimuli close to host body temperatures 
(i.e. range of 37 °C of humans to 43 °C of birds), peaking at maximum attraction at 40 °C which 
is considered the minimum temperature for fever (≥ 40 °C) in most domestic mammalian species 
(Robertshaw, 2004). How clinical illness and symptoms affect mosquito behavior in association 
with virus transmission still requires further investigation.  
In addition to the potential variation based on the vertebrate host, the effect of mosquito 
saliva in the animal models may be virus-specific. Our understanding of how mosquito saliva 
modulates encephalitic flavivirus infections has been largely derived from West Nile virus mouse 
models (Moser et al., 2016; Schneider et al., 2007; Schneider et al., 2010; Schneider et al., 2006; 
Styer et al., 2011). In the available West Nile virus infection models, it has been implicated that 
mosquito saliva enhances the systemic infection followed by the development of more severe 
neuroinvasive diseases. However, our work and that of others suggest that mosquito saliva may 
potentially play a different role in modulating the outcomes of JEV infections in the vertebrate 
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host, but the results are variable and inconsistent from one another. For example, the co-injection 
of SGE or saliva collected from Cx. pipiens or Ae. albopictus and JEV had no demonstrable impact 
in the viremia and mortality of BALB/c mice in comparison with intradermal inoculation of JEV 
alone (de Wispelaere et al., 2017). In contrast, high viremia and high mortality from viral 
encephalitis with apparent neurological signs were induced by bites from JEV-infected Cx. pipiens 
in newborn ducklings (Di et al., 2020), which normally do not demonstrate such clinical outcomes 
to JEV by needle inoculation (Xiao et al., 2018b). These variations in infection outcomes again 
could most likely be due to the differences in the disease pathogenesis of JEV in different 
vertebrate species. 
These inconsistent results could also potentially be due to differences in experimental 
methodology, such as the use of SGE to emulate mosquito saliva or bite. However, the effects of 
SGE and mosquito saliva or bite have been proven to create similar effects in the vertebrate host 
(Le Coupanec et al., 2013; Moser et al., 2016; Schneider et al., 2004; Styer et al., 2011) and virus 
replication in the vector has been shown to not be necessary for the disease enhancement effects 
to be observed (Edwards et al., 1998; Styer et al., 2011). Moser et al. (2016) showed that as little 
as 0.01 μg of SGE protein, which is approximately equivalent to 0.01 salivary gland pairs, could 
cause enhancement of West Nile virus infection in mice and dose-dependent enhancement 
occurred with increasing concentration of SGE or number of mosquitoes spot-feeding at the 
inoculation site.  
Additionally, the effects of mosquito saliva could be mosquito species-dependent. For 
example, while mortality rates significantly increased from Rift Valley fever virus when SGE from 
Ae. vexans and Ae. aegypti were used, SGE from Cx. pipiens, although a competent vector of Rift 
Valley fever virus, did not produce any observable effects on mice survival (Le Coupanec et al., 
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2013). Vector competence was also considered not an important factor in another study, in which 
outbred mice resistant to infection of Cache Valley virus by subcutaneous injection became 
viremic and developed antibodies when the virus was injected into sites that were spot-fed by 
mosquito species that are not natural vectors of the virus, such as Ae. triseriatus, Ae. aegypti, and 
Cx. pipiens (Edwards et al., 1998). To complicate this further, other factor may be involved in how 
mosquito saliva may impact virus infection because mosquito saliva or certain SGE fractions from 
Ae. aegypti caused reduction of dengue virus infectivity in vitro (Ader et al., 2004; Conway et al., 
2014a; Conway et al., 2014b), but enhancement of dengue disease using the same mosquito species 
was reported in another study (Cox et al., 2012; Huang et al., 2019). In our study, the use of Culex 
species mosquito that are involved in natural transmission of JEV (Weng et al., 1999) ensures the 
biological relevance of the model developed to study the modulation of JEV infections by 
mosquito saliva. Ultimately, the different results may be due to the inherent differences in the 
interactions among the mosquito, virus, and vertebrate host such that effects of mosquito saliva 
may vary depending on the source, type, and species of the players involved in the arbovirus 
transmission. Differences in our and others’ observations highlight the complexity of interactions 
among mosquitoes, JEV, and vertebrate hosts.  
Collectively, our study demonstrates for the first time the utility of pigs to study the 
modulation of JEV infection by mosquito saliva. Our findings further highlight the complex and 
unique differences involved in the mosquito-virus-host interactions. Investigating the mechanisms 
responsible for these differences may be of importance to improve our understanding of the 
ecology and pathogenesis of arboviruses to develop the appropriate risk mitigation strategies and 
effective countermeasures for their transmission and disease. 
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The studies from Aims 1 and 2 demonstrated the susceptibility of North American domestic 
pigs to JEV and characterized their infection and disease outcomes. While wild or feral pigs are 
thought to be important in the enzootic transmission of JEV, no direct challenge studies have been 
conducted to support this statement. The objective of Aim 3 was to determine the susceptibility of 
feral pigs to JEV and characterize the infection outcome, using the Sinclair miniature research 
swine breed as a feral pig representative of North America. The Sinclair miniature pig, also known 
as the Minnesota or Hormel miniature pig, is an established research colony developed by 
crossbreeding four feral pig strains found in the United States (McAnulty et al., 2011; Schook and 
Tumbleson, 1996). This model was used because hunting, transporting, and possessing feral pigs 
is illegal in Kansas (2020; Bevins et al., 2014). The study will test the working hypothesis that 
feral pigs are capable of developing viremia and similar pathologic outcomes observed in domestic 
pigs. Results from this animal study were compared with those obtained from the domestic pigs in 
the JEV-only group in Aim 2. The work displayed here in this chapter will be prepared for future 




Introduction   
  Wild boars or feral pigs are becoming increasingly recognized to have high 
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epidemiological importance in the transmission or maintenance of several zoonotic pathogens 
including viruses, such as hepatitis E virus and influenza virus, and bacterial enteropathogens 
(Meng et al., 2009; Miller et al., 2017; Petersen et al., 2020; Ruiz-Fons, 2017). By definition, wild 
or feral boars are a group of Sus scrofa biotypes that includes feral or escaped domestic pigs, 
Eurasian or Russian wild boars, and their cross-bred hybrids (Ruiz-Fons, 2017). A list of the 
pathogens with public health significance most likely to be transmitted from the wild or feral pig 
population to humans are provided in Table 5.1. Feral pigs are also reservoirs for pathogens 
important to the domestic swine industry, such as pseudorabies virus, Brucella suis, and porcine 
reproductive and respiratory syndrome virus (Wyckoff et al., 2009). The importance of feral pigs 
for these diseases primarily rises from the concern that they may serve as an unmonitored pathogen 
source of potential spillover to the livestock and human population (Petersen et al., 2020; Pierce 
et al., 2020). Potential routes of exposure to pathogens from wild pigs include consumption of their 
undercooked or raw meat products, direct contact, indirect contact via their interaction with 
livestock and companion animals, handling of their carcass, consumption of contaminated food 
and water, and bites from arthropod vectors (Ruiz-Fons, 2017). For example, there has been a case 
report of hepatitis E virus transmission to human in Japan from the consumption of infected wild 
boar meat (Li et al., 2005). Feral pigs have been implicated to be involved in various brucellosis 
outbreaks in the United States affecting a cattle herd, several domestic swine farms, and 
subsequently humans (Glazier, 2017; Wyckoff et al., 2009). Additionally, it is estimated that up to 
60% of the several outbreaks of classical swine fever that affected the domestic pigs in Germany 
in the 1990s were due to direct or indirect contact with infected wild boars (Moennig, 2015).  
These cross-species disease transmission events are primarily due to the increasing 
interaction among wild swine, domestic livestock, and humans as a consequence to the growing 
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population and expanding geographic distribution of wild pigs (Miller et al., 2017). In the United 
States, a dramatic increase in the feral pig population has been recorded over the past 30 years 
(Bevins et al., 2014; Snow et al., 2017), as shown in Figure 5.1. There is also an overall increase 
in overlap in terms of locality of feral pigs with livestock and humans, as presented in Figure 5.2. 
Data from GPS (geographic positioning system) movement tracking have demonstrated that feral 
swine frequently interact with domestic swine that are kept in outdoor pens (Wyckoff et al., 2009). 
In fact, close interactions and co-mingling between feral pigs and domestic livestock is common 
in general throughout North America in areas where they allow sharing of outdoor pasture 
resources (Miller et al., 2017). As such, there is a growing concern that wild or feral pigs may act 
as a source of pathogens that could be introduced into livestock and human populations (Peper et 
al., 2021). With arthropod-borne diseases, a susceptible population of feral pigs could modulate 
vector density and possibly impact the maintenance or persistence of the pathogen in nature if they 
are capable of being an amplifying host (Ruiz-Fons, 2017).   
 
Table 5.1. List of zoonotic pathogens identified as the most prone to be transmitted from wild 
swine to humans and/or domestic livestock. 
Viruses Bacteria Parasites 
• Hepatitis E virus 
• Influenza virus 
• Nipah virus 
• Japanese encephalitis 
virus  
• Salmonella species 
• Shiga toxin-producing 
Escherichia coli 
• Campylobacter species 
• Leptospira species 
• Brucella suis 
• Mycobacterium bovis 
 
• Trichinella species 




Figure 5.1. Expanding distribution of feral pigs in the United States. 
Distribution data showing the spread of invasive wild pigs Sus scrofa throughout four time periods 
in the continental USA. Counties reported to be occupied by invasive wild pigs at the beginning 
of each time period were designated as initial range, and any other counties occupied throughout 
each time period were designated as expanded range. (Image taken from Snow et al. (2017); 
Contributed by U.S. government employees and published in the public domain). 
 
 
Figure 5.2. Overlapping distribution of feral pigs with those of domestic pig farms or rural 
human population. 
County level co-occurrence of wild pigs, agricultural commodities, and rural human populations 
in the contiguous United States for 2012. Red shading denotes by quartile the absolute farms 
density (farms per km2) or rural human population density (people per km2) within counties co-
occurring with wild pigs while blue shading indicates counties without wild pigs. (Image modified 
from Miller et al. (2017); Published under the Creative Commons Attribution License).  
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 Available evidence suggests that wild boars or feral pigs may contribute to the spread and 
maintenance of JEV through enzootic transmission in the endemic regions. However, there have 
not been experimental data to validate this hypothesis due to the complicated logistics involved in 
procuring and handling the wild animals which may have hindered these investigations. 
Additionally, legislations and regulations sometimes prohibits their hunting and transport in some 
areas. Nevertheless, understanding the kinetics of JEV in feral pigs by experimental inoculation 
and infection is essential for the development and establishment of appropriate control measures 
for potential JE disease outbreaks. At present, available data regarding JEV in wild swine are 
mainly derived from JE-endemic regions based on serological studies (Hamano et al., 2007; 
Nidaira et al., 2014; Nidaira et al., 2007; Ohno et al., 2009; Yang et al., 2012a) with limited reports 
on RNA detection (Nidaira et al., 2008; Tan et al., 2012). Based on the high seroprevalence, it has 
been suggested that wild swine may be frequently exposed and are susceptible to JEV similar to 
their domestic counterparts and could be important amplifiers of JEV in nature. Accordingly, wild 
or feral pigs have been recognized as potential relevant drivers of JEV outbreaks in endemic areas 
(Hamano et al., 2007; Nidaira et al., 2014; Ruiz-Fons, 2017). Nevertheless, although 
epidemiological links have been suggested, the exact role of feral pigs as potential virus reservoirs 
and a possible source of infection is still unclear. Further studies are thereby required to establish 
the viral titers in feral pigs to assess their susceptibility to disease and infection by JEV.  
 Domestic pigs are highly susceptible to JEV infection and are important amplifying hosts 
of JEV in both enzootic and epizootic transmission cycles. Wild boars or feral pigs are closely 
related species. Therefore, it is reasonable to hypothesize that feral pigs could also act as important 
reservoirs of JEV in nature but direct data is needed to support this statement. The objectives of 
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this study were to address this gap of knowledge by determining the susceptibility of North 
American feral pigs to JEV, to characterize and compare the pathogenesis of JEV in feral pigs to 
what has been observed in domestic pigs, and to establish an alternate feral pig model for JEV.  
The Sinclair miniature research pig was used as a representative model of feral pigs to 
accomplish Aim 3. It is an established colony developed by the Hormel Institute at the University 
of Minnesota by crossbreeding four feral pig strains found in the United States (i.e. Guinea hog 
from Alabama, wild boar from Catalina Island, Piney wood pig from Louisiana, and dwarf Ras-n-
Lansa pig from Guam in the Mariana Islands) with a domestic Yorkshire boar (McAnulty et al., 
2011; Schook and Tumbleson, 1996). It is the first strain of miniature pig developed and made 
available to scientists for research purposes (Bouchard et al., 1996). Sinclair miniature feral pigs 
have been used as an animal model for translational medical research in multiple field areas, such 
as oncology (Misfeldt and Grimm, 1994), toxicology (Brown and Hutcheson, 1973), neural 
development (Ryan et al., 2018), and metabolic disease (Stricker-Krongrad et al., 2016), as well 
as miniature models for diseases of conventional domestic pigs (Blagburn et al., 1991; Turnquist 
et al., 1993) due to their smaller size, ease in handling, and thus, lower cost associated with 
husbandry.  
To the best of our knowledge, our study is the first use of Sinclair miniature pigs as a viral 
infection model and the first study designed to evaluate if pigs with feral genetics and phenotypes 
are susceptible to JEV. In this study, the Sinclair miniature pigs were intradermally inoculated 
with a representative strain for genotype Ib (JE-91 strain) to determine their susceptibility and 
characterize the disease pathogenesis. As illustrated in Figure 5.3, a total of 14 three-week-old 
Sinclair miniature piglets were randomly allocated into the following two experimental groups: 
mock group (n = 4) and JEV group (n = 10). The mock animals were intradermally inoculated with 
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100 µl of sterile saline while the animals in the JEV group received 100 µl of 107 TCID50 of JEV 
JE-91 strain. To characterize the acute and convalescent stages of infection, groups of seven pigs 
(five infected and two control pigs) were sacrificed at days 3 and 28 post-infection, respectively. 
 
 
Figure 5.3. Schematic diagram of Aim 3 experimental design. 
DPI = days post-infection. JEV = Japanese encephalitis virus.  
 
Establishment of JEV infection and pathogenic outcomes were demonstrated by the 
detection of infectious viruses and viral genomes in multiple tissues, as previously performed for 
Aims 1 and 2. Intradermal JEV challenge of these pigs resulted in high viremia, viral nasal 
shedding, and systemic dissemination comparable to JEV infection in domestic pigs. These 
findings are the first direct evidence to show that feral pigs can support the enzootic transmission 





All animals in the study were apparently healthy and seronegative against JEV prior to the 
start of the experiment. Infection outcomes, such as clinical disease, viremia kinetics, and viral 
tissue dissemination pattern, were compared to those observed from the group of domestic pigs 
from Aim 2 that were intradermally challenged with JEV only.  
 
 Clinical outcomes of feral pigs infected with JEV 
Fever and mild to no clinical signs are typically reported in domestic pigs infected with 
JEV (Park et al., 2018; Platt and Joo, 2006; Ricklin et al., 2016b). Overall, JEV infection in the 
Sinclair miniature feral pigs progressed similarly to what has been described in domestic pigs in 
terms of clinical disease. There were no overt signs of illness. Only one feral pig was depressed 
for two days at day 4 post-infection, but recovered to normal mentation and activity. Elevated body 
temperatures (≥ 40 °C) of only 1 to 2 day duration was recorded in 60% (3/5) of the feral pigs in 
the convalescent group. In comparison, domestic pigs from Aim 2 had a range of 1 to 6 day 
duration of fever in 80% (4/5) of the pigs in the corresponding group. As presented in Figure 5.4 
and Table 5.2, the average temperature peak in the feral pigs (39.69±0.42 °C) occurred at day 4 
post-infection, in which 40% (2/5) of the feral pigs had elevated body temperatures of greater than 
40°C. The average temperature peak also occurred at day 4 post-infection for JEV-infected 
domestic pigs, reaching a mean of 40.13±0.35 °C in which 80% (4/5) of the domestic pigs were 
febrile. Despite some of these differences, there was no statistical significance in the peak 
temperatures nor incidence of fever between the feral and domestic pigs at day 4 post-infection 
(Dunn-Bonferroni test, p ≥ 0.999 for temperature and one-tailed Fisher’s exact test, p = 0.500 for 
fever incidence). Overall, the body temperatures of the control pigs from the domestic group 
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appeared higher than those in the feral group, but there was also no demonstrable statistical 
difference between the two control groups (Dunn-Bonferroni test, 0.938 ≤ p ≤ 0.999). The range 
of the average temperatures from day 0 to day 7 post-challenge was 38.66 °C to 39.36 °C and 
38.51 °C to 39.77 °C for the non-infected feral and domestic pigs, respectively.  
 
 
Figure 5.4. Temperature profiles of feral pigs after JEV challenge. 
Body temperatures recorded from the non-infected and infected feral pigs were compared to those 
collected from the domestic pigs in Aim 2. DPI = day post-infection.  
 
 
Table 5.2. Number of JEV-infected animals with fever (≥ 40 °C). 
Group 1 DPI 2 DPI 3 DPI 4 DPI 5 DPI 6 DPI 7 DPI 
Feral pigs  
















Domestic pigs  
















DPI = days post-infection. ID = intradermal. JEV = Japanese encephalitis virus. Yellow box = 
peak incidence.  
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 Mild to moderate hindlimb ataxia was observed in some of the JEV-challenged feral pigs 
past the acute phase of infection, as summarized in Table 5.3. Four out of the five (80%) feral 
animals developed hindlimb ataxia around 11 to 15 days post-infection and recovered to normal 
ambulation in 1 to 8 days. Despite the earlier onset of ataxia in the feral pigs, the incidence and 
duration of ataxia were comparable to what was demonstrated with domestic pigs infected with 
JEV (one-tailed Fisher’s exact test, p =0.262 for incidence and Mann-Whitney U test, p = 0.233 
for duration). All feral pigs survived the challenge to the end of the study and developed a mean 
geometric PRNT50 titer of 121.26, which was comparable to the titer (91.9) calculated for the 
domestic pigs (Mann-Whitney U test, p = 0.690). 
 
Table 5.3. Timetable for the onset of ataxia in JEV-infected feral and domestic pigs. 
 
D = day. A (in green box) = ataxia.  
 
 Viremic profiles of JEV-infected feral pigs 
Intradermal inoculation with JEV led to detectable viremia of high magnitude and duration 
in the Sinclair miniature feral pigs similar to JEV-infected domestic pigs in Aim 2, suggesting that 
feral pigs are susceptible to JEV infection and can potentially play the role of amplifying hosts. 
The kinetics of viremia depicted by plaque assay and RT-qPCR were consistent to each other. As 
shown in Figure 5.5, viremia was detected at day 1 post-infection and lasted 4 to 5 days similarly 
to what was previously characterized in the experimental infection of domestic pigs. However, 
Group D0 D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 D18 D19 D20 D21 D22 D23 D24 D25 D26 D27 D28
Domestic
Domestic
Domestic A A A A A A A A A A A A A A
Domestic A A
Domestic
Feral A A A A A A
Feral A A A A
Feral A
Feral A A A A A A A A
Feral
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viremia in the feral pigs reached its peak in both infectious titers and viral RNA loads a day earlier 
when compared to the domestic pigs challenged with JEV only in Aim 2. The peak mean infectious 
titer and viral load for the feral pigs occurred at day 2 post-infection and was 7.0x104±1.1x105 
PFU/ml and 5.6x104±9.7x104 geq-TCID50/ml, respectively. Despite this early viremic peak, these 
viral titers were not significantly different when compared to the levels detected in day 2 or day 3 
(i.e. day of peak viremia) post-infection in infected domestic pigs (Dunn-Bonferroni test, p ≥ 0.999 
for both infectious titer and RNA load). The viral burden in the serum at 1 day post-challenge 
appeared higher in the feral pigs (9.3x102±8.6x102 PFU/ml or 9.0x102±6.0x102 geq-TCID50/ml) 
compared to the corresponding titers from the domestic pigs (1.3x101±1.7x101 PFU/ml or 
6.6x101±7.0x101 geq-TCID50/ml), but they were also not statistically different from each other 
(Dunn-Bonferroni test, p = 0.809 for infectious titer and p = 0.456 for viral RNA load). Following 
the trend observed with the clinical signs, the kinetics of viremia were indistinguishable between 
the feral and domestic pigs after JEV challenge, strengthening the possibility that feral pigs can 




Figure 5.5. Magnitude and duration of viremia of feral pigs after JEV challenge. 
Viral infectious titers (A) and RNA loads (B) detected in the serum from the infected feral pigs 
were compared to those obtained from the domestic pigs infected with JEV alone in Aim 2. DPI = 
day post-infection. PFU = plaque forming units. Geq-TCID50 = genome equivalent-50% tissue 
culture infectious dose.   
 
 Kinetics of viral nasal shedding 
Comparable viral burdens were detected in the nasal secretions of the Sinclair miniature 
feral pigs after JEV challenge to those collected from the infected domestic pigs (Dunn-Bonferroni 
test, p ≥ 0.999 for infectious titers and viral RNA load), as depicted in Figure 5.6. In terms of 
infectious titers, only 40% (2/5) of the infected feral pigs shed an average of 1.8x101±1.0x101 
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PFU/ml for 1 to 2 days starting at day 3 post-challenge whereas 80% (4/5) of the infected domestic 
pigs shed an average of 2.8x101±1.9x101 PFU/ml for 2 to 3 days starting at day 2 after inoculation. 
Data analyzed with RT-qPCR was consistent with the results from the plaque assay. While the 
RNA loads detected at any time point were not statistically different between the two groups of 
animals (Dunn-Bonferroni test, p ≥ 0.999), the duration of nasal shedding was significantly longer 
in the JEV-infected domestic pigs (one-tailed t-test, t = -3.055, p = 0.008). Infected feral pigs shed 
for only 1±1 days while infected domestic pigs shed for 3.8±1.8 days. For both types of pigs, the 
highest average RNA loads detected in the nasal swabs were on day 4 post-infection with 6.1±8.2 
geq-TCID50/ml and 1.9x10
1±1.6x101 geq-TCID50/ml in the feral and domestic pigs, respectively. 
The overall shedding incidence and the shedding incidence at day 4 (i.e. day of peak nasal titers) 
post-infection were not statistically different between the two groups of infected pigs (one-tailed 
Fisher’s exact test, p = 0.222 for overall incidence and p = 0.262 for incidence at day 4 post-
infection) (Table 5.4). No positive JEV detection was made after the first week post-challenge in 




Figure 5.6. Nasal shedding of JEV by JEV-infected feral pigs. 
Viral infectious titers (A) and RNA loads (B) detected in the nasal swabs from the infected feral 
pigs were compared to those obtained from the domestic pigs infected with JEV alone in Aim 2. 
DPI = day post-infection. PFU = plaque forming units. Geq-TCID50 = genome equivalent-50% 
tissue culture infectious dose.   
 
Table 5.4. Number of nasal shedders of JEV RNA in each experimental group. 
Group 1 DPI 2 DPI 3 DPI 4 DPI 5 DPI 6 DPI 7 DPI 
Feral pigs  
















Domestic pigs  
















DPI = days post-infection. ID = intradermal. JEV = Japanese encephalitis virus. Yellow box = 
peak incidence. 
 
 Viral burdens of different tissues at the acute phase of infection 
Evidence of systemic dissemination of JEV at the acute phase of infection was 
demonstrated based on the detection of infectious viruses and JEV RNA in different tissues 
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sampled from the Sinclair miniature feral pigs at day 3 post-challenge. The presence of infectious 
viruses and viral RNA in several CNS tissues also demonstrated that JEV can lead to neuroinvasion 
in feral pigs similar to domestic pigs (Park et al., 2018; Ricklin et al., 2016b; Yamada et al., 2004; 
Young et al., 2020). Infectious titers of homogenized nervous and lymphoid tissues did not show 
demonstrable differences between infected feral and domestic pigs (Dunn-Bonferroni test, p ≥ 
0.999 and Mann-Whitney U tests, 0.095 ≤ p ≤ 0.999), and ranged from 2.6x101±3.2x101 PFU/g 
(medial iliac lymph node) to 5.4x103±1.0x104 PFU/g (mesenteric lymph node). Analysis by RT-
qPCR validated the results from the plaque assay. Consistent with the infectious titers, JEV RNA 
loads in the homogenized tissues were not significantly different between those sampled from the 
infected feral and domestic pigs (Dun-Bonferroni test, p ≥ 0.999 and Man-Whitney U tests, 0.056 
≤ p ≤ 0.999) except for piriform cortex (Mann-Whitney U test, p = 0.016) and occipital lobe 
(Mann-Whitney U test, p = 0.016), as shown in Figure 5.7. The average viral load of homogenized 
piriform cortex was 3.5±6.9 geq-TCID50/g and 1.3x10
3±2.0x103 geq-TCID50/g in the feral and 
domestic pigs, respectively. The average viral load was also significantly lower in the occipital 
lobe of feral pigs (1.9x101±3.7x101 geq-TCID50/g) in comparison to those from the domestic pigs 
(1.8x103±3.1x103 geq-TCID50/g). This may suggest that while JEV is similarly neuroinvasive in 
the feral pig as in the domestic pig, the dissemination within the brain could potentially be slightly 
different. In summary, the overall tissue dissemination pattern of JEV was comparable between 




Figure 5.7. Tissue dissemination pattern of JEV in feral pigs after challenge. 
Viral RNA loads detected in several different tissues collected at day 3 post-infection from the 
infected feral pigs were compared to those obtained from the domestic pigs infected with JEV 
alone in Aim 2. Geq-TCID50 = genome equivalent-50% tissue culture infectious dose. Asterisk (*) 
indicates the significant difference when feral and domestic pig groups were compared to each 
other using non-parametric Mann-Whitney U test.  
 
 Persistent infection of JEV in feral pigs 
Based on the detection of JEV RNA in tissues collected at day 28 post-infection by RT-
qPCR, persistent infection of JEV was demonstrated in the Sinclair miniature feral pig, suggesting 
that they can also be used as an additional model of JEV persistence. In contrast to the domestic 
animals of the JEV-only group in Aim 2, viral RNA was not detected in the brain at 28 day post-
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infection. The one pig from the JEV-only domestic group that was ataxic in the hindlimbs until 
the end of the study was the only animal that had persistent JEV RNA present in the brain (i.e. 
olfactory peduncle, piriform cortex, and midbrain) in Aim 2. On the other hand, all infected feral 
pigs that developed ataxia recovered fully in 9 to 10 days prior to the end of the study, possibly 
providing an explanation to this difference. Nevertheless, persistent infection of the tonsils and 
thymus was demonstrated in the JEV-infected feral pigs. As presented in Figure 5.8, similar viral 
RNA loads were detected in both lymphoid structures of the feral pigs in comparison to those from 
the domestic pigs (Mann-Whitney U test, 0.222 ≤ p ≤ 0.690). Mean viral loads of the thymus was 
9.9x100±1.2x101 geq-TCID50/g for the feral pigs and 1.6x10
1±2.0x101 geq-TCID50/g for the 
domestic pigs. The average viral loads of the tonsil were slightly higher than the thymus, reaching 
3.4x103±3.0x103 geq-TCID50/g in the feral pigs and 9.7x10
2±1.3x103 geq-TCID50/g in the 
domestic pigs.  
In summary, the susceptibility, infection course, and clinicopathological outcomes of JEV 
infection in the feral pig were comparable to what has been previously characterized in the 




Figure 5.8. Persistent infection of lymphoid tissues collected from JEV-infected feral pigs. 
Viral RNA loads detected in lymphoid tissues collected at day 28 post-infection from the infected 
feral pigs were compared to those obtained from the domestic pigs infected with JEV alone in Aim 
2. Geq-TCID50 = genome equivalent-50% tissue culture infectious dose.   
 
Discussion 
 While domestic and wild or feral pigs are taxonomically closely related, genetic differences 
exist between them that could reflect the variation in susceptibility profiles or disease outcomes 
against a specific pathogen (Conyers et al., 2012; Costa et al., 2012; Lowden et al., 2002). As a 
result, studying the infection outcome or clinical disease course directly in the animal of interest 
is justified and provides the direct evidence showing that feral pigs may play a role in the 
maintenance of zoonotic pathogens. The results from this study demonstrated that feral pigs from 
North America are susceptible to JEV infection similarly to their domestic counterparts with some 
minor differences. Using the Sinclair miniature pigs as a model of North American feral pigs, the 
miniature pigs infected with JEV developed mild to no clinical signs including fever, depression, 
and hindlimb ataxia of short duration. The clinical disease observed in the infected feral pigs were 
119 
comparable to those observed previously in domestic pigs (Park et al., 2018; Ricklin et al., 2016b; 
Yamada et al., 2004). No demonstratable differences were also observed in the kinetics of viremia, 
viral titers of nasal secretions, nor in the overall tissue tropism between the feral and domestic pigs 
after intradermal JEV challenge. The infected feral pigs also exhibited JEV persistence in the 
lymphoid tissue up to day 28 post-challenge (Figure 5.8), demonstrating that they can be used as 
an infection model for flavivirus persistence.   
 A significant finding from this study is that the potential amplifying role of feral pigs in 
JEV transmission was highlighted based on their ability to develop viremia of high magnitude. 
While the peak viral burden in the serum in both infectious viral titers and JEV RNA loads 
appeared a day earlier on day 2 post-infection in the infected feral pigs compared to the domestic 
pigs, the overall kinetics of viremia between the two groups of animals were not statistically 
different from one another, as summarized in Figure 5.5. Additionally, the high seropositive rate 
of JEV reported in the wild or feral pigs captured in the endemic areas (Hamano et al., 2007; 
Nidaira et al., 2014; Nidaira et al., 2007; Ohno et al., 2009; Yang et al., 2012a) suggests that 
mosquitoes that are competent for JEV transmission readily feed on these vertebrate hosts. 
Therefore, our work and the seosurveillance studies from JE-endemic regions (Hamano et al., 
2007; Nidaira et al., 2014; Nidaira et al., 2007; Ohno et al., 2009; Yang et al., 2012a) altogether 
demonstrates that wild or feral pigs are amplifying hosts of JEV. At the same time, it is important 
to interpret our results with some caution. While young Sinclair miniature feral piglets were used 
as representative models of feral pigs of North America, the observations may not be directly 
extrapolated to the disease pathogenesis of JEV in adult wild or feral pigs in nature. Inoculation of 
older Sinclair feral pigs could be conducted in the future because age-related difference in 
susceptibility and clinical course has been demonstrated in feral pigs (Kaden et al., 2004). For 
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example, young wild boars frequently developed longer viremia of classical swine fever virus 
whereas the viremia was often short and transient in adult wild boars (Kaden et al., 2004). 
Additionally, it would be interesting to investigate whether or not the feral pigs are capable of 
developing secondary viremia or systemic infection with heterologous JEV strains, as observed in 
domestic pigs experimentally challenged with different JEV genotypes (García-Nicolás et al., 
2017), because the findings could potentially impact our understanding of the virus ecology. 
Nevertheless, the susceptibility of young feral pigs to JEV remains important and relevant as there 
are continuously stable populations of piglets due to the high turnover rate of feral pigs in nature 
similar to domestic pigs in swine or pork production.  
 Among the minor differences in infection outcomes observed in our study, the duration of 
nasal shedding of JEV RNA was found to be significantly shorter in the infected feral pigs as 
compared to the infected domestic pigs, as summarized in Figure 5.6 and Table 5.4. However, 
this finding may be due to differences in methodology. At the same ages (i.e. three-week-old prior 
to the start of the study), the miniature feral pigs were much smaller in size than the domestic pigs. 
Due to the size difference, pediatric-sized cotton swabs were used for the duration of the study 
instead of the regular-sized cotton swabs that were used for the domestic pigs in Aims 1 and 2 to 
fit the smaller nostrils of the feral pigs for the nasal swab collection. This could result in smaller 
amount of samples eluted from the swabs, leading to lower amount of virus and higher chance to 
be undetected even by the sensitive method of RT-qPCR. Regardless, the nasal shedding viral 
titers that were detected by plaque assay and RT-qPCR were above the levels demonstrated to be 
infectious by direct oral and/or nasal contact with naïve domestic pigs (Ricklin et al., 2016a). 
However, it is unknown if vector-free transmission also applies to feral pigs. JEV RNA has only 
been detected in the serum (Nidaira et al., 2008) and tonsils (Tan et al., 2012) of wild pigs from 
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JE-endemic regions. No infectious viruses have been isolated from wild or feral pigs as of yet. The 
ability of JEV-infected feral pigs to transmit the virus through direct nose-to-nose contact with 
other naïve feral or domestic pigs and vice versa could have significant implications as contact 
between feral and domestic pigs in outdoor pens is a common occurrence (Miller et al., 2017; 
Wyckoff et al., 2009). This potential route of transmission should be investigated in the future.  
 The other difference demonstrated by statistical analysis was the variation in viral burden 
in certain CNS tissues sampled at day 3 post-infection (Figure 5.7). Infected feral pigs had 
significantly lower viral titers in the piriform cortex and occipital lobe compared to those from 
infected domestic pigs. However, the viral burden in the rest of the CNS and lymphoid tissues 
were comparable between the two groups of animals. Overall, the infection and clinical disease 
course including viremia kinetics, tissue tropism, and viral persistence were similar and 
indistinguishable when compared between both types of animals, suggesting that this finding could 
be of minor importance. At the same time, it could also be a reflection of the potential differences 
in their immune response that could influence the dissemination pattern of the virus in the brain. 
While domestic and feral pigs have close taxonomic relationship (i.e. both classified under Sus 
scrofa), they are genetically distinct and belong to different subspecies (Sánchez-Cordón et al., 
2019; Watanobe et al., 1999). Differences in genetics could reflect in differential susceptibility to 
disease or infection as genetics play a key role in immune kinetics for diseases. For example, the 
white blood cell count has been documented to be significantly lower in wild pigs compared to 
those of domestic pigs at baseline (Tan et al., 2012). There are also reports on how the T cell 
responses vary between wild and domestic pigs against a specific pathogen such as African swine 
fever virus (Hühr et al., 2020; Schäfer et al., 2021). Therefore, how a virus disseminates in the host 
body or gets cleared from the system could be slightly different between the two types of animals. 
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More data in terms of additional early time points may be necessary to investigate if there is a true 
difference in the dissemination pattern of JEV in the acute phase of infection between feral and 
domestic pigs. 
 Variation in infection or clinical disease outcomes between wild or feral pigs have been 
observed in other pathogenesis studies, primarily with African swine fever (Hühr et al., 2020; 
Schäfer et al., 2021; Zani et al., 2018) and classical swine fever viruses (Brugh et al., 1964). For 
example, while most minipigs and domestic pigs recovered from a moderately virulent strain of 
African swine fever virus infection, all wild boars succumbed to its infection (Zani et al., 2018). 
The difference in infection outcome was determined to be primarily due to the variations in T cell 
responses in wild and domestic pigs. The strong bias in wild pigs for higher regulatory T cells, 
which can inhibit host antiviral responses, and perforin+ cytotoxic T lymphocytes compared to 
domestic pigs were identified to be responsible for the more severe inflammation, tissue damage, 
and ultimately death after challenge with the particular strain of African swine fever virus (Hühr 
et al., 2020; Schäfer et al., 2021). Similarly, Brugh et al. (1964) demonstrated that wild swine had 
shorter prodromal periods and faster rates to death from classical swine fever virus infection 
compared to domestic pigs. However, other studies have demonstrated that classical swine fever 
virus infection outcomes were comparable between wild and domestic pigs (Depner et al., 1995; 
Fukai et al., 2020). In addition to host genetic and virus strain differences, inoculum dosage versus 
animal size (Brugh et al., 1964), internal parasite load (Brugh et al., 1964; Fukai et al., 2020), 
differences in levels and periods of stress (Sánchez-Cordón et al., 2019), and gut microbiota 
(Zhang et al., 2020) are some potential factors that could contribute to the observed differences in 
infection or disease outcome between wild or feral and domestic pigs. Additionally, comparisons 
of clinical signs are sometimes made difficult by the fact that wild animals tend to conceal disease 
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by minimizing sickness behavior (Hühr et al., 2020; Tizard, 2008). 
 Altogether, our study demonstrates for the first time that feral pigs of North America can 
contribute to the JEV transmission cycle as amplifying hosts. It also highlighted the use of Sinclair 
miniature feral pigs as relevant viral infection models for JEV infection and disease and for 
flavivirus persistence. Additionally, the importance of studying pathogens directly in the animal 
of interest was emphasized through this study. Although they were minor differences, statistically 
significant variations in certain infection outcomes were identified between the feral and domestic 






Chapter 6 - Conclusion, final remarks, and future directions 
 
 
Conclusion and final remarks 
Japanese encephalitis virus is a neurotropic flavivirus capable of causing fatal encephalitis 
and is currently endemic to the Asia-Pacific region (World Health Organization, 2019). Its 
potential dispersal into new geographic regions is an important public and veterinary health 
concern, especially into areas where its major players of enzootic transmission cycle (i.e. mosquito, 
avian, and swine species) may be present. Our work described in this dissertation demonstrated 
that North American domestic and feral pigs are susceptible to JEV infection via either intravenous 
or intradermal inoculation. They were also capable of developing pathological outcomes 
comparable to what has been previously described for JEV disease in pigs and humans (Park et 
al., 2018; Ricklin et al., 2016a; Ricklin et al., 2016b; Yamada et al., 2004), as presented in Figure 
6.1. The common pathological and infection outcomes included viremia indicative of transmission 
potential, viral shedding, systemic infection, and persistent infection. Since no apparent differences 
were observed in the pathological outcomes of JE using North American pigs, the findings from 
these studies are relevant to the biology of JEV. Our work was able to address major questions 
such as the following: (1) Does mosquito saliva affect the pathogenesis of JEV? If so, how? 
(investigated in Aim 2) and (2) Are feral pigs susceptible to JEV infection? What potential role 
could they have in JE transmission? (examined in Aim 3). Collectively, our studies have improved 




Figure 6.1. Schematic diagram summarizing the results from this dissertation. 
JEV = Japanese encephalitis virus. DPI = day post-infection.  
 
The studies described in this dissertation also provide important contribution to the 
advancement of JEV research. Altogether, they (1) identified appropriate alternative samples 
applicable in the field for veterinary diagnosis and surveillance, (2) generated an additional animal 
model for human JE to aid in pre-clinical studies of antiviral or vaccine development, and (3) 
increased our understanding of how JEV may behave in North America. Ultimately, our work 
provided additional background knowledge to pursue future research avenues and further our 
knowledge of JE disease and ecology. 
 
 Improvements in veterinary diagnosis and surveillance of JEV 
Currently, the diagnosis of JEV in pigs can be based on virus isolation on CNS tissues, 
viral RNA detection in samples such as blood, brain, placental tissues, and cerebrospinal fluid, 
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and/or via the detection of JEV-specific antibodies in cerebrospinal fluid or serum samples (World 
Health Organization, 2019; Yang, 2019). However, the collection of the samples needed to 
perform these OIE-recommended diagnostic tests are often invasive, time-consuming, and require 
technical or veterinary expertise. Our studies identified alternative samples that could be used to 
diagnose and surveil JEV infection in pigs. At the individual level, nasal swabs can be used to 
collect nasal secretions for the detection of JEV RNA via RT-qPCR, as demonstrated in Aims 1, 
2, and 3. At the pen level, collection of oral fluid via rope can be practically implemented to detect 
the oral shedding of JEV RNA via RT-qPCR (Lyons et al., 2018), as shown in Figure 6.2. 
Although both types of samples are easy and non-invasive to collect, the timing of collection is 
crucial because viral RNA shedding via nasal secretions or oral fluid can only be detected between 
2 to 10 days post-infection (Figure 6.1 and 6.2). In addition, it is difficult to estimate how much 
time has passed since the infection or exposure because infected pigs often develop no to mild 
nonspecific clinical signs, the most consistent being the elevation of body temperature (Park et al., 
2018; Platt and Joo, 2006; Ricklin et al., 2016b; Young et al., 2020). Detection of IgM and IgG 
antibodies against JEV could provide such estimation. Moreover, the appropriate selection of RT-
qPCR assay for JEV detection is crucial because not all available qPCR assays can detect nor 
differentiate between different genotypes (Lyons et al., 2018). If these diagnostic samples were to 
be implemented into a surveillance system, weekly collection of nasal swabs or pooled oral fluid 





Figure 6.2. Detection of JEV genome in oral fluid collected from intradermally challenged 
domestic pigs (A) and Sinclair miniature pigs (B) between 0 and 28 days post-infection.  
Quantities of JEV genome detected by assay 2 (based on NS5) and assay 3 (based on 3′ UTR) are 
shown in black and blue, respectively. Only data collected from the samples containing detectable 
level of JEV genome (Cq value < 34) are shown. TCID50 = 50% tissue culture infectious dose. 




Domestic pigs are routinely used as sentinel animals to monitor JEV activity in the endemic 
countries (Cappelle et al., 2016; Di Francesco et al., 2018; Nitatpattana et al., 2011). However, the 
data demonstrated from our work and recently by others suggest that pigs may not be the most 
ideal sentinel animal to use for JEV surveillance. Although highly susceptible to JEV infections 
and a primary player in both the enzootic and epizootic transmission cycles, pigs have the capacity 
for vector-free transmission of JEV via the oral-nasal route (Ricklin et al., 2016a), leading to a 
potential misrepresentation of JEV prevalence or risk in the study region (Cappelle et al., 2016; 
Kading et al., 2019). As a result, support for an integrated surveillance program that involves 
sampling both the vector and vertebrate hosts may be optimal (Lustig et al., 2018). At a minimum, 
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sentinel animals should be susceptible to infection, able to seroconvert, and survive the infection 
(Halliday et al., 2007; Langevin et al., 2001). Ideally, the animals should also not contribute to the 
arbovirus transmission cycle as amplifying hosts and should not be capable of spreading the 
infection directly to cage mates via direct transmission because this could lead to misinterpreting 
the actual risk for mosquito-borne transmission (Halliday et al., 2007; Langevin et al., 2001). An 
alternate sentinel animal that has been used for JEV surveillance are adult chickens, which meet 
the minimum criteria, develop low viremia, and are inefficient viral shedders (Auerswald et al., 
2020; Nemeth et al., 2012; Yap et al., 2019). 
At this time, there is no JEV-specific active surveillance system in North America. Instead, 
there are existing field and laboratory programs of reporting and surveillance for related 
flaviviruses that are endemic to the region, such as West Nile and St. Louis encephalitis viruses 
(Kading et al., 2019). For example, there are state-specific mosquito surveillance programs aimed 
to monitor select domestic arboviruses (Lustig et al., 2018). There is also a comprehensive national 
surveillance database platform called ArboNET that passively monitors infections of nationally 
notifiable arboviruses, such as Eastern equine encephalitis, Powassan, and West Nile viruses, and 
some travel-associated significant arboviruses, such as chikungunya and yellow fever viruses, in 
humans, mosquitoes, birds, and other animals (Lindsey et al., 2012; Lustig et al., 2018). These 
programs potentially could also simultaneously support vector and host surveillance for JEV 
because some of these nationally monitored, such as West Nile and St. Louis encephalitis viruses, 
share similar enzootic transmission patterns involving Culex species mosquitoes and birds (Diaz-
Badillo et al., 2011; Schweitzer et al., 2009). However, because these are related flaviviruses, 
implementation of JEV diagnostics must be specific enough to differentiate from the other viruses. 
Cross-reactivity between these closely related flaviviruses is an issue since they also belong in the 
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same serocomplex. Cases of JEV could thereby go undetected unless JEV-specific tests are utilized 
routinely. False positive results can sometimes occur for closely related flaviviruses even with the 
use of the gold standard PRNT (Hirota et al., 2010; Maeki et al., 2019). Cross-reactivity in 
serological assays can be potentially reduced further through the use of epitope blocking ELISAs 
(Kitai et al., 2007; Tsai, 1990) or by using novel antigens such as modified E proteins with mutated 
cross-reactive epitopes (Roberson et al., 2007) and virus-specific recombinant NS1 proteins 
(Cleton et al., 2015; Mora-Cárdenas et al., 2020). 
 
 Pigs as a biologically relevant animal model for human JE 
In addition to identifying additional samples for veterinary JE diagnosis, our studies also 
provide contribution to the development of therapeutic research against JEV. The work in this 
dissertation demonstrated that young pigs can develop neurotropic disease resembling human JE 
and identified pathological outcomes that can be markers for protection (Park et al., 2018), making 
pigs a potential model organism for the pre-clinical development of preventative or therapeutic 
treatments against JEV infections. As shown in Aims 1, 2, and 3, JEV consistently invaded the 
brain after peripheral needle inoculation during the acute phase of infection, targeted lymphoid 
and nervous tissues, and was shed through the oral-nasal secretions as observed in human JEV 
infections (Bharucha et al., 2018; Ghosh and Basu, 2009; Lyons et al., 2018; Park et al., 2018; 
Platt and Joo, 2006). Therefore, pigs could function as a biologically relevant model of human JE 
disease for pre-clinical and translational research. For example, the Yucatan miniature swine 
model was useful in evaluating the protective efficacy of selected monoclonal antibodies against 
JEV challenge in a recent study conducted by Young et al. (2020) and others.  
Currently, the main animal models to study and characterize human JE disease and develop 
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therapeutic strategies include non-human primates like rhesus macaques (Gardner and Luciw, 
2008; Myint et al., 2014; Myint et al., 1999; Raengsakulrach et al., 1999) and mice (Li et al., 2012; 
Mathur et al., 1983; Tsuchiya, 1968). The major differences among those established models and 
the pig are summarized in Table 6.1. Both rhesus macaques and mice are good models of fatal JE, 
but they each have their own limitations. While rhesus macaques are highly susceptible to lethal 
JEV infection, that disease outcome can only be induced noninvasively by intranasal inoculation 
(Myint et al., 2014; Myint et al., 1999; Raengsakulrach et al., 1999). Additionally, non-human 
primates are often prohibitively expensive and associated with regulatory issues that can hinder 
research progress. On other hand, mice are highly accessible, and various strains are commercially 
available. Mice are susceptible to neuroinvasive disease through a variety of inoculation routes 
including intracerebral, intraperitoneal, intradermal, and intranasal (Kimura et al., 2010). 
However, there is considerable variation in the pathogenesis depending on the inoculation method 
and they must be young and/or a high viral titer must be used to induce the pathological outcome 
(Kimura et al., 2010). In pigs, the different modes of JEV infection (i.e. needle [intravenous and 
intradermal], oronasal, direct contact, etc.) result in similar pathologic outcomes and immune 
responses (Redant et al., 2020; Ricklin et al., 2016a). Neuroinvasion can also be observed in 
challenged pigs up to 9 weeks of age (Redant et al., 2020). Pigs offer other advantages over mice. 
In addition to anatomic and physiologic similarities, pigs have comparable immune system to 
humans more than humans do with mice (Gerdts et al., 2015; Meurens et al., 2012). Although 
rodents are evolutionarily more closely related to humans than are pigs to humans, large scale 
genomic comparisons of immune functions have strongly suggested that pigs and human share 
more similarities in their immune systems (Bailey et al., 2013; Dawson, 2011; Meurens et al., 
2012). Pigs and humans are similar for greater than 80% of the immune parameters analyzed 
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compared to less than 10% for mice and humans (Bailey et al., 2013; Dawson, 2011; Meurens et 
al., 2012). At the same time, an advantage of non-human primates and mice over the pig is that 
they are capable of developing the fatal encephalitis as seen in severe human JE cases while most 
infections in pigs are often self-limiting, primarily due to the difference in the acute inflammatory 
responses in the brain (Kimura et al., 2010; Redant et al., 2020). However, kinetics and severity 
of disease symptoms and pathological outcomes (i.e. duration and magnitude of fever, viremia, 
viral nasal shedding, and/or neuroinvasion) can be used as markers of infection and disease to 
thoroughly evaluate the safety and protective efficacy of candidate treatments without requiring 
an extreme challenge outcome. Pigs are, therefore, an appropriate alternative model for human JE. 
 
Table 6.1. Comparison of animal models of JEV disease. 
Non-human primates Mice Pigs 
▪ Only susceptible to 
neuroinvasive disease via 
IN route 
▪ Capable of developing 
lethal infection that 
resembles fatal human 
disease 
▪ Very expensive and 
stringent regulations 
make research practically 
prohibitive 
▪ Must be young or use 
high titer virus to be 
susceptible to 
neuroinvasive disease 
with IC, IP, ID, and IN 
routes but there is 
considerable variation in 
the pathogenesis 
depending on the 
inoculation method 
▪ Capable of developing 
lethal infection that 
resembles fatal human 
disease 
▪ Limitations for 
translational research  
 




outcomes regardless of 
route of challenge (i.e. 
IV, SQ, ID, IN) 
▪ Miniature pig models 
available for easier 
handling and husbandry 
▪ More similar to the 
human immune system, 
anatomy, and physiology 
than mice are to humans 
IN = intranasal. IC = intracerebral. IP = intraperitoneal. ID = intradermal. IV = intravenous. SQ = 
subcutaneous. 
References: (Gardner and Luciw, 2008; Kimura et al., 2010; Meurens et al., 2012; Ricklin et al., 




 Implications of JEV transmission in North America 
Overall, the research presented in this dissertation increased our understanding of how JEV 
may behave in North America. The findings from our work and others demonstrated that all three 
major players of the JEV transmission cycle (i.e. mosquitoes, birds, and pigs) are now known to 
be present in North America (Huang et al., 2016a; Huang et al., 2015; Nemeth et al., 2012; Park 
et al., 2018). Based on a qualitative risk assessment, the likelihood of introduction is small, but the 
potential still exists (Oliveira et al., 2019). Pathways of entry may include the transport of infected 
mosquito (via human aid through aircraft or cargo ship) and viremic birds or pigs from JE-endemic 
regions (via legal or illegal importation, migratory routes, etc.) (Kading et al., 2019; Oliveira et 
al., 2019). Cases of JEV-infected human travelers coming from the endemic countries have been 
occasionally reported but humans do not develop sufficient viremia levels to introduce the agent 
to a susceptible vector (Hills et al., 2019). Nevertheless, once introduced in the United States, an 
enzootic transmission cycle could potentially become established in North America since all of the 
key players of the mosquito-vertebrate host cycle are immunologically naïve to the virus, present 
in the wild, and in close proximity with humans. However, this probability can be variable as the 
vectorial capacity and host density vary with a high degree of uncertainty depending on the region 
of introduction (Oliveira et al., 2019). Additionally, both the predictable and stochastic factors 
influencing an introduction are complex, making risk assessment efforts very challenging and 
difficult to predict (Kading et al., 2019).  
At the same time, there have been several arboviruses that have recently undergone 
dramatic dispersal events, including African swine fever virus and Zika virus, leading to significant 
disease burden in the new regions (Kading et al., 2019; Yadav et al., 2016). West Nile virus, a 
closely related flavivirus to JEV, is an example of an exotic virus that was introduced in the United 
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Stated in 1999 and became established. The exact mechanism of introduction still remains to be 
determined but the common culprits (i.e. transport or arrival of infected mosquitoes or birds) have 
been suggested (Reed et al., 2003; Roehrig, 2013). Based on sequencing and phylogenetic analysis, 
the New York strain is most closely related to isolates from the 1998 outbreak in Israel but no 
commerce links between them were made (May et al., 2011; Roehrig, 2013). Nevertheless, once 
introduced in New York, the virus rapidly spread along the eastern seaboard and from east to west 
across the country most likely due to the presence of competent mosquitoes and susceptible 
amplifying migratory avian species (Diaz-Badillo et al., 2011; Reed et al., 2003). Similar to JEV, 
West Nile virus relies on Culex species mosquitoes as vectors and birds as amplifying hosts with 
humans remaining as dead-end hosts. As such, JEV could potentially exploit the same mechanisms 
and become established in the region after an introductory event. However, there are some 
differences between these two viruses that may add more complexity to this theory. For example, 
JEV is more connected to agriculture. Transmission and thereby most epidemics in Asia are driven 
by the close association between the amplifying hosts and humans with mosquitoes linking the 
two types of hosts: (1) domestic pigs and humans in backyard pig farming and (2) water-wading 
birds and humans in rice paddy fields (Le Flohic et al., 2013; Tsai, 1990). On the other hand, rice 
production is very limited to certain concentrated locations in the United States (U.S. Department 
of Agriculture, 2021) and the majority of commercial swine farms are indoor containment facilities 
(U.S. Department of Agriculture, 2008, 2019; Wyckoff et al., 2009). However, there are a variety 
of avian species other than the typical water-wading birds that are highly susceptible amplifying 
hosts of JEV capable of developing high viremia present in North America (Nemeth et al., 2012). 
Moreover, pigs from indoor facilities can still be exposed to insects including flies and mosquitoes, 
which have been reported to be responsible for the mechanical transmission of several swine 
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pathogens between nearby farms (Otake et al., 2001; Otake et al., 2002; Schurrer et al., 2006; Yang 
et al., 2012b), and there is a large immunologically naïve population of feral pigs available in the 
wild (Ruiz-Fons, 2017). Therefore, how successful JEV, an agricultural rural pathogen, will be at 
establishing a permanent transmission cycle in the new territory will most likely vary significantly 
based on the region of introduction.  
Another important factor at play is that the presence of other flaviviruses in North America 
may also influence how JEV may behave in the environment. Prior to the introduction of West 
Nile virus, St. Louis encephalitis virus was the only endemic mosquito-borne flavivirus in the 
United States but was competitively displaced by the emerging virus (Curren et al., 2018; Reisen, 
2003). Not only do they share the same enzootic transmission cycle characteristics, but studies 
have also demonstrated that birds infected with West Nile virus developed sterilizing immunity to 
St. Louis encephalitis virus while birds previously infected with St. Louis encephalitis virus were 
still capable of becoming viremic with West Nile virus infection (Fang and Reisen, 2006; Reisen, 
2003). Similar results have been demonstrated with JEV. Pigs or birds infected first with West 
Nile virus and then challenged with JEV were only able to develop low to undetectable levels of 
JEV viremia and had a booster effect on their already existing antibodies against West Nile virus 
(Ilkal et al., 1994; Nemeth et al., 2009; Williams et al., 2001). In terms of disease, immunity to 
West Nile virus reduced the severity of infection and clinical outcome of JEV in macaques 
(Goverdhan et al., 1992) and mice (Price et al., 1967). These results suggest that pre-existing 
immunity to West Nile virus may potentially dampen transmission of JEV while simultaneously 
complicating the serologic diagnosis of JEV (Nemeth et al., 2009). However, approximately 1,500 
to 4,000 JE cases are still reported every year in India where both West Nile virus and JEV can be 
found (Kabilan, 2004; Tiwari et al., 2012). Additionally, JEV has become established in northern 
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Australia despite the presence of other flaviviruses in that country, such as West Nile and Murray 
Valley encephalitis viruses (van den Hurk et al., 2019). Coupled with the fact that JEV is a highly 
neurotropic virus, dispersal of JEV into North America is still a true concern of public and 
veterinary health importance. 
 
Future directions 
Based on data presented in this dissertation, future work could focus on two major topics: 
improving our understanding of (1) the ecological role of persistence of JEV infection and (2) 
impact of mosquito-borne transmission in JEV disease in pigs.  
First, JEV RNA was consistently detected in the pig tonsils long after the acute phase of 
infection in Aims 1, 2, and 3. While our studies demonstrated persistent infection at 28 days post-
infection, García-Nicolás et al. (2017) showed that JEV can persist in the tonsils even longer, up 
to 46 days after challenge. Therefore, pigs can be a good model for persistent flavivirus infections. 
For viruses to establish persistent infection in in vitro or in vivo, specific host defenses need to be 
evaded or controlled in order to maintain viral genomes within a small proportion of infected cells 
(Guo et al., 2018; Mlera et al., 2014). Accordingly, JEV persistence in the pig tonsils may be partly 
associated with decreased activation of certain immune responses such as IFITM3 (interferon 
induced transmembrane protein 3), which is considered to be one of the most important IFN-
stimulated protein directed against flaviviruses, possibly resulting in the reduced ability of the cells 
to clear intracellular JEV (Gorman et al., 2016; Xi et al., 2020). Since these findings were based 
on in vitro pig tonsillar epithelial cells, it would be interesting to investigate if they also apply in 
in vivo. Alternatively, the persistent viral genome detected in the pig tonsils can be sequenced to 
examine whether or not the accumulation of certain mutations is what allows a more efficient 
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immune evasion and/or if they are primarily persistent defective viral genomes. Nevertheless, the 
significant biological question that needs to be addressed is whether or not the persistent JEV in 
the tonsil has the ability to become reactivated. Reactivation of JEV has been possible in studies 
involving mice and certain cell lines through immunosuppressant drugs (Mathur et al., 1986b), 
pregnancy (Mathur et al., 1982; Mathur et al., 1986a, b), and allogeneic (Mathur et al., 1986a) or 
xenogeneic (Sharma et al., 1991) stimulation. Other animal viruses that persistently infect tonsils, 
such as bovine herpesvirus 1 (Winkler et al., 2000) and porcine reproductive and respiratory 
syndrome virus (Bierk et al., 2001; Pileri and Mateu, 2016), have been documented to be able to 
reactivate and cause secondary infections. In a recent study with Seneca Valley virus conducted 
by Maggioli et al. (2019), stress stimulation in the forms of transportation stress, 
immunosuppressive drugs, or parturition stress, which are common stressors that affect pigs in 
commercial farms, were all capable of inducing intermittent viremia and virus shedding that were 
detectable up to day 60 post-infection. Feral or wild pigs routinely experience additional levels 
and periods of stress (Sánchez-Cordón et al., 2019). These findings warrant the investigation to 
determine if pigs, in addition to being efficient amplifiers, can also function as “silent” carriers of 
JEV, capable of re-shedding and/or developing recurrent infections after initial exposure. Such 
knowledge can help better define the roles of pigs as an amplifying host in nature. 
Second, Aim 2 investigated the impact of mosquito saliva in the disease pathogenesis of 
JEV through the established method of supplementing the virus inoculation with mosquito SGE. 
An additional study approach would be to compare JEV infection via SGE supplementation and 
through direct bites from infected mosquitoes in pigs, especially if pigs are to be used as model 
organisms for human JE. While these two methods produced comparable infection outcomes and 
host responses in several pathogenesis studies (Le Coupanec et al., 2013; Moser et al., 2016; 
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Schneider et al., 2004; Styer et al., 2011), a recent investigation with dengue virus showed they 
can result in different outcomes important for preclinical evaluation of vaccine or therapeutic 
candidates (McCracken et al., 2020). For example, rhesus macaques infected with dengue virus 
with SGE or via infected mosquitoes developed similar local inflammation and immune response 
at the inoculation site but, while close, the addition of SGE did not recapitulate dengue infection 
via mosquitoes in terms of viremia kinetics or serum cytokine profile (McCracken et al., 2020). 
The authors argued that these differences associated with the challenge modality could potentially 
have great influence over the disease pathogenesis and, consequently, influence the apparent 
efficacy of a candidate vaccine or treatment strategy. Therefore, it may be necessary in the future 
to examine the effect of JEV infection via the natural transmission with mosquitoes in pigs in order 
to potentially improve the challenge model for human JE.  
Together, the findings from our studies provide a better understanding of how JEV behaves 
in its enzootic hosts – the domestic and feral pigs. The knowledge generated from the studies will 
make a positive impact on public health and the security of U.S. agriculture and livestock. The 
animal models generated through this dissertation work will provide invaluable aid in the 
development and implementation of effective countermeasures against this disease and in the 
research of efficacious therapeutic or prophylactic treatments. Ultimately, data generated through 
our studies will help support additional future investigations to further our knowledge of JE disease 
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